 
  
 
Protocol J2I -MC-JZMA(d)  
  A Phase 1 Multicenter  Global First in Human Study of the CD73 Inhibitor 
LY3475070 as Monotherapy or in Combination with Pembrolizumab in Patients 
with Advanced Solid Malignancies  
 
 [STUDY_ID_REMOVED]   Approval Date: 02 -Sep-2020 
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 1Title P a ge 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of cli ni c al i n v e sti g at or s.  It i s t h e pr o p ert y of 
Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al 
i n v e sti g ati o n of L Y 3 4 7 5 0 7 0 , u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt wit h Eli Lill y a n d C o m p a n y or it s 
s u b si di ari e s.  
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a a n d/ or c o m m er ci all y c o nfi d e nti al 
i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e.  Eli Lill y a n d C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y 
p u bli c r el e a s e.  I n t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) E x e m pti o n 4 a n d m a y n ot b e 
r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s. 
Pr ot oc ol Title: A P hase 1 M ul ti ce nter Gl o b al  Fi rst i n H u ma n St u d y  of  t he C D 7 3 In hi bit or 
L Y 3 4 7 5 0 7 0 as Mo n ot hera p y  or i n Co m bi nat i o n wit h Pe m br o liz u ma b i n Pat ie nt s wi t h  A d va nce d 
S oli d Mali g na ncies 
Pr ot oc ol N u m ber: J 2I -M C -J Z M A 
A me n d me nt N u m ber : d
C o m p o u n d N u m ber: L Y 3 4 7 5 0 7 0 
St u d y P h ase: Earl y P h ase 1 
S h ort Title: A P hase 1 St u d y o f t h e C D 7 3 I n hi bit or L Y 3 4 7 5 0 7 0 i n Patie nts wit h A d va nce d 
S oli d Mali g na ncies 
S p o ns or N a me: El i Lill y a n d C o m pa n y 
Le g al Re gistere d A d dress: I n di a na p olis, I n dia na U S A 4 6 2 8 5 
Re g ul at or y A ge nc y I de ntifier N u m ber(s) 
I N D :  1 4 4 9 0 3 
E u dr a C T:  2 0 1 9- 0 0 3 2 7 0- 6 4 
A p pr o v al D ate:   Pr ot oc ol El e ctr o ni call y Si g ne d a n d A p pr o ve d b y Lill y : 2 3 -A u g -2 0 1 9 G M T .
Pr ot oc ol A me n d me nt (a) Electr o nicall y Si g ne d a n d A p pr o ve d b y Lill y o n : 0 2- Oct -2 0 1 9 G M T .
Pr ot oc ol A me n d me nt ( b) El e ctr o ni call y Si g ne d a n d A p pr o ve d b y Lill y o n :2 4- Fe b- 2 0 2 0 G M T. 
Pr ot oc ol A me n d me nt ( c) Electr o nicall y Si g ne d a n d A p pr o ve d b y Lill y o n :2 2- Mar -2 0 2 0 G M T. 
Pr ot oc ol  A me n d me nt ( d) Electr o nicall y Si g ne d a n d A p pr o ve d b y Lill y o n t he date bel o w. 
A p pr o v al D at e: 0 2- S e p- 2 0 2 0 G M T 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 2Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Protocol J2I -MC -JZMA 23-Aug -2019
Protocol J2I -MC -JZMA Amendment (a) 02-Oct-2019
Protocol J2I -MC -JZMA Amendment (b) 24-Feb-2020
Protocol J2I -MC -JZMA Amendment (c) 22-Mar -2020
Amendment d
This amendment is considered to be non-substantial based on the criteria set f orth in Art icle 
10(a) of Direct ive 2001/20/EC of the European Parliament and the Council o f the European 
Unio n.
Overall Rationale for the Amendment:
The purpose of this amendment is to allow metastati c castrate -resistant prostate cancer (m CRP C)
patients wi th non- measurable disease for trial partici pation.
Section # and Name Description of Change Brief Rationale
Secti on 1.1 Synopsis; 
Secti on 4.1 Overall Design; 
4.1.1 Dose Escalat ion; 
Secti on 9.2 Sample Size 
Determinat ionAdded language for backfill 
patients; updated l anguage for 
sample sizeBackfill patients included to 
improve understanding of 
safet y,PK, and 
pharmacodynamic sof 
LY3475070
Secti on 1.1 Synopsis; 
Secti on 4.1 Overall Design; 
Secti on 6.1 Study  
Intervention(s) 
AdministeredAdded additional guidance on
BID dosingAddit ional guidance and 
clarity regarding BID dosing
Secti on 1.3, Schedule of 
Activities (Baseline, On-
Study  and Post -Study  
Treatment Follow -up)Revised CT/MRI assessment 
windowUpdated to correct 
discrepancy betwee n Section 
1.3 and Section 8.1 for 
enrollment and study 
participat ion purposes
Secti on 1.3, Schedul e of 
Activities (Baseline, On-
Study  and Post -Study  
Treatment Follow -up)Added addit ional PSA sampling, 
radionuclide bone scanUpdated for enrollment and 
study participati on purposes
Secti on 1.3, Schedul e of 
Activities (Cont inued 
Access Fo llow-up Vi sits)Clarified pregnancy testing 
requi rements during continued 
access periodClarificat ion
Secti on 1.3.1 Sam pling 
Schedule for 
Pharmacokinet ics and 
BiomarkersAdded sampling for circulat ing 
tumor cells for m CRPC pati ents 
onlyUpdated for enrollment and 
study  participati on purposes
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 3Secti o n # a n d N a me Descri pti o n of C h a n ge Brief R ati o n ale 
Secti o n 5. 1 I ncl usi o n 
Cri teria F or I ncl usi o n Cri t eri a 3f a n d 7f , 
a d de d e xcl usi o n f or C R P C 
pati e nts wi t h  s mall -cell or 
ne ur oe n d ocri ne hist o l o gies. 
I ncl usi o n Cri t eri a 1 1, a d de d 
e xce pti o n f or pati e nts i n P hase 1a 
p orti o n of  tri al  ( d ose escalat i o n) 
a n d m C R P C pat ie nt s i n C o h orts 
D 1 a n d D 2 t h at t hese pat ie nt s are 
n ot re q uire d t o ha ve meas ura ble 
di sease. U p date d f or e nr oll me nt a n d 
st u d y  p arti ci pati o n p ur p oses 
Secti o n 6. 5 C o nc o mita nt 
T hera p y U p date d c o nc o mita nt me dicat i o n 
la n g ua ge t o reflect greater 
certai nt y re gar di n g e nz y mes 
i n v o l ve d i n t he meta b olis m o f 
L Y 3 4 7 5 0 7 0. 
U p date d l a n g ua ge re gar di n g 
c o nc o mita nt use of z ole dr o nic 
aci d a n d de n os u m a b. 
Re m o ve d r ef ere nces t o s pecific 
f o o ds or be ha vi ors t o a v oi d. Cl arificat i o n
Secti o n 8. 1. 3 Efficac y 
Assess me nt f or m C R P C 
P ati e nts A d de d ne w sect i o n t o descri be 
assess me nts t o be use d f or 
m C R P C patie nts wit h meas ura ble 
or n o n -meas ura ble disease. U p date d f or e nr oll me nt a n d 
st u d y  partici pati o n p ur p oses 
Secti o n 8. 8 Bi o m ar kers A d de d te xt t o all o w f or 
s u b missi o n of arc hi val ti ss ue 
fr o m  rece nt bi o ps y .  
A d de d te xt f or use of fi ne -nee dle 
as pi rat i o n s peci me ns f or N S C L C 
pati e nts o nl y  u p o n disc ussi o n  
wi t h  Lill y  C R P/ C R S .U p date d f or e nr oll me nt a n d 
st u d y  partici pati o n p ur p oses 
Secti o n 1 0. 2 A p pe n di x 2: 
Cli nical La b orat or y  Tests A d de d a m ylase a n d li pase t o 
l o cal cli nical c he mistr y  a nal y t es A m ylase a n d li pase were 
a d de d i n or der t o detect a n y  
p ossi ble cases of 
i m m u ne -me diate d pa ncreatit is 
T hr o u g h o ut pr ot oc ol Mi n or f or m atti n g a n d e dit orial 
c ha n ges Mi n or, t heref ore n ot detaile d C CI 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 4Table of Contents
Protocol Amendment Summary of Changes Table .................................................................. 2
1. Protocol Summary ...................................................................................................... 7
1.1. Synopsis ....................................................................................................................... 7
1.2. Schema ....................................................................................................................... 11
1.3. Schedule of Act ivities (SoA) ...................................................................................... 13
1.3.1. Sampling Schedule for Pharmacokinetics and Biomarkers .......................................... 22
2. Introduction .............................................................................................................. 25
2.1. Study  Rati onale .......................................................................................................... 25
2.2. Backgro und................................................................................................................ 26
2.2.1. LY3475070 ................................................................................................................ 26
2.2.2. Pembrolizumab ........................................................................................................... 27
2.3. Benefit/Risk Assessment ............................................................................................ 27
3.
Objectives and Endpoints ......................................................................................... 29
4. Study Design ............................................................................................................. 33
4.1. Overall Design ............................................................................................................ 33
4.1.1. Dose Escal ation.......................................................................................................... 34
4.1.2. In Vitro Di agnost ic Utilizat ion.................................................................................... 35
4.2. Scientific Rationale for Study  Design ......................................................................... 36
4.3. Justification for Dose .................................................................................................. 36
4.3.1. LY3475070 ................................................................................................................ 36
4.3.2. Pembroliz umab ........................................................................................................... 37
4.4. End of Study  Definit ion.............................................................................................. 38
5. Study Population ...................................................................................................... 39
5.1. Inclusio n Cri teria........................................................................................................ 39
5.2. Exclu sion Criteria....................................................................................................... 43
5.3. Lifest yle Considerat ions............................................................................................. 46
5.4. Screen Failures ........................................................................................................... 46
6. Study Intervention .................................................................................................... 47
6.1. Study  Intervent ion(s) Administered ............................................................................ 47
6.1.1. Definit ion of DLT and DLT -ET.................................................................................. 48
6.1.2. Definit ion of RP2D ..................................................................................................... 50
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 50
6.3. Measures to Minimize Bias:  Rando mizat ion and Blinding ......................................... 50
6.4. Study  Intervent ion Compliance ................................................................................... 50
6.5. Concomitant Therapy .................................................................................................51
6.5.1. Palliat ive Medicine and Supportive Care for LY3475070 ........................................... 52
6.6. Dose Modificat ion...................................................................................................... 53
6.6.1. Dose Modificat ion and Toxi city Management of LY3475070 for 
Non-immune -mediated AEs Associated with LY3475070 and/or 
in Combination wit h Pembro lizumab .......................................................................... 53
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 56.6.2. Dose Modificat ion and Toxi city Management for Immune -
Related AEs Associated with LY3475070 and/or in Co mbinat ion 
with Pembro lizumab ................................................................................................... 62
6.6.3. Other allowed dose interruption for pembrolizumab ................................................... 67
6.7. Intervention after the End of the Study ........................................................................ 67
6.7.1. Treatment after Study  Com pletion.............................................................................. 67
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 68
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 68
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 69
7.2.1. Discontinuati on of  Inadvertent ly Enrolled Patients ..................................................... 69
7.3. Lost to Follow up ....................................................................................................... 70
8. Study Assessments and Procedures ......................................................................... 71
8.1. Efficacy Assessments ................................................................................................
.71
8.1.1. RECIST V1.1 for Tumor Response Assessment .......................................................... 71
8.1.2. iRECIST For Confirmat ion of PD in Clinically  Stable Patients 
and Radio logic PD per RECIST v1.1. ......................................................................... 72
8.1.3. Efficacy Assessment for mCRPC Patients .................................................................. 75
8.2. Safety Assessments .................................................................................................... 75
8.2.1. Clinical Safety  Laboratory  Assessments ..................................................................... 76
8.3. Adverse Events and Serious Adverse Events .............................................................. 78
8.3.1. Time Period and Frequency  for Collect ing AE and SAE 
Inform ation................................................................................................................. 80
8.3.2. Follow-up of  AEs and SAEs ....................................................................................... 81
8.3.3. Regulatory  Reporting Requirements for SAEs ............................................................ 81
8.3.4. Pregnancy ................................................................................................................... 81
8.3.5. Cardi ovascular and Death Events ................................................................................ 81
8.3.6. Com plaint Handling ................................................................................................... 82
8.3.7. Events of Clinical interest ........................................................................................... 82
8.4. Treatment of Overdose ............................................................................................... 82
8.5. Pharmacokinet ics........................................................................................................ 82
8.6. Pharmacodynamics ..................................................................................................... 83
8.7. Genet ics..................................................................................................................... 83
8.7.1. Who le Blood Sample for Pharmacogenet ic Research .................................................. 83
8.8. Biomarkers ................................................................................................................. 84
8.8.1. Tumor Ti ssue Sam ples f or Determinat ion of CD73 Expressio n................................... 86
8.9. Medical Resource Utilizat ion and Healt h Economics .................................................. 86
9. Statistical Considerations ......................................................................................... 87
9.1. Statistical Hypotheses ................................................................................................
.87
9.2. Sample Si ze Determinat ion......................................................................................... 87
9.3. Popul ations for Analyses ............................................................................................ 89
9.4. Statistical Analyses ..................................................................................................... 89
9.4.1. General Statist ical Considerat ions............................................................................... 89
9.4.2. Treatment Group Comparabilit y................................................................................. 89
9.4.3. Efficacy Analyses ....................................................................................................... 90
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 69. 4. 4. S af et y A nal yses .......................................................................................................... 9 2 
9. 4. 5. P har mac o ki net ic/ P har mac o d y na mic A nal yses ............................................................ 9 2 
9. 4. 6. Ot her A nal yses ........................................................................................................... 9 3 
9. 5. I nteri m A nal yses ......................................................................................................... 9 3 
1 0. S u p p orti n g D oc u me nt ati o n a n d O per ati o n al C o nsi der ati o ns ................................ 9 5 
1 0. 1. A p pe n di x 1:  Re g ulat or y , Et hi cal, a n d St u d y  O versi g ht 
C o nsi derati o ns ............................................................................................................ 9 5 
1 0. 1. 1. Re g ulat or y  a n d Et hi cal  C o nsi derat i o ns ........................................................................ 9 5 
1 0. 1. 2. I nf or m e d C o nse nt Pr ocess .......................................................................................... 9 5 
1 0. 1. 3. Data Pr otecti o n ........................................................................................................... 9 6 
1 0. 1. 4. Di sse mi nat i o n of Cli nical St u d y  Data ......................................................................... 9 6 
1 0. 1. 5. Data Q ualit y Ass ura nce .............................................................................................. 9 6 
1 0. 1. 6. S o urce D oc u me nts ...................................................................................................... 9 7 
1 0. 1. 7. St u d y  a n d Si t e Cl os ure ................................................................................................ 9 8 
1 0. 2. A p pe n di x 2:  Cli nical La b orat or y  Tests ....................................................................... 9 9 
1 0. 3. A p pe n di x 3:  C o ntrace pti ve G ui da nce a n d C ollecti o n of 
Pre g na nc y I nf or mati o n ............................................................................................. 1 0 2 
1 0. 4. A p pe n di x 4:  Li ver Safet y:   S u g geste d Acti o ns a n d F oll o w -u p 
Assess me nts ............................................................................................................. 1 0 5 
1 0. 5. ................................................. 1 0 6 
1 0. 6. A p pe n di x 6:  Creati ni ne Cleara nce F or m ula .............................................................. 1 0 8 
1 0. 7. A p pe n di x 7:  C o u ntr y -s pecific Re q uire me nts ............................................................ 1 0 9 
1 0. 7. 1. Di sc o nti n uati o n of  I na d verte nt l y E nr olle d Patie nts i n t he U K ................................... 1 0 9 
1 0. 8. A p pe n di x 8:  D ose -Fi n di n g Al g orit h m of t he M o difie d T o xicit y 
Pr o ba bilit y I nter val -2 Met h o d S h o wi n g N u m ber of Patie nts 
Treate d ..................................................................................................................... 1 1 0 
1 0. 9. A p pe n di x 9:  A b bre viat i o ns ...................................................................................... 1 1 1 
1 0. 1 0. A p pe n di x 1 0:  Pr ot oc ol A me n d me nt Hist or y ............................................................ 1 1 6 
1 1. Refere nces ............................................................................................................... 1 2 0 C CI 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 71. Protocol Summary
1.1. Synopsis
Protocol Title: A Phase 1 Multicenter Gl obal First in Human Study  of the CD73 Inhibitor
LY3475070 as Monotherapy or in Combinat ionwith Pembro lizumab in Pat ientswith Advanced 
Solid Malignancies
Short Title: A Phase 1 Study o f the CD73 Inhibit or LY3475070 in Patients with Advanced 
Solid Malignancies
Rationale :Approximately 50to 80% of advanced cancers patients experience progressive 
disease (PD) as thei r best objective response to immune checkpo int inhibitors (ICIs) such as 
ipilimumab, nivolumab, pembro lizumab or atezolizumab , suggest ing the presence of tumor 
clones that are primarily resistant to ICI monotherapy . In addition, mostpatients whose tumor 
initially responded to ICI eventually  devel op PD, further suggesting thattumor clones can
acqui re resistance in the face of active therapies . 
While immune escape by  cancer i s likely  a mul ti-faceted pheno menon, adenosine signaling 
within the tumor microenvironment has been shown to prom ote immunosuppressio n and cancer 
growth. CD73, an ecto-5′-nucleotidase , catalyzes the conversio n of adenosine m onophosphate to 
adenosine, an immune suppressive metabo lite.  The CD73 -adenosine axis facilitates cancer cell 
immune escape and prom otes resistance to ICIs; therefore , targeting CD73 has the potential to 
beco me a novel cancer t reatment .J2I-MC-JZMA (hereafter known as JZMA) will evaluat e
safet y, tolerabili ty and ant i-tumor activit y of LY3475070 alone or in combinat ion with 
pembro lizumab in advanced cancer patients. 
Objectives and Endpoint s: 
Phase 1a: 
Object ives Endpoints
Primary
To determine a safe dose of 
LY3475070 as monotherapy  and in 
combinat ion treatment with 
pembro lizumab to be further evaluated 
and confirmed in the Phase 1b porti on 
of the study (recommended Phase 1b 
dose)DLTs 
Assessment of safet y including, but not 
limited to, TEAEs, SAEs, deaths, and 
clinical lab abnormalit ies per CTCAE 
v5.0 
Secondary
To characterize the LY3475070 PK 
profile as mo notherapy  and in 
combinat ion with pembrolizumabCmax,trough (C min,Csteady state ), AUC steady
state
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 8Object ives Endpoints
To characterize the clinical act ivity of 
LY3475070 as monotherapy  and in 
combinat ion with pembrolizumab as 
assessed by  the invest igator using 
RECIST v1.1ORR
DCR
PFS 
Abbreviations:  AUC = area under the curve; C max= maximum blood plasma concentration; C min= minimum blood 
plasma concentration; CTCAE = Common Terminology Criteria in Adverse Events; DLT = dose limiting 
toxicities; DCR = disease control rate; ORR = overall response rate; PFS = progression -free survival; PK = 
pharmacokinetics; RECIST = Response Evaluation Criteria in Solid Tumors; SAE = serious adverse event; 
TEAE = treatment -emergent a dverse event .
Phase 1b: 
Object ives Endpoints
Primary
To establish the RP2D of LY3475070 
as monotherapy  and in combination 
treatm ent wi th pembro lizumab
To assess the safet y, tolerabilit yand 
clinical act ivityof LY3475070 as 
monotherapy  and in combinat ion with 
pembro lizumabAssessment of safet y including, but 
not limited to, TEAEs, SAEs, deaths, 
and clinical lab abnormalit ies per 
CTCAE v5.0
Invest igator assessed ORR per 
RECIST v 1.1
Secondary
To characterize the LY3475070 PK 
profile as mo notherapy  and in 
combinat ion with pembrolizumabCmax,trough (C min, Csteady state ), 
AUC steady state
To characterize the clinical act ivity of 
LY3475070 as monotherapy  and in 
combinat ion with pembrolizumab as 
assessed by  the invest igator using 
RECIST v1.1DOR
DCR
TTR
PFS 
OS
Abbreviations:  AUC = area under the curve; C max= maximum blood plasma concentration; C min= minimum blood 
plasma concentration; CD73 = cluster of differentiation 73; CTCAE = Common Terminology Criteria in Adverse 
Events; DCR = disease control rate; DOR = duration of response; NSCLC = non -small cell lung cancer ; ORR = 
overall response rate; OS = overall survival; PD-1/L1 = programmed cell death protein -1/ligand 1; PFS = 
progression -free survival; PK = pharmacokinetics; RECIST = Response Evaluation Criteria in Solid Tumors; 
SAE = serious adverse event; RCC = renal cell carcinoma; RP2D = recommended phase 2 dose; TEAE = 
treatment -emergent adverse event; TTR = time to response .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 9Overall Design :
Study  JZMA is a n open -label ,multi
-center, Phase 1 study  of LY3475070, a CD73 inhibitor,
alone or in combinat ion with pembro lizumab in patients wi th advanced solid tumors.
In Cohort A of Phase 1a, single agent LY3475070 will be e valuated in at least 3 evaluable 
patients per dose level (DL) .Dose escalat ion will be guided by the modified toxicit y probabilit y 
interval  2 (mTPI-2) method.  It is ant icipated that 4 dose l evels will be evaluated to determine the 
recommended phase 1b dose of single agent LY3475070.  Once the dose level DL2 (300 mg 
once a day  [QD]) for single agent LY3475070 has been determined safe and tolerable, 
LY3475070 in co mbination wit h pembro lizumab is planned to be evaluated at 3 dose levels in 
Cohort B , starting at combinat ion dose level 1 (150 mg QD) . 
Phase 1bof the study  aims to confirm the recommended phase 2 dose ( RP2D )for LY3475070 
monotherapy  and LY3475070 in combination wit h pembrolizumab , and to further evaluate 
safet y and preliminary  efficacy in 3patient cohorts: 
Cohort Cwill consist of patients with programmed cell death protein- 1/ligand 1 
(PD-1/L1 )refractory  non-small cell lung cancer , renal cell cancer , ormelanoma who are
positiveforCD73 expressio ncentrally -assessed by immuno -histochemistry .  To 
minimize physician/pat ient selection bias, patients will be randomized to ei ther single 
agent LY3475070 (Cohort C2) or combination therapy  of LY3475070 and 
pembro lizumab (Cohort C1) .
Cohort Dwill consist of men wi th metastati c castrate resi stant pros tate cancer; eligible 
patients m ust be naïve to PD -1/L1 therapy .  To minimize physician/pat ientselectionbias, 
patients will  be randomized to ei ther single agent LY3475070 (Cohort D2) or
combinat ion therapy  of LY3475070 and pembro lizumab (Cohort D1) .
Cohort Ewill con sistof patients with metastati c triple negat ive breast cancer who have
received at least 1 line ofsystemic treatm ent for metastati c disease; pri orPD-1/L1 
inhibitor i s allo wed but not required .Patients will receive co mbinat ion therapy  of 
LY3475070 and pembrolizumab.
Disclosure Statement : This is a treatm entstudy  with dose escalation and dose expansion phases
thathas no blinding or masking.
Number of Participant s:
Dose Escal ation(Phase 1a): Maximum of 62 patients
Monotherapy Cohort (Cohort A) : Approximately  12 to 24 patients will be enro lled.
Combinat ion Cohort (LY3475070 with pembro lizumab ; Cohort B ):Approximately 9 to
18 patients will be enrolled.
Backfill patient s to both Cohort A and Cohort B : up to 20 patien ts.
In the dose e scalat ion phase, once a given DLis cleared for DLT evaluation and is deemed safe, 
the dose cohort may be expanded (i.e., backfilled ) to further invest igate the safet y, 
pharmacokinet ic (PK), pharm acodynamic, and clinical activity.  
Dose expansio n (Phase 1b):  Approximately up to 140patients
Cohort C(patients with CD73+ tumors): up to 50 patients will  be enrolled
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 10Cohort D(castrate resistant prostate cancer): up to 50 patients will be enro lled
Cohort E(triple negat ive breast cancer): up to 40 
patients will be enro lled
Intervention Groups and Duration
Cohort Dose Level Oral LY3475070 IV P embrolizumab
Cohort ADL1 150mg QD N/A
DL2 300mg QD N/A
DL3 600mg QD N/A
DL4 1000mg QD N/A
Cohort BCDL1 150mg QD 200 mg Q3W
CDL2 300mg QD 200 mg Q3W
CDL3 600mg QD 200mg Q3W
Cohorts C1, D1 and E RP1D c RP1D/MTD 200 mg Q3W
Cohorts C2 and D2 RP1D m RP1D/ MTD N/A
Abbreviations:  CDL = combination dose level; DL = dose level; IV = intravenous; MTD = maximum tolerated 
dose; N/A = not applicable; Q3W = every 3 weeks; QD = once a day; RP1D = recommended phase 1 dose; 
RP1D c= recommended phase 1 dose (for combination therapy); RP1D m= recommended phase 2 dose (for 
monotherapy) .
Note :  Pembrolizumab should be administered for a maximum duration of 24 months (35 cy cles).
LY3475070 i s to be administered until PD, unacceptable toxicit y or other cri terion for study 
discontinuat ion is met. In the absence of PD, unacceptable toxicit y or other cri terion for study  
discontinuat ion ismet;pembro lizumab may be administered for a m aximum  durati on of  24 
months (35 cy cles). 
The above table shows the provisio nal dose levels that will be explored ,ranging fro m 150mg to 
1000 mg QD of LY 3475070
. Depending on PK, pharmacodynamic ,and safetydata observed ,
not all the provi sional dose l evels may be explored.  A dose level −1 (DL −1 = 75 m g) may be 
explored if a dose of 150 mg QD (DL1) is not tolerated or if otherwise warranted based on the 
assessment of PK, PD, and safet ydata.  Intermediate and/or hi gher dose l evels as well as 
alternat ive schedules (e.g. ,2 times a day [ BID] dosing instead of QD) may be explored after 
discussio n between Lilly and invest igators if deemed appropriate based on the assessment of 
patient safet y, PK, and PD data.   The total dose of LY3475070 is not pl anned to exceed 1200 mg 
per 24 hours. If BID dosing is evaluated ,patients will take doses 12 ±2 hours apart ( i.e., 10 to 14 
hours between doses ).There should at least be 10 hours between each subsequent dose. 
Data Monitoring Committee:  No
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 111.2. Schema

CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 12Abbreviations: CD73 = cluster of differentiation 73; CDL = combination dose level; DL = dose level; mCRPC = 
metastatic castrate resistant prostate cancer; MTD = maximum tolerated dose; NSCLC = non -
small cell lung 
cancer; PD -1 = programmed cell death -1; PD -1/L1= programmed cell death -1/ligand 1; R = randomization; 
RCC = renal cell carcinoma ; ref = refractory; RP1D = recommended phase 1 dose; TNBC = triple negative 
breast cancer .
aIf supported by data analysis, an additional 20 patients will be added (i.e., backfilled)
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 131.3. Schedule of Activities (SoA)
This sect ion includes the fo llowing SoAs:
 Baseline , 
On-Study  and Post -Study  Treatm entFollow -Up SoA 
 Continued Access SoA
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 14Baseline, On -Study and Post -Study Treatment Follow -up SoA
Baseline Cycle = 21 days Short-Term Follow UpaLong -
Term 
Follow -Upb
(Day Relative to 
C1D1)Cycle 1 Cycle 2Cycle 
3-n801 802 803 804-X Instructions
(±3 days) (±3 days)(±3 
days)30 day 
follow -
up ±5 
days60 day 
follow -
up ±5 
days90 day 
follow -
up ±5 
daysQ90D
≤28 ≤7 D1 D2 D8 D15 D1 D2 D1
Procedure
Informed consent (Main 
and Phase 1b Cohort C 
consent)XMain ICF must be signed before any 
protocol -specific procedures are performed 
and Phase 1b Cohort C ICF prior to tissue 
collection for CD73 testing
Inclusion/exclusion criteria X
Medical history XIncluding assessment of preexisting 
conditions and historical illnesses, and 
habits (such as tobacco and alcohol use).
Cancer treatment history X Record prior anticancer therapy
Concomitant medication X X X X X See Section 6.5
Physical examination X X X X X XCollect weekly during Cycle 1, and then on 
D1 of every cycle thereafter.
A partial physical examination may be 
performed by a healthcare professional other 
than the physician on C1D8 and C1D15.
Vital signs X See Section 1.3.1. X XCollect weekly during Cycle 1, and then on 
D1 of every cycle th ereafter.
Please collect vitals as follows:
-At baseline only :  Height,
-At D1 of every cycle :  Weight, 
-At every schedule visit :  Temperature, 
blood pressure, pulse rate, respiratory rate, 
and pulse oximetry. 
Please refer to Section 1.3.1. for detailed 
collection pertaining to collection on C1D1 -
C3-n (D1) . 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 15Baseline, On -Study and Post -Study Treatment Follow -up SoA
Baseline Cycle = 21 days Short-Term Follow UpaLong -
Term 
Follow -Upb
(Day Relative to 
C1D1)Cycle 1 Cycle 2Cycle 
3-n801 802 803 804-X Instructions
(±3 days) (±3 days)(±3 
days)30 day 
follow -
up ±5 
days60 day 
follow -
up ±5 
days90 day 
follow -
up ±5 
daysQ90D
≤28 ≤7 D1 D2 D8 D15 D1 D2 D1
Procedure
AE collection X XCollect continuously at every visit and 
throughout the study using CTCAE Version 
5.0.  During the 30 -, 60-, and 90 -day follow -
up visits, collect all AEs/SAEs.  Thereafter, 
collect only SAEs related to study treatment 
or protocol procedures
Collection of survival 
informationX Telephone contact is acceptable.
Collection of poststudy -
treatment anticancer 
therapy informationX
ECOG PS X X X X XDuring study treatment, perform ≤3 days 
prior to scheduled visits
ECHO or MUGA X Please perform locally.
ECGSee Section 
1.3.1.See Section 1.3.1.See 
Section 
1.3.1.Please perform locally.
Hematology X X X X X X XSee Appendix 2 .  Please collect weekly
during cycle 1, then Q3W thereafter .  If 
baseline testing is collected ≤3 days prior to 
C1D1, repeat testing is not required.
Coagulation X X X X X X XSee Appendix 2 .  Please collect weekly 
during cycle 1, then Q3W thereafter .  If 
baseline testing is collected ≤3 days prior to 
C1D1, repeat testing is not required.
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 1 6 B aseli ne, O n -St u d y a n d P ost -St u d y Tre at me nt F oll o w -u p S o A 
B aseli ne C ycle = 2 1 d a ys S h ort -Ter m F oll o w U p aL o n g -
Ter m 
F oll o w -U p b
( D a y Rel ati ve t o 
C 1 D 1) C ycle 1 C ycle 2 C ycle 
3- n 8 0 1 8 0 2 8 0 3 8 0 4 - X I nstr ucti o ns 
( ± 3 da ys) ( ± 3 da ys) ( ± 3 
da ys) 3 0 da y 
f oll o w -
u p ± 5 
da ys 6 0 da y 
f oll o w -
u p ± 5 
da ys 9 0 da y 
f oll o w -
u p ± 5 
da ys Q 9 0 D 
≤ 2 8 ≤ 7 D 1  D 2  D 8 D 1 5 D 1  D 2  D 1 
Pr oce d ure 
Cli nical c he mis tr y X X X  X  X X  X Please c ollect wee kl y d uri n g c ycle 1, t he n 
Q 3 W t hereafter .  If baseli ne testi n g is 
c ollecte d ≤ 3 da ys pri or t o C 1 D 1, re peat 
testi n g is n ot re q uire d .  See A p pe n di x 2. 
Uri nal ysis X X X X  X Please c ollect p er S o A .  If baseli ne testi n g is 
c ollecte d ≤ 3 da ys pri or t o C 1 D 1, re peat 
testi n g is n ot re q uire d .  See A p pe n di x 2. 
X X X X  X Please c ollect D 1 of first 3 c ycles .  T h e n 
Q 6 W t hereafter ( e. g., C 5 D 1, C 7 D 1 etc .) .  If 
baseli ne testi n g is c ollecte d ≤ 7 da ys pri or t o 
C 1 D 1, re peat testi n g is n ot re q uire d .  See 
A p pe n di x 2. 
T h yr oi d f u ncti o n testi n g X XSee 
I nstr u 
cti o ns XStarti n g C 3 D 1, t he n D 1 e ver y ot her c ycle .  
If baseli ne testi n g is c ollecte d ≤ 3 da ys pri or 
t o C 1 D 1, re peat testi n g is n ot re q uire d .  See 
A p pe n di x 2. 
T u m or mar kers X See I nstr ucti o ns C ollect t u m or mar kers o nl y f or 
c orres p o n di n g t o ca ncer t y pe: 
P S A -Pr ostate 
F or m C R P C patie nts wit h n o n meas urea ble 
disease ,P S A s h o ul d be c ollecte d e ver y 
3wee ks (f or t he first 1 2 wee ks of t hera p y) 
a n d e val uate d e ver y 9 wee ks f or pr o gressi o n 
after t he first e val uati o n peri o d (at 
1 2 wee ks). See Secti o n  8. 1. 3 a n d 
A p pe n di x 2f or f urt her details. 
C E A - Pa ncreatic 
C A -1 2 5 -O varia n 
C A 1 9 -9 -Pa ncreatic 
F or ot her i n dicati o ns p lease c ollect rele va nt 
t u m or mar kers (e. g., C A 1 9 -9) Q 6 W C CI 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 17Baseline, On -Study and Post -Study Treatment Follow -up SoA
Baseline Cycle = 21 days Short-Term Follow UpaLong -
Term 
Follow -Upb
(Day Relative to 
C1D1)Cycle 1 Cycle 2Cycle 
3-n801 802 803 804-X Instructions
(±3 days) (±3 days)(±3 
days)30 day 
follow -
up ±5 
days60 day 
follow -
up ±5 
days90 day 
follow -
up ±5 
daysQ90D
≤28 ≤7 D1 D2 D8 D15 D1 D2 D1
Procedure
throughout the study (C1D1, C3D1, etc .).  
See Appendix 2.
Pregnancy test X ≤24h See Instructions X X XApplies only to women of childbearing 
potential. See Section 8.3.4. for 
pembrolizumab -specific requirements and 
Appendix 2. Pregnancy test required at 
monthly intervals during study treatmen t in 
both treatment arms and up to 120 days after 
studytreatment discontinuation for patients 
receiving LY3475070 and pembrolizumab 
and at 7 days after study treatment 
discontinuation for patients receiving 
LY3475070 monotherapy per Section 8.3.4.
Tumor assessment -
radiological imagingX See Instructions See InstructionsPerform locally according to RECIST 1.1, 
using the same imaging method (e.g., CT or 
MRI) at each assessment every 9weeks ± 7
days for the first year and every 12 weeks 
(±7 days) thereafter until a discontinuation 
criteria is met . 
Disease progression should be confirmed per 
iRECIST by the site 4 to 8 weeks after site -
assessed first radiologic evidence of PD in 
clinically stable participants. Participants, 
who have unconfirmed disease progression 
may continue on treatment at the discretion 
of the investigator until progression is 
confirmed by the site.
Note:  Imaging must be performed within 28 
days before C1D1 .  See Section 8.1Radionuclide bone scan X See Instructions See Instructions
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 18Baseline, On -Study and Post -Study Treatment Follow -up SoA
Baseline Cycle = 21 days Short-Term Follow UpaLong -
Term 
Follow -Upb
(Day Relative to 
C1D1)Cycle 1 Cycle 2Cycle 
3-n801 802 803 804-X Instructions
(±3 days) (±3 days)(±3 
days)30 day 
follow -
up ±5 
days60 day 
follow -
up ±5 
days90 day 
follow -
up ±5 
daysQ90D
≤28 ≤7 D1 D2 D8 D15 D1 D2 D1
Procedure
Radionuclide bone scans should be 
performed only for patients with mCRPC.   
See Section 8.1.3 .
Tumor assessment -
measurement of palpable 
and/or visible lesionsX See Instructions See Instructions See Section 8.1
Whole blood (PK) See Section 1.3.1. See Section 8.5.
Urine (PK)See 
Sec
tion 
1.3.
1.See Section 8.5.
Serum 
(Pharmacodynamics)See Section 1.3.1. See Section 8. 6.
Whole Blood (PGx) See Section 1.3.1. See Section 8.8.
Plasma See Section 1.3.1.See 
Section 
1.3.1.See Section 8.8.
Serum (Biomarkers) See Section 1.3.1. See Section 8.8.
Whole Blood (CTCs)See 
Section 
1.3.1See Section 1.3.1See
Section 
1.3.1For mCRPC patients only.  Samples to be 
taken every 3 weeks. See Section 8.8.
TissueSee 
Section 
1.3.1See Section 1.3.1. See Section 8.8., 8.8.1.
Patient dosing diary X
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 1 9 B aseli ne, O n -St u d y a n d P ost -St u d y Tre at me nt F oll o w -u p S o A 
B aseli ne C ycle = 2 1 d a ys S h ort -Ter m F oll o w U p aL o n g -
Ter m 
F oll o w -U p b
( D a y Rel ati ve t o 
C 1 D 1) C ycle 1 C ycle 2 C ycle 
3- n 8 0 1 8 0 2 8 0 3 8 0 4 - X I nstr ucti o ns 
( ± 3 da ys) ( ± 3 da ys) ( ± 3 
da ys) 3 0 da y 
f oll o w -
u p ± 5 
da ys 6 0 da y 
f oll o w -
u p ± 5 
da ys 9 0 da y 
f oll o w -
u p ± 5 
da ys Q 9 0 D 
≤ 2 8 ≤ 7 D 1  D 2  D 8 D 1 5 D 1  D 2  D 1 
Pr oce d ure 
A d mi nister L Y 3 4 7 5 0 7 0 X See Secti o n 6. 1 
A d mi nister pe m br oliz u ma b 
(f or patie nts assi g ne d t o 
c o m bi nati o n treat me nt) X X X See Secti o n 6. 1 
A b bre viati o ns: A E = a d verse e ve nt; C A -1 2 5 = ca ncer a nti ge n ; C A 1 9- 9 = car b o h y drate a nti ge n 1 9 - 9 ; C E A = carci n oe m br y o nic a nti ge n ;  
; C T = c o m p ute d t o m o g ra p h y ; C T C = circ ulati n g t u m or cell; C T C A E = C o m m o n Ter mi n ol o g y ;E C G = electr ocar di o gra m; E C H O = 
ec h ocar di o gra m; E C O G P S = Easter n C o o perati ve O nc ol o g y Gr o u p perf or ma nce stat us; I C F = i nf or me d c o nse nt f or m; i R E CI S T = i m m u ne Res p o nse 
E val uati o n Criteria i n S oli d T u m ors ; m C R P C = metastatic castrate -resista nt pr ostate ca ncer; M RI = ma g netic res o na nce i ma gi n g; M U G A = m ulti gate d 
ac q uisiti o n; P D = pr o gressi ve disease; P G x = p har mac o ge netics ; P K = p har mac o ki netics; P S A = pr ostate -s pecific a nti ge n; Q 3 W = e ver y 3 wee ks; Q 6 W = 
e ver y 6 wee ks; Q 9 0 D = e ver y 9 0 da y s; R E CI S T = Res p o nse E val uati o n Criteria i n S oli d T u m ors; S A E = seri o us a d verse e ve nt ; S O A = sc he d ule of acti vities .
aS h ort -ter m f oll o w -u p be gi ns w he n t he patie nt a n d i n vesti gat or a gree t hat t he patie nt will n o l o n ger c o nti n ue st u d y treat me nt. 
bL o n g -ter m f oll o w -u p be gi ns w he n s h ort -ter m f oll o w -u p peri o d is c o m plete d a n d c o nti n ues u ntil deat h, st u d y wit h dra wal, or t he patie nt is l ost t o f oll o w -u p.  I n 
all cases, n o f oll o w -u p pr oce d ures will be pe rf or me d f or a patie nt w h o wit h dra ws i nf or me d c o nse nt u nless he or s he has e x plicitl y pr o vi de d per missi o n a n d 
c o nse nt. C CI 
C CI 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 20Continued Access Schedule of Activities
Continued Access TreatmentContinued Access
Follow -Up Visitsa
InstructionsVisit30-Day 60-Day 90-Day
501-5XX 901 902 903
Procedure
AE collection X X X XPer CTCAE v5.0, for post follow -up, the investigator should only be made aware 
of collected SAEs related to study regimen or protocol procedures.   As part of 
AE collection, monitor vital signs and perform standard laboratory tests 
(hematology, chemistry, urinalysis, and pregnancy testing) at the same frequency 
as during the study treatment period.  All laboratory tests during the continued 
access p eriod will be performed in the local laboratories only. Pregnancy testing 
applies only to women of childbearing potential.  See Section 8.3.4 for 
pembrolizumab -specific requirements and Appendix 3.  Pregnancy test required 
at monthly intervals during study treatment in both treatment arms and up to 120 
days after study treatment discontinuation for patients receiving LY3475070 and 
pembrolizumab and at 7 days after study treatment discontinuation for patients 
receiving LY3475070 monotherapy per Section 8.3.4 and Appendix 3 .
Collect AEs for 30 days following cessation of study treatment and SAEs for 90 
days or 30 days following cessation of study treatment if the participant initiates 
new anticancer treatment, whichever comes first.
Note :  All pregnancies and exposure during breastfeeding must be reported, from 
time of treatment through 120 days following cessation of treatment, or 30 days 
following cessation of treatment.
PK, IG and exploratory hypersensitivity
In the event of hypersensitivity, blood samples will be collected for PK, IG and 
exploratory hypersensitivity analyses at the following time points, as close as 
possible to :  (i) the onset of the hypersensitivity, (ii)the resolution of the 
hypersensitivity, and (iii) 30 [±3] days following the hypersensitivity.  
Exploratory hypersensitivity samples may be analyzed for markers of:
 Tryptase
 ADA and LY 3475070 concentration (PK )
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 21Continued Access Schedule of Activities
Continued Access TreatmentContinued Access
Follow -Up Visitsa
InstructionsVisit30-Day 60-Day 90-Day
501-5XX 901 902 903
Procedure
Administer LY3475070 X See Section 6.1 for Dosing.
Administer pembrolizumab X See Section 6.1 for Dosing.
Abbreviations :  ADA= antidrug antibody; AE = adverse event; IG = immunoglobulin; PK = pharmacokinetics.
aContinued access follow -up begins when the patient and the investigator agree that the patient will no longer continue treatment in the continued acc ess 
period and lasts approximately 90days.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 221.3.1. Sampling Schedule for Pharmacokinetics and Biomarkers
Sampling DayTime 
relative to 
LY3475070 
doseVital SignsdECGWhole 
Blood (PK)Urine (PK)Serum 
(Pharmaco
dynamics)Whole 
Blood 
(PGx)PlasmaSerum ( B io-
markers )Whole 
Blood for 
CTCs –
mCRPC 
Patients 
OnlyTissue
Baseline ≤28 
days prior C1D1X X X Xa
Cycle 1 Day 1 Predose X X X X X X X X
Cycle 1 Day 1 0.5h±5m XcX
XeX
Cycle 1 Day 1 1h±5m XcX X
Cycle 1 Day 1 2h±10m XcX X X
Cycle 1 Day 1 4h±30m XcX X
Cycle 1 Day 1 6h±30m XcX X
Cycle 1 Day 1 8h±30m XcX X
Cycle 1 Day 2 Predose X X X X
Cycle 1 Day 2 1h±5m Xc
Cycle 1 Day 8 Predose X X X X
Cycle 1 Day 15 Predose X X X X X X
Xb
Cycle 2 Day 1 Predose X X X X X
Cycle 2 Day 1 0.5h±5m XcX X
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 23Sampling DayTime 
relative to 
LY3475070 
doseVital SignsdECGWhole 
Blood (PK)Urine (PK)Serum 
(Pharmaco
dynamics)Whole 
Blood 
(PGx)PlasmaSerum ( B io-
markers )Whole 
Blood for 
CTCs –
mCRPC 
Patients 
OnlyTissue
Cycle 2 Day 1 1h±5m XcX X
Cycle 2 Day 1 2h±10m XcX X
Cycle 2 Day 1 4h±30m XcX X
Cycle 2 Day 1 6h±30m XcX X
Cycle 2 Day 1 8h±30m XcX X
Cycle 2 Day 2 Predose X X X
Cycle 3 Day 1 Predose X X X X X X X
Cycle 4 -6 Day 1 Predose X X X X X
Cycle 7 -n Day 1 Predose X X X
At progression X X X Xf
V801 X X X X X Xf
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 24Abbreviations: C1D1 = cycle 1 day 1; CTCs =circulating tumor cells; ECG=electrocardiogram; h = hour; m = min; mCRPC =metastatic castrate resistant 
prostate cancer ; PGx = pharmacogenetics ; PK = pharmacokinetics .
aPhase 1a = optional; Phase1b = mandato ry 
(exception sapply to Cohorts D1 and D2, see section 8.8) fresh biopsy c ollection required following determination 
of eligibility and before initiating study treatment .  This final screening procedure will serve as the pre -treatment sample for biomarker testing (See Sections 
5.1, 8.8,and 8.8.1) .
bPhase 1a = optional; Phase 1b = mandatory  (exception sapply to Cohorts D1 and D2, see section 8.8 ) fresh biopsy collection required on-treatment (see 
Section 8.8) within C1D 15to C2D1 window .
cOnly blood pressure and pulse are required at postdose collections
dVital signs should be taken after at least 5 minutes supine and prio r to any  scheduled blood draws at the same time point.
eUrine output following dose administration, from 0 to 8hours on Cycle 1 Day 1will be pooled for a total collection and sampled for PK and creatinine .
fOptional collection
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 2 5 2. I ntr o d ucti o n 
2. 1. St u d y R ati o n ale 
T he i m m u ne s yste m has de vel o pe d m ult i ple re g ulat or y  m ec ha nis m st o c o ntr ol  f or self -t ol era nce 
a n d li mit tiss ue a n d or ga n da ma ge d uri n g act i ve res p o nses t o pat h o ge ns. T hi s is partl y ac hie ve d 
b y a h ost of i n h i bit or y  rece pt ors e x presse d o n cells of t he i m m u ne s yste m t hat u p o n acti vat i o n 
s u p presses t he i nfla m mat or y  res p o nses of i m m u ne cells. T hese pat h wa ys are referre d t o as 
“i m m u ne c hec k p o i nt s” ( Bra h mer a n d Par d oll 2 0 1 3). Se veral s uc h c hec k p o i nt s ha ve bee n 
i d e nt ifie d o ver t he last deca des, wit h pr o gra m me d cell deat h pr otei n 1 (P D - 1) a n d c y t ot o xi c T -
l y m p h oc y t e -ass oci ate d pr otei n 4 (C T L A - 4 )n o w ha vi n g bee n vali date d as tar gets t o m o d ulate t he 
i m m u ne s yste m t o fi g ht ca ncer. I n a d dit i o n t o t he i n hi bit or y  rece pt or s e x presse d o n t he i m m u ne 
cells, t here are als o s ol u ble li ga n ds a n d meta b o lit es wi t hi n t he t u m or micr oe n vir o n me nt t h at ca n 
tri g ger t he c hec k p oi nt pat h wa y s ( Le o ne et al .2 0 1 5). 
E xtracell ular n ucle oti des s uc h as a de n osi ne -tri p h os p hate ( A T P) pla y  a n i m p orta nt  r ole i n cell 
meta b o lis m a n d bi o l o gical pr ocesses ( D u b ya k a n d El -M oatassi m 1 9 9 3). I n t he e xtracell ular 
s pace, A T P gets c o n verte d t o a de n osi ne m o n o p h os p hate ( A M P) b y  t he ect o - 5’- n ucle oti dase 
C D 3 9. S u bse q ue ntl y, C D 7 3, a d o w nstrea m ect o - 5′- n ucle oti dase, c atal yzes t he c o n versi o n of 
A M P t o a de n osi ne, w hic h acts as a n i m m u ne s u p pressi ve meta b o lit e ( H ore nstei n et al .2 0 1 9).  
A de n osi ne si g nals b y  bi n di n g t hr o u g h f o ur G pr otei n -c o u pl e d rece pt ors, A 1A, A 2 A , A 2 B a n d A 3
( R o be va et al .1 9 9 6).  T he m ost u bi q uit o usl y e x presse d rece pt or s u bt y pe o n i m m u ne cells is A 2 A 
a n d u p o n acti vati o n e xerts a s u p pressi ve effect of t he i nfla m mat or y  i m m u ne res p o nse b y 
m o d ulat i n g C D 4 a n d C D 8 +T- cells a n d d o w nre g ulati n g c yt o ki ne e x pressi o n ( Fis h ma n et al .
2 0 0 9).  T he i m m u ne s u p pressi ve effect of A 2AR acti vat i o n is s o pr of o u n d t hat i n A 2 A R k n oc k o ut 
mice ,tri g geri n g a n i nfla m mat or y  res p o nse b y e xter nal sti m uli has a let hal effect ( O hta a n d 
Si t k o vs k y  2 0 0 1) .  Ot her a de n osi ne rece pt ors, s uc h as A 2 B R a n d A 3rece pt ors, ha ve als o bee n 
s h o w n t o be e x presse d b y  i m m u ne cells ( Le o ne a n d E m e ns 2 0 1 8; Va n Der P utte n et al . 2 0 1 9 ), 
s u g gest i n g a de n osi ne ca n si g nal t hr o u g h differe nt rece pt or s u bt y pes t hat ha ve differe nt bi n di n g 
affi nit y t o war ds a de n osi ne as well as dist i nct d o w nstrea m effects , res ul ti n g i n c o nte xt de pe n de nt 
i m m u ne -m o d ul at i o n. D ue t o t he c o m ple xit y a n d t he differe nt e x pressi o n of a de n osi ne rece pt ors 
o n t he vari o us i m m u ne cells, a n d t he vari o us affi nit y  a de n osi ne rece pt ors ha ve t o its li ga n d, 
l o weri n g a de n osi ne c o nce ntrati o ns wi t hi n t he t u m or micr oe n vir o n me nt ( T M E) b y tar geti n g t he 
ect o -e nz y mes ma y be a better strate g y t ha n tar geti n g s pecific a de n osi ne rece pt or s u bt y p e s.  
Im m u ne c hec k p o i nt  i n hi bit ors (I CI) ha ve yiel de d si g nifica nt i m pr o ve me nts i n t u m or res p o nse 
rates, d urati o n of t u m or res p o nses a n d o verall s ur v i va l i n m ult i p le a d va nce d ca ncer se tti n gs s uc h 
as me la n o ma, re nal cell carci n o ma, a n d n o n -s mall cell l u n g ca ncer (F u k u m ur a et al .2 0 1 8 ).  
H o we ver, des pite t h e o bser ve d efficac y  wi t h  I CIs, de pe n di n g u p o n t he t u m or t y pe, 5 0 t o 8 0 % of  
a d va nce d ca ncer patie nts will e x perie nce disease pr o gressi o n w hile recei vi n g I CI treat me nt or 
wi t hi n 3 t o 6 m o nt hs of treat me nt c o m plet i o n. T his varia bilit y ma y be d ue t o varia bilit y i n t he 
T M E t h at ca n s u p press T cell act i vat i o n, necessitati n g n o vel  c o m bi nat i o ntreat m e nt a p pr oac hes 
t o o verc o me resista nce t h at de vel o ps t o I CI treat me nt ( O’ D o n nell 2 0 1 6 ; F u k u m ura et al . 2 0 1 8 ). C CI C CI 
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 2 6 Se veral A 2AR i n hi bit ors, s o me of  w hic h ha vi n g bee n e val uate d i n l ar ge P hase 3 tri als f o r 
ne ur o de ge nerat i ve diseases , h a ve rece ntl y e ntere d t h e cli nic ,e val uat i n g t h ei r utili t y  i n tr e ati n g 
pa ti e nts wi t h  a d va nce d s o li d ma li g na ncies ( Le o ne a n d E me ns 2 0 1 8). C PI -4 4 4, a n a nta g o nist of 
A2 A R, has s h o w n res p o nses as a si n gle a ge nt a n d i n c o m bi nati o n wit h atez oliz u ma b i n pat ie nt s 
wi t h  m etastati c n o n- s mall cell l u n g ca ncer ( N S C L C )a n d metastatic re nal cell  carci n o ma (R C C )
( F o n g et al . 2 0 1 7).  Pat ie nt st h at ha d bee n o n a pr o gra m me d cell deat h pr otei n -1/li ga n d 1 ( P D -
1/ L 1 )f o r a pr ol o n ge d d urati o n pri or t o st u d y  e ntr y  s h o we d e vi de nce of ele vate d A 2AR a n d C D 7 3 
e x pressi o n, s u g gest i n g t h e a de n osi ne pat h wa y  m ay pla y  a r ol e i n ac q ui re d resista nce t o P D - 1 / L 1 
treat m e nt ( H ots o n et al. 2 0 1 7).   Rece nt p u blis he d data fr o m a n o n g oi n g P hase 1 tri al  e val uati n g 
t h e A 2 A R a nta g o nist A Z D 4 6 3 5 as si n gle a ge nt or i n c o m bi nati o n wit h t h e P D - 1/ L 1 tar gete d 
a nt i b o d y  d ur val u ma b, has s h o w n ra di o l o gi cal res p o nses i n metastatic castrate resista nt pr ostate 
pati e nts, a n i n dicat i o n t hat has n ot ge nerall y bee n res p o nsi ve t o a nti -P D - 1 / L 1 treat me nt al o ne 
(De B o n o et al. 2 0 1 8 ; Be n dell et al ., 2 0 1 9).   A d diti o nall y, C D 7 3 u pre g ulat i o n has als o bee n 
d e m o nstrate d i n t u m ors wi t h  o nc o ge ni c dri ver m ut ati o ns s uc h as e pi der mal gr o wt h fact or 
rece pt or m utati o n ( E G F R m )N S C L C, a n d ma y  e x plai n t he li mite d res p o nse pat ie nt s wi t h  
E G F R m ha ve t o I CI treat me nt ( Strei c her et al . 2 0 1 7; Hi g gs et al . 2 0 1 8 ). 
Gi ve n t he r ole t he a de n osi ne bala nce pla ys i n t he i m m u ne s yste m, t he c urre nt st u d y ,J 2I -M C -
J Z M A (J Z M A), will e val uate safet y,  t olera bilit y a n d a nti -t u m or c o ntr ol  of  C D 7 3 i n hi bit or 
L Y 3 4 7 5 0 7 0 (a d mi nistere d as m o n ot hera p y  or i n c o m bi nat i o n wi th pe m br oliz u ma b )i n a d va nce d 
ca ncer patie nts wit h mali g na ncies tra dit i o nall y  u nres p o nsi ve t o si n gle a ge nt I CI treat me nt.   
2. 2. B ac k gr o u n d 
2. 2. 1. L Y 3 4 7 5 0 7 0 
L Y 3 4 7 5 0 7 0 is a n orall y bi oa vaila ble u nc o m pet it i ve , p ote nt, a n d select i ve i n hi bit or of C D 7 3 wi t h  
cl eara nce t hat a p pears relate d t o meta b o lis m b y .  T he m o d e of  acti o n is b y 
bi n di n g t o t he e nz y me -p h os p hate c o m ple x of  C D 7 3 .  I n precli nical m o dels , L Y 3 4 7 5 0 7 0 has 
d e m o nstrate d r o b ust resc ue of a de n osi ne -me diate d s u p pressi o n of T -cell pr o liferat i o n a n d 
c y t o ki ne secret i o n, c orrel ate d wit h a re d ucti o n i n a de n osi ne l e vels u n der e x peri me ntal c o n di ti o n s 
w here A M P/a de n osi ne le vels are hi g h . A n i m m u ne -s u p pressi ve T M E is ofte n c haracteri ze d b y  
si g nifica nt l y ele vate d le vels of a de n osi ne, li kel y li mit i n g t he cli nical ut ilit y of  c o m p eti ti ve 
i n hi bit ors of C D 7 3 a n d a de n osi ne rece pt or a nta g o nists. O wi n g t o its dist i nct u nc o m pet it i ve 
mec ha nis m o f acti o n ( M O A) , it  is a nt ic i pate d t h at L Y 3 4 7 5 0 7 0 ma y d e m o n str at e mor e c o m plete 
tar get i n hi bit i o na n d s u p pressi o n of i m m u ne -s u p pressi ve a de n osi ner gic si g nali n g . 
T he p har mac o l o gi cal pr o perti es of  L Y 3 4 7 5 0 7 0 were c haracterize d b ot h i n vi v o a n d i n vitr o i n 
n o ncli nical p har mac o l o g y  st u di es, a n d ca n be s u m marize d as f o ll o ws: 
It i s o rall y bi oa vaila ble 
It s h o ws r o b ust tar get i n hi bit i o n e x vi v o i n w h o le bl o o d a n d i n t u m or s m o d el swi t h  a 
well -defi ne d p har mac o ki net ic ( P K )/ p har mac o d y na mic relat i o ns hi p
It d e m o nstrate sa n acce pta ble t o xic o l o g y  pr ofile i n 1 -m o nt h r at a n d d o g re peat d o se 
t o xi c o l o g y  st u di es (see Sect i o n 2. 3 of cli nical pr ot oc ol a n d Secti o n 4. 2. 1 of I B) 
T he pr oj ecte d h u ma n efficaci o us d ose ( 1 4 8 m g o nce a da y  [ Q D ]) a n d hi g h Ma xi m u m 
A bs or ba ble D ose ( 8 6 0 m g) pr oj ect i o ns all o w greater d osi n g fle xi bilit y i n cli nic C CI 
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 2 7 A d dit i o nal i nf or mati o n ma y  b e f o u n d i n t he I B f or L Y 3 4 7 5 0 7 0 .
2. 2. 2. Pe m br oliz u m a b 
Pe m br oliz u ma b is p ote nt h u ma nize d i m m u n o gl o b uli n G 4 (I g G 4) m o n ocl o nal  a nt i b o d y  ( m A b)  
wi t h  h i g h s pecificit y of  b i n di n g t o t h e pr o gra m me d cell deat h 1 ( P D -1) rece pt or, t h us i n hi bit i n g 
it s i nt eracti o n wi t h  pr o gra m me d cell deat h li ga n d 1 ( P D -L 1) a n d pr o gra m me d cell deat h li ga n d 2 
( P D -L 2) .  Base d o n precli nical i n vitr o data, pe m br oliz u ma b has hi g h affi nit y a n d p ote nt rece pt or 
bl oc ki n g acti vit y f o r P D - 1 .  Pe m br ol iz u ma b has a n acce pta ble precli nical safet y pr ofile a n d is i n 
cli nical de vel o p m e nt as a n i nt ra ve n o us (I V) i m m u n ot hera p y  f or a d va nce d mali g na ncies .  
Ke ytr u da ®(pe m br o liz u ma b ) is i n dicate d f o r t h e treat m e nt of  p ati e nts acr oss a n u m ber of 
i n dicat i o ns .  F or m o re details o n s pecific i n dicati o ns refer t o t he I n vest i gat or’s a Br oc h ure. 
Refer t o t h e I n vest i gat or’s Br oc h ure (I B)/a p pr o ve d la beli n g f o r detaile d bac k gr o u n d i nf or mat i o n 
o n M K - 3 4 7 5 ( Pe m br oliz u ma b) .
T hera pe ut ic st u dies i n m o use m o dels ha ve s h o w n t hat a d mi nistrati o n o f a nt i b o dies bl oc ki n g P D -
1/ P D -L 1 i nteracti o n e n ha nces i nfiltrati o n of t u m or -s pecific C D 8 + T cells a n d ult i matel y lea ds t o 
t u m or r ej ect i o n, ei t h er as a m o n ot hera p y  or i n c o m bi nat i o n wi t h  ot her treat me nt m o dalit ies 
( Str o m e et al . 2 0 0 3; Bla n k et al. 2 0 0 4; Hira n o 2 0 0 5; C urra n 2 0 1 0; Pil o n et al . 2 0 1 0; We ber 2 0 1 0; 
S pra n ger 2 0 1 4) .  A nt i- m o use P D -1 or a nti -m o use P D -L 1 a nt i b o dies ha ve de m o nstrate d 
a nt it u m or res p o nses i n m o dels o f s q ua m o us cell carci n o m a, pa ncreat ic carci n o ma, m ela n o ma, 
ac ute m yel o i d l e u ke mia a n d c ol orectal  carci n o ma ( Str o m e et al . 2 0 0 3; Z ha n g et al. 2 0 0 4; N o mi 
et al . 2 0 0 7; C urra n et al. 2 0 1 0; Pil o n et al . 2 0 1 0) .  I n s uc h st u dies, t u m or i nfiltrati o n b y C D 8 + T 
cells a n d i ncrease d I F N -γ, gra nz y me B a n d perf ori n e x pressi o n were o bser ve d, i n dicat i n g t hat 
t h e mec ha nis m u n derl yi n g t he a ntit u m or acti vit y of P D -1 c hec k p o i nt  i n hi bit i o n i n v o l ve d l ocal 
i nfiltrat i o n a n d act i vat i o n of effect or T cell f u nct i o n i n vi v o ( C urra n 2 0 1 0) . E x peri me nts ha ve 
c o nfir me d t he i n vi v o efficac y o f a nt i- m o use P D -1 a nti b o d y  as a m o n ot hera p y , as well as i n 
c o m bi nat i o n wi t h  c he m ot h era p y , i n s y n ge neic m o us e t u m or m o d el s (see t he I B). 
2. 3. Be nefit / Ris k Assess me nt 
L Y 3 4 7 5 0 7 0 was e val uate d i n 1 -m o nt h dail y  or al -d osi n g t o xi c o l o g y st u dies i n S pra g ue- Da wle y  
rats a n d Bea gle d o gs .  Safet y p har mac o l o g y  para meters were e val uate d i n vitr o ( h u ma n et her á -
g o- g o –relate d ge ne) a n d as part of t he re peat -d ose t o xicit y st u d y  i n d o gs.  Ge net ic t o xicit y was 
e val uate d i n a bacterial m utati o n ( A mes ) assa y , a n i n vitr o micr o n ucle us ( M N) assa y a n d a n i n 
vi v o rat M N assa y .  Base d o n n o ncli nical st u d y  f i n di n gs, p ote ntial t o xicit ies i ncl u de  
 All n o ncli nical t o xic ol o g y  fi n di n gs i n rats a n d d o gs were 
re versi ble after a 1 -m o nt h rec o ver y  p eri o d.  
T he e x perie nce s o far wit h ot her A 2 A R a nta g o ni sts a n d C D 7 3 i n hi bit ors i n cli nic s u g gest 
treat m e nt t o be we ll t olerate d ( Ha user et al. 2 0 1 4; F o n g et al. 2 0 1 7 ; H ots o n et al . 2 0 1 7 ;C hia p p ori  
et al . 2 0 1 8; S ui  et al . 2 0 1 8; Be n dell et al . 2 0 1 9 ; L u ke et al 2 0 1 9). T he ma i n t o xicit ie s t hat ha ve 
e m er ge d ha ve bee n m ai nl y gastr o -i nt est i nal ( na usea, v o mit i n g, di arr hea), n e ur ol o gi cal  
( hea dac he, dizzi ness, s o m n o le nce, i ns o m nia), a n d c o nstit uti o nal ( wei g ht l oss, fat i g ue). P ossi ble C CI 
C CI C CI 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 28immune related adverse events (irAEs) , such as pruri tis, pneumo nitis, rash, hypothy roidism  and 
hepat itis have also been reported. Based on these reports and the preclinical safet y of 
LY3475070 ,GI-related events such as vo miting, nausea and fat igue may be expected. Due to 
the immune st imulatory  mechanism  of action, irAEs such as rash, colit is, and hypothy roidism  
may also be experienced. In com bination treatm ent wi th other checkpoint inhibitors, there may  
be potenti al for increased incidence of irAEs.  More informat ion about the known and expected 
benefits, risks, serious adverse events (SAEs) and reasonably anticipated adverse events (AEs) of 
LY34 75070 may be found in the IB.
More detailed informat ion about the known and expected benefits and risks of pembro lizumab 
may be found in the locally approved product label .
Pembrolizumab is a PD -1 blocking ant
ibody  with global regulatory  approvals in sever al 
indicat ions (pembro lizumab USPI).  The ri sk profile of pembro lizumab is well characterized, and 
the management of irAEs associated with pembro lizumab is part of nat ional guidelines and 
clearly  described in this protocol.
Secti on 2.1 provi des the rati onale for the expected benefit, supporting the invest igation of
LY34 75070 in co mbination wit h pembro lizumab. Preclinical and clinical data suggest that 
adenosine mediated signaling may be invo lved in mediat ing resistance to inhibit ionof PD-1/L1
signaling . Therefore, combining the CD73 inhibit or LY3475070 with PD
-1/L1 blockade is 
hypothesized to increase efficacy in settings where adenosine mediated immune -suppressio n 
may limit clinical responses seen with PD -1/L1blockade . Agents targeting the purinergic 
pathway , such as A 2ARantagonists or CD73 monoclonal ant ibodies, ha venot shown incidence 
of irAEs to the sam e degree as PD-1 or CTLA -4 inhibitors. However, acombinat ion of 2 agents 
targeting the immune system has the possibilit y to induce more frequent irAEs than each agent 
alone. Although it is not possible to extrapolate findings fro m other studi es that ha vecombined 
2 checkpo int inhibitors to the combinat ion of LY3475070 and pembro lizumab, the treatment 
protocol  will provide clear dose m odificat ions for irAEs to mit igate for possible irAEs.  Given 
limited treatment options for the targeted patient populat ion, and well established protocols for 
the management of irAEs, the risk remains acceptable. 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 293. Objectives and Endpoints
Phase 1a: 
Object ives Endpoints
Primary
To determine a safe dose of 
LY3475070 as monotherapy  and in 
combinat ion treatment with 
pembro lizumab to be further evaluated 
and confirmed in Phase 1b porti on of  
the study (recommended Phase 1b 
dose)DLTs 
Assessment of safet y including, but not 
limited to, TEAEs, SAEs, deaths, and 
clinical lab abnormalit ies per CTCAE 
v5.0 
Secondary
To characterize the LY3475070 PK 
profile as mo notherapy  and in 
combinat ion with pembrolizumabCmax,trough (C min,Csteady state), AUC steady 
state
To characterize the clinical act ivity of 
LY3475070 as monotherapy  and in 
combinat ion with pembrolizumab as 
assessed by  the invest igator using 
RECIST v1.1ORR
DCR
PFS 
Terti ary/Exploratory
To evaluate target occupancy of 
LY3475070 Percentage of target inhibit ion of 
adenosine in peripheral serum
To assess the relat ionship between 
biomarkers, dose/exposure, and clinical 
outcom esResults of bio marker assessments
Clinical outcomes data
To characterize the anti -tumor activit y, 
as determined by  the invest igator, of 
LY3475070 in co mbination wit h 
pembro lizumab in subjects with 
indicated tum or types based on 
iRECIST criteria iORR
iPFS
iDCR
To estimate the renal clearance of 
LY3475070 and conduct exploratory  
metabo lite identificat ion on blood and 
urine samples.Metabo lite profiling 
Renal clearance
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 30Abbrev iations: AUC = area under the curve; Cmax= maximum blood plasma concentration; Cmin= minimum blood 
plasma concentration; CTCAE = Common Terminology Criteria in Adverse Events; DLT = dose limiting 
toxicities; DCR = disease control rate; iDCR = immune disease control rate ; iORR = immune overall response 
rate; i PFS = immune pr
ogression -free survival ; iRECIST = immune Response Evaluatio n Criteria in Solid 
Tumo rs; ORR = overall response rate ; PFS = progression -free survival; PK = pharmacokinetics; RECIST = 
Response Evaluation Criteria in Solid Tumors; SAE = serious adverse event; TEAE = treatment -emergent 
adverse event .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 31Phase 1b: 
Object ives Endpoints
Primary
To establish the RP2D of LY3475070 
as monotherapy  and in combination 
treatm ent wi th pembro lizumab
To assess the safet y, tolerabilit y and 
clinical act ivityof LY3475070 as 
monotherapy  and in combinat ion with 
pembro lizumabAssessment of safet y including, but not 
limited to, TEAEs, SAEs, deaths, and 
clinical lab abnormalit ies per CTCAE 
v5.0
Invest igator assessed ORR per RECIST 
v 1.1
Secondary
To characterize the LY3475070 PK 
profile as mo notherapy  and in 
combinat ion with pembrolizumabCmax,trough ( Cmin, Csteady state ), AUC steady 
state
To characterize the clinical act ivity of 
LY3475070 as monotherapy  and in 
combinat ion with pembrolizumab as 
assessed by  the invest igator using 
RECIST v1.1DOR
DCR
TTR
PFS 
OS
Terti ary/Expl oratory
To assess the relat ionship between 
biomarkers, dose/exposure, and clinical 
outcom esResults of bio marker assessments
Clinical outcomes data
To characterize the immune mediated 
anti-tumor activi ty of LY3475070 as 
monotherapy  or in co mbinat ion with 
pembro lizumab based on iRECIST 
criteriaiORR
iPFS
iDOR
iDCR
To evaluate the relationship between 
anti-tumor activi ty of LY3475070, as 
monotherapy  and in combinat ion with 
pembro lizumab , and bio markers 
predi cting efficacy and resistance in 
obtained tumor tissues or blood samplesResults of bio marker analyses
Clinical outcom es
To evaluate target occupancy of 
LY3475070Percentage of target inhibit ion of 
adenosine in peripheral serum
To estimate the renal clearance of 
LY3475070 and conduct exploratory  Metabo lite profiling 
Renal clearance
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 32metabo lite identificat ion on blood and 
urine samples.
Abbreviations:  AUC = area under the curve; C max= maximum blood plasma concentration; C min= minimum blood 
plasma concentration; CD73 = cluster of differentiation 73;CTCAE = Common Terminology Criteria in Adverse 
Events; DCR = disease control rate; DOR = duration of response; iDCR = immune disease control rate; iDOR = 
immune duration of response; iORR = immune overall response rate; iPFS = immune progression -free survival; 
iRECIST = immune Response Evaluation Criteria in S olid Tumors; NSCLC = non -small cell lung cancer ; ORR 
= overall response rate; OS = overall survival; PD-1/L1 = programmed cell death protein -1/ligand 1; PFS = 
progression -free survival; PK = pharmacokinetics; RECIST = Response Evaluation Criteria in Solid Tumors;  
RP2D = recommended phase 2 dose; SAE = serious adverse event; RCC = renal cell carcinoma; RP2D = 
recommended phase 2 dose; TEAE = treatment -emergent adverse event; TTR = time to response
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 334. Study Design
4.1. Overall Design
Study  JZMA is an open -label, multicenter, gl obal, 2-part Phase 1 study of LY3475070 alo ne or 
in combinat ion with pembro lizumab in advanced cancer patients. 
Phase 1a of the study  will target the fo llowing tumor ty pes: triple negat ive breast cancer, 
pancreat ic cancer, PD -1 refractory NSCLC, PD -1 refractory  RCC, PD -1 refractory  melano ma, 
metastati c castrate resistant prostate cancer ( mCRP C
)and ovarian cancer .  In Cohort A in 
Phase 1a, escalat ing doses of single agent LY3475070 will be evaluated in at least 3 evaluable 
patients per dos e level (i.e., DLA1-A4, see Schema in Section  1.2). However, based on the 
observed PK, pharmacodynamic ,and safet y data observed, not all provisio naldose levels may be 
explored . Interm ediate and/or hi gher dose as well as alternat ive schedu les of administration 
(BID dosing) will be explored if deemed necessary after discussio n between Lilly  and 
investigators .The dose limit ing toxicit y (DLT )observat ion peri od will  be 28days. The first 
patient of  each DLwill be observed for 48 hours before addit ional pat ients are enrolled to that 
DL.The totalit y of safet y data will be reviewed by  the Lilly clinical research physician /clinical 
research scientist (CRP /CRS )and study invest igators prior to escalat ing to a next DL. 
Intrapatient dose escalat ion is not allowed. In the dose escalat ion phase, o nce a given DL is 
cleared for DLT evaluation and is deemed safe, the dose cohort may  be expanded (i .e., 
backfilled) to a m aximum  of 20 pati ents to further investigate the safet y, PK,pharmacodynamic,
and clinical activit y.  Enrollment of patients to the dose cohort for DLT evaluat ion/dose 
escalat ion will take precedent.   To ensure that patients are not unnecessarily enrolled to 
subtherapeutic dose levels, these backfills will not b e undertaken unt il a DL al ready declared 
safe also demonstrates evidence of therapeutic exposures.  However, continuous safet y 
monitoring (Section 9.2) will be implemented to ensure ongo ing evaluation o f patient safet y in 
backfill pat ients. In the event that backfill enro llment/escalat ion is paused, the aggregated safet y 
data will be evaluated to determine if the dose level in quest ion (and higher dose l evels) shoul d 
be permanent ly discontinued. In general, all available toxicit y and PK data will be utilized, 
including DLT equivalents observed from backfill patients, to recommend an escalat ion/de-
escalat ion decisio n, and to inform the select ion of the RP2D.
It is ant icipated that a minimum of 4DLs will  be evaluated in Cohort A to determine the MTD of 
single agent LY3475070, or, in the absence of MTD, a recommended Phase 1b dose of single 
agent LY3475070. The MTD will be the dose for which the est imated toxicit y rate i s the cl osest 
to the target toxicit y rate of  30% and less than 35% .  The recommended Phase 2 dose (RP2D ) to 
be formally established in Phase 1b part of the study will be based upon the totalit y of safety , PK 
and pharmacodynamic data, and thus may be lower than the MTD or the recommended Phase 1b 
dose i dentified in the Phase 1a part of the study . 
Once the DLA2 (300 m g QD) for single agent LY3475070 is determined safe and tolerable, 
LY3475070 in co mbination wit h pembro lizumab isplanned to be evaluated in Cohort B starting 
at combination DL1 (150mg QD LY3475070 and pembro lizumab) and escalated , independent ly 
from ongoing m onotherapy  dose escalation, to the recommended Phase 1b dose or MTD of 
LY3475070 single agent.  At the first dose l evel, there will be at least a 48-hour delay between 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 34dosing the first patient and additional pat ients.  
There will be no dose escalat ions for 
pembro lizumab, which will be given at 200 mg every  3 weeks ( Q3W ). The dose given in the 
dose escalat ion inCohort B should not exceed the maximum dose shown to be safe in Cohort A.
In Phase1b of the study , the recommended phase 1 dose (RP1D) or MTD, as determined in the 
Phase 1a part, of LY3475070 alone or in combinatio n with pembro lizumab will be evaluated in
3distinct cohorts :  Cohorts C, D, and E.  The RP2D will be determined at the end of the Phase 
1b part of the study  based on the totalit y of data.
Cohort Cwill consist of pat ients that have been treated with and are refractory  to PD-1/L1
inhibitor treatment with the following malignancies: NSCLC, RCC or melano ma. To be 
eligible, Cohort Cwill consist of patients with NSCLC, RCC, or melano ma that progressed on 
anti-PD1- L1 inhibitor therapy .Exception for prior anti-PD-1/L1 requi rement will be given for 
NSCLC pat ients withEGFR activating mutations, as these patients do not respond to PD-1/L1 
directed therapy , which may be due tohigh CD73 expressio n (Higgs et al . 2017; Streicher et al. 
2017).   In addit ion, patientsmust undergo a pretreatment b iopsy and be positive forCD73 
expressio n by central immunohistochemistry ( IHC)testing.
Cohort Dwill consist of men with mCRPC ; eligible pat ients must be PD-1/L1 inhibitor naïve. 
To minimize physician/pat ient biasand to prom otebalanced pat ient chara cteristics between 
treatm ents, pati ents in Cohorts C and Dwill be randomized to either single agent LY3475070 or 
LY3475070 and pembrolizumab.
Cohort Ewill consist of patients with previously treat edmetastatic triple negat ive breast cancer 
(mTNBC) who will re ceive LY3475070 and pembrolizumab. Patients must have received at 
least one prior cy totoxi c regimen .  Pri or anti  PD-1/L1 treatm ent is not a requirement. 
4.1.1. Dose Escalation
Dose escalat ion of LY3475070 will be driven by the modified toxicit y probabil ity interval -2 
(mTPI-2)method (Guo et al. 2017) where a pre -calculated decisio n table (Appendix 8) will 
guide the dose recommendat ions unt il the MTD is determined (e.g., when all planned patients 
have been tested, or when no higher candidate DLcan be tes ted). Dose escalation decisio n will 
also takeinto consideration available PK and pharmacodynamic data fro m previous DLs.  
Although mTPI -2 allows flexible number of patients in each dosing cohort, a minimum o f 3 
evaluable pat ients are required for the DLT evaluatio n at each DL.  
The first patient of each DL
(in Phase 1a) will be observed for 48 hours before addit ional pati ents are enrolled to that DL.  
Intrapatient dose escalat ion is not allowed.
Like the 3+3 desi gn, the m TPI-2method incorporates prespecified escalat ion rules.  In contrast, 
the mTPI-2method is based on quant itative models that incorporate uncertainty into the decisio n 
rules, thereby allowing more precise RP2D select ion.  If 3 or 6 patients are enrolled in a cohort, 
the escalation rule parallels a tradit ional 3+3 design. However, it a llows flexible number of 
patients in a cohort. For e xample , with 2 DLTs per 6 pati ents enrolled, the mTPI -2would 
recommend staying at the current dose, as analogy to 1 DLT per 3 patients enrolled in 3+3 
design; therefore, it allows more patients for a mo re preci se est imate of the DLT rate at this DL.
Following a discussio n between the Lilly CRP/CRS and the invest igators, a more conservative 
dose sel ectionmay be applied to the next cohort (for instance, if PK/ pharmacodynamics data 
suggest that further dos e increas e woul d not beexpected to yield addit ional benefit).  For 
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 3 5 e xa m ple , if  t he r ule i n dicates “ E” t o escalate, t he d ose ma y st a y at t he c urre nt D L ,be de -
escalate d t o a l o wer le vel , or escalat i o n ma y cease .  I n t he m T PI - 2 , t he c o h ort size is n ot fi xe d.  
H o we ver, eac h D L i n t his st u d y  will be teste d wit h a mi ni m u m o f 3 e val ua ble pat ie nt s, u nless t he 
escalat i o n r ul es di ctate t hat t he d ose s h o ul d be de -escalate d ( “ D” or “ D U”).  D oses ca n be 
escalate d, de -escalate d, a n d re -escalate d . If t h e d ose deci si o n  was “ D U,” t he d ose ca n n ot be re -
escalate d t o t hat le vel. 
T his st u d y  i s desi g ne d t o i de ntif y a D L wi t h  a d ose -li mit i n g tar get t o xicit y rate of 3 0 %.  T he 
m T PI -2 m et h o d c o nsi ders a n e q ui vale nce i nter val ( EI) ar o u n d t he tar get t o xicit y rate.  F or t hi s 
st u d y, t he EI is elicit e d t o be ( 2 5 %, 3 5 %), res ult i n g i n t he r ules bel o w. 
S af et y data, i n partic ular D L T s, will be t he pri mar y criteria f or t he d ose escalat i o n.  I n a d di ti o n, 
if a vaila ble at t he ti me of d ose escalat i o n decisi o n, P K /p har mac o d y na mics res ul ts (f or e xa m ple, 
Cma x, area u n der t he c o nce ntrati o n c ur ve (A U C ), p har mac o d y na mics res ults) will be use d as 
sec o n dar y/s u p p or ti n g data f or d ose escalati o n. 
I nter m e diate a n d/ or hi g her d ose as well as alter nat i ve sc he d ules of a d mi nistrati o n will be 
e x pl ore d if dee m e d necessar y  af ter disc ussi o n  bet wee n Lill y a n d i n vest i gat ors a n d ta ki n g i nt o 
acc o u nt patie nt safet y a n d P K/ p har mac o d y na mics data.   If nee de d, a d dit i o nal patie nts ma y  b e 
e nr o lle d t o f urt her assess P K/ p har mac o d y na mics or t ol era bili t y .
I n or der t o be D L T -e val ua ble , patie nts m ust ha ve recei ve d 7 5 % of L Y 3 4 7 5 0 7 0 sc he d ule d d ose 
wi t hi n t he 2 8 -d a y  D L T p eri o d u nl ess patie nts ha ve a D L T q ualif yi n g e ve nt. F o r pati e nts treate d 
wi t h  t he c o m bi nat i o n treat me nt, patie nts m ust ha ve recei ve d 7 5 % of L Y 3 4 7 5 0 7 0 a n d a mi ni m u m 
of  1 pe m br oliz u ma b i nf usi o n wi t hi n t he 2 8 -d a y  D L T peri o d. 
I n t he d ose escalat i o n p hase , o nce a gi ve n D L is cleare d f or D L T e val uati o n a n d is dee me d safe, 
t h e d ose c o h ort ma y be e x pa n de d t o f urt her i n vesti gate t he safet y,  P K , p har mac o d y na mic , a n d 
cli nical act i vit y of  L Y 3 4 7 5 0 7 0 a n d t he c o m bi nati o n wit h pe m br oliz u ma b .T here will be u p t o 
2 0 bac kfill pat ie nt s e nr olle d acr oss all d ose le vels i n c o h ort sA a n d B c o m bi ne d i n t h e p hase 1a 
st u d y .A n y  A Es re p orte d b y  t h ose bac kfille d pat ie nt s t hat meet t he D L T cri t eri a as defi ne d i n 
Secti o n  6. 1. 1. 1 a n d occ ur i n t h eD L T peri o d are c o nsi dere d D L T -e q ui vale nt t o xicit ies 
( Secti o n 6. 1. 1. 2 ).  T he c u m ulat i ve safet y data fr o m t he c o h orts pre vi o usl y  declare d safe a n d t he 
c urre nt d ose c o h ort u n der e val uat i o n will be c o nti n u o usl y m o nit ore d.  A Ba yesia n t o xicit y 
m o nit ori n g r ul e will  b e i m ple me nte d f or D L T -e q ui vale nt t o xicit ie s a d de d fr o m bac kfill pat ie nt s 
(Secti o n  9. 2 ).T hese a g gre gate safet y data will be i ncl u de d i n defi ni n g t he R P 2 D. 
4. 1. 2. I n Vitr o Di a g n ostic Utiliz ati o n 
A n i n vest i gat i o nal C D 7 3 I H C assa y will  b e utilize d t o deter mi ne C D 7 3 pr otei n e x pressi o n stat us 
i n patie nts t h at ot her w ise meet all ot her eli gi b ilit y cri teria f o r e nr oll me nt i n P hase 1 b C o h ort C. 
T he t est will be perf or m e d at a ce ntral la b orat or y f oll o wi n g r o uti ne pr ocess i n g f o r hist ol o gical  
e val uat i o n usi n g a c o m mercial a ut ostai ner platf or m a n d will be int er pret e d b y q ualifie d 
pat h ol o gi sts. Pat ie nt s will be re q uire d t o u n der g o a ma n dat or y  fres h bi o ps y  of  a pri mar y  or 
metas t ati c si t e t o o btai n t u m or tiss ue f o r deter mi ni n g C D 7 3 e x pressi o n.   P ati e nts t hat are n ot 
p osi ti ve f o rC D 7 3 e x pressi o n, des pite meeti n g all ot her eli gi bilit y cri teria, will be scree n fail ures. 
I n a n i nit ial s ur ve y of f o r m al i n -fi xe d paraffi n -e m be d de d ( F F P E) t u m or sa m ples c o n d ucte d 
wi t h  a n i n vesti gati o nal I H C assa y , C D 7 3 e x pressi o n  was o bser ve d i n  of  l u n g t u m ors 
.  Rece ntl y discl o se d e xter nal st u dies, usi n g I H C -base d assess me nt of C D 7 3 e x pressi o n, C CI 
C CI 
C CI 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 36have reported an o verall prevalence o f CD73 in RCC of 22% (25/112 [Tripathi et al. 2019]). 
Tumor cell  CD73 expressi on has been detected in 54% (62/114) of metastatic melano ma 
(Monteiro et al. 2018 ), and in 73% and 40% of adenocarcino ma and squamous cell carcino ma of 
the lung respectively ( Salazar et al . 2018 ).
4.2. Scientific Rationale for Study Design
Multiple tum or types ha veshown CD73 expressio nto have a prognostic value (Allard et al .
2019), including tumors insensit ive to PD - 1/L1or CTLA -4 checkpo int blockade such as TNBC 
(Loi et al . 2013) and m CRPC (Leclerc et al .2015). In preclinical models of such “immune cold” 
tumors,combined treatm ent targeting CD73 and checkpo ints CTLA4 or PD -1/L1 showed 
synergy  in compar ison to single ag ent treatm ent (Allard et al. 2012).  Several agents targeting 
A2
AR and CD73 ha verecent ly entered the clinic and are being evaluated in pat ients with solid
tumors(Leone and Emens 2018) . Responses ha vebeen noted either as single agent treatment ,or 
in combinat ion with PD-1/L1 targeting ant ibodies ,including in immune “cold”tumors not 
sensit ive to ICI such as mCRPC, ovari an and pancreatic cancer (Suiet al. 2018; Bendell et al. 
2019) . In addit ion,transl ational data fro m the ongoing Phase 1/2 study  with CPI-444, an 
antagonist of A 2
AR, has suggested that patients with higher tumoral expressio n of CD73 and 
A2AR benefi t from treatment ( Hotson et al. 2017) .  Interestingly, patients that had been on a PD-
1/L1 for a prolonged duration prior to s tudy entry  had elevated A 2AR and CD73 expressio n 
suggest ingtheadenosine pathway  may play  a rol e in acquired resistance to PD -1/L1 treatm ent.
Addit ional work on patient samples from this study also revealed patients that had a high 
intratum oral activation of the adenosine pathway to benefit fro m study  treatm ent in co mpar ison 
to patients with a low activat ion signature (Willingham et al. 2018).
Study  JZMA will evaluate thesafety  and efficacy  of LY3475070 either as single agent or in 
combinat ion with pembr olizumab in tum ors known to be immune “cold” such as mCRPC ,as 
well as immune “inflamed” tumors that are unresponsive to check point inhibit ion, as a 
consequence o f an immune suppressive TME infilt rated by myelo idand other immune 
regul atory  cells. The underlying clinical hypothesis is that targeting CD73 within the TME will 
reduce l ocal adenosine levels ,an important immune -suppressive metabo lite. This can be 
expected to reduc ethe inhibitory  signals of immune suppressive cells ,which may  lead to 
increased T
-cell infiltrat ion and activat ion within the TME andlead to im proved clinical 
responses .
Owing to the primary  focus on pati ent safety  in early  clinical  devel opment an open label study  is 
appropriate and an mTPI-2 based dose escalat ion is an appr opriate desi gn feature as i t allows f or 
more com prehensive and nuanced decisio n makingin Phase 1a of this study . In Phase 1b , 
rando mizat ion of patients to monotherapy  or combinat ion therapy  in 2 of 3 cohorts is an 
appropriate means of ensuring balanced p atient characterist ics in both treatment arms.
4.3. Justification for Dose
4.3.1. LY3475070
A clinical starting dose of150 m g QD of LY3475070 administered orally  in humans is 
anticipated to be safe and have the potenti al for clinical efficacy .  Based on predicted human 
pharmacokinet ics and a PK/ pharmacodynamic model established on the basis of 
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 3 7 p har mac o d y na mic data  
a d ose of 1 5 0 m g Q D is 
a nt ic i pate d t o res ult i n a n a vera ge tar get i n hi bit i o n of   o ver t he d osi n g i nter val a n d   at 
Cmi n (r ef er t o Secti o n 4. 2. 3 of t he I B f or details).  Tar get i n hi bit i o n of t his ma g nit u de is e x pecte d 
t o res ul t i n cli nicall y mea ni n gf ul re d uct i o n of a de n osi ne f or mat i o n b y C D 7 3.  Mar gi n of Safet y 
f o r or al  a d mi nistrati o n of  L Y 3 4 7 5 0 7 0 base d o n a d mi nistere d d ose a n d p re dict e d e x p os ure is 
prese nte d bel o w .
M ar gi n of S afet y f or Or al A d mi nistr ati o n of L Y 3 4 7 5 0 7 0 B ase d o n A d mi nistere d D ose a n d 
Pre dicte d E x p os ure 
D ose 
( m g/ k g) D ose 
( m g/ m 2)D ose M ulti ple at o 
St arti n g D ose (t o 
m a xi m u m d ose) A U C 
( n g * h/ m L) E x p os ure M ulti ple b
t o St arti n g D ose (t o 
m a xi m u m d ose) 
H u m a n ( 1 5 0 m g) c – –
H u m a n ( 1 0 0 0 m g) d – –
R at N O A E L e3 2 x ( 4. 9 x) 4 3 x ( 6. 5 x) 
D o g N O A E L f2 2 x ( 3. 2 x) 1 4 x ( 2. 2 x) 
A b bre viati o ns:  A U C = area u n der t he c ur ve; I VI V E = i n vitr o t o i n vi v o e xtra p olati o n; N O A E L = n o -o bser ve d -
a d verse -effect le vel. 
aD ose m ulti ple is t he d ose i n a ni mals/ d ose i n h u ma ns base d o n m g/ m 2.  D oses were c o n verte d fr o m m g/ k g t o 
m g/ m 2usi n g a k m c o n versi o n fact or of 6 f or t he rat, 2 0 f or t he d o g, a n d 3 7 f or a 6 0 -k g h u ma n .  
bE x p os ure m ulti ple is t he calc ulate d A U C i n a ni mals/ pre dicte d A U C i n h u ma ns. 
cCli nical starti n g d ose ( 1 5 0 m g) .  E x p os ure is pre dicte d A U C usi n g I VI V E of he pat oc yte cleara nce. 
dMa xi m u m pla n ne d cli nical d ose ( 1 0 0 0 m g) .  E x p os ure is pre dicte d A U C usi n g I VI V E of he pat oc yte cleara nce. 
eN O A E L i n a rat 1 -m o nt h re peat d ose t o xicit y st u d y ( St u d y 8 4 0 1 9 1 3) .  A vera ge of male a n d fe male rat A U C o n 
Da y  2 8. 
fN O A E L i n a d o g 1 -m o nt h re peat d ose t o xicit y st u d y ( St u d y 8 4 0 1 9 1 4) .  A vera ge of male a n d fe male d o g A U C o n 
Da y  2 8. 
4. 3. 2. Pe m br oliz u m a b 
T he pl a n ne d d ose of pe m br o liz u ma b f o r t his st u d y  i s 2 0 0 m g Q 3 W. Base d o n t he t otalit y of  data 
ge nerate d i n t he Ke ytr u da de vel o p me nt pr o gra m, 2 0 0 m g Q 3 W is t he a p pr o priate d ose of 
pe m br o liz u ma b f o r a d ul ts acr oss all i n dicat i o ns a n d re gar dless of t u m or t y pe .  As o utli ne d bel o w, 
t hi s d ose i s j ust ifie d b y: 
Cli nical data fr o m  8 ra n d o mize d st u dies de m o nstrati n g flat d ose- a n d e x p os ure -efficac y  
r el at i o ns hi ps fr o m 2 m g/ k g Q 3 W t o 1 0 m g/ k g e ver y  2 wee ks ( Q 2 W), 
Cli nical data s h o wi n g mea ni n gf ul i m pr o ve me nt i n be nefit -ri s k i ncl u di n g o verall s ur vi val 
at 2 0 0 m g Q 3 W acr oss m ul ti ple i n dicat i o ns, a n d 
P har mac o l o g y  data s h o wi n g f ull tar get sat urati o n i n b ot h s yste mic circ ulat i o n (i nferre d 
fr o m P K  data) a n d t u m or (i nferre d fr o m  p h ysi o l o gicall y - base d P K [ P B P K] a nal ysis) at 
2 0 0 m g Q 3 W .C CI 
C CI C CI C CI C CI 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 38Amo ng the 8 randomized dose -comparison studies, a total of 2262 parti cipants were enrolled 
with melano ma and non -small  cell lung cancer (NSCLC), covering different disease settings 
(treatment naïve, previously treated, PD -L1 enriched, and all -comers ) and different treatment 
settings (monotherapy  and in co mbinat ion with chem otherapy ). Five studies co mpared 2 mg/kg 
Q3W versus 10 mg/kg Q2W (KN001 Cohort B2, KN001 Cohort D, KN002, KN010, and 
KN021), and 3 studies compared 10 mg/kg Q3W versus 10 mg/kg Q2W (KN001 Cohort B3, 
KN001 Cohort F2 and KN006). All of these s tudies demonstrated flat dose -and exposure -
response relat ionships across the doses studied represent ing an approximate 5 -to 7.5 -fold 
difference in exposure. The 2 mg/kg (or 200 mg fixed -dose) Q3W provi ded similar responses to 
the highest doses studied. Subsequently, flat dose
-exposure -response relat ionships were also 
observed in other tumor ty pes incl uding head and neck cancer, bladder cancer, gastric cancer and 
classical Hodgkin Lymphoma, confirming 200 mg Q3W as the appropriate dose independent of 
thetumor type. These findings are consistent with the mechanism o f action of pembro lizumab , 
which acts by  interact ion with immune cells, and not via direct binding to cancer cells.
Addit ionally , pharmacol ogy data cl early  show target saturation at 200 mg Q3W . First, PK data 
in KN001 evaluating target -mediated drug disposit ion (TMDD) conclusively demo nstrated 
saturation of PD -1 in systemic circulation at doses much lower than 200 mg Q3W. Second, a 
PBPK analysis was conducted to predict tumor PD -1 saturation over a wi de range o f tumor 
penetrati on and PD -1 expressio n. This evaluat ion concluded that pembro lizumab at 200 m g 
Q3W achieves full PD -1 saturati on in both blood and tumor.
Finally , popul ation PK analysis of pembro lizumab , which characterized the influen ce of  body  
weight and other participant covariates on exposure, has shown that the fixed -dosing provi des 
similar control of PK variabilit y as wei ght based dosing, with considerable overlap in the 
distribut ion of exposures fro m the 200 m g Q3W fixed dose and 2 mg/kg Q3W dose. Supported 
by these PK characteristics, and given that fixed -dose has advantages of reduced dosing 
complexi ty and reduced potential o f dosing errors, the 200 mg Q3W fixed -dose was sel ected for 
evaluat ion across all pembro lizumab protocol s.
4.4. End of Study Definition
The end o f the study  is defined as the date of the last vi sit of the l ast parti cipant in the study  or 
last scheduled procedure shown in the SoA (Section 1.3) for the last participant in the study
globally .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 395. Study Population
Prospe ctive approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
5.1. Inclusion Criteria
Type of Participant and Disease Characteristics for Phase 1a
Parti cipants are eligible to be included in the study only if the following cohort -specific criteria 
apply:
1.Patients m ust be, in the j udgement of the invest igator, an appropriate candidate for 
experimental therapy  and m ust have progressed through or be int olerant to therapi es known 
to confer clinical benefit.
2.Patients m ust have archived tum or tissue available for biomarker analysis or be able and 
willing to undergo a baseline biopsy. On -treatm ent bi opsy  is opti onal (See Secti on 8.8).
3.Male or female particip ant wi th histol ogical  or cy tological evidence of 1 of the f ollowing 
cancers that is metastatic, unresectable locally  advanced , or locally  recurrent : 
a. Triple negat ive breast cancer . Triple -negat ive receptor status is defined as ≤10% for 
estrogen and progesterone receptor expressio n, and human epidermal growth factor 
receptor 2 (HER2 )negative per ASCO/CAP HER2 testing guideline. 
i. Patient m ust have received treatm ent for metastatic disease
ii. Prior PD-1/L1 inhibitor is allowed;
b. Pancreat ic cancer
i. Must have received chem otherapy for advanced or metastatic disease (e.g.
gemcitabine containing regimen or m odified FOLFIRINOX );
ii. Patients wi th known microsatellite instabilit y-high (MSI-H)tumor shoul d have 
received pri or PD -1/L1 inhibitor therapy ;
c. Non-small cell  lung cancer
i. Patient m ust have experienced progressive disease on or within 3 months of 
completing priorPD-1/L1 based inhibitor therapy (i.e., have refractory disease) .
ii. Patients m ust have received treatment for metastatic disease. Patients wi th 
targetabl e mutations (e.g., ROS1, ALK, BRAF, and EGFR) must have received 
approved mutation -targeted therapy ; 
iii. Patients wi th targetabl e mutati onsare not required
to have received PD-1/L1
inhibitors 
d.
Renal cell carcino ma, clear cell  predominant subt ype
i. Patient m ust have experienced progressive disease on or within 3 months of 
completing prior PD-1/L1-based inhibitor therapy (i.e., have refractory disease) .
e. Cutaneous melano ma(CM)
i. Patient m ust have experienced progressive disease on or within 3 months of 
completing prior -PD-1/L-based inhibitor therapy (i.e., have refractory disease) .
f. Castrate resistant prostate cancer
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 40i. Patient m ust have received treatm ent for metastatic di sease; which should have
included at least 1 next generation hormonal agent (e .
g.,Abiraterone, 
enzalutamide)
ii. Patients wi th small -cell or neuro -endocrine histol ogies will  be excluded 
g. Epithelial ovarian cancer
i. Patient m ust have received treatm ent for metastatic di sease , including a 
platinum -based therapy . Patients in first relapse after adjuvant plat inum therapy 
whose disease is plat inum -sensit ive shoul d have received treatment with 
platinum -based therapy  for recurrent di sease.
Type of Participant and Disease Characteris tics for Phase 1b
4.Patients m ust be, in the j udgement of the invest igator, an appropriate candidate for 
experimental therapy  and m ust have ei ther ref used, progressed through or be intolerant to 
therapi es known to confer clinical benefit.
5.Patients m ust have metastati c, unresectable locally advanced, or locally recurrent disease.
6.Patients m ust be able and willing to provide the protocol required biopsies atbaseline and 
during study  treatm ent peri od (See Section 8.8) . For patients enro lled in Cohorts D1 and D 2,
biopsies are only required if patient has accessible soft tissue metastasis . 
7.Cohorts C1 and C2: Patients positive for CD73 expressio n (CD73 expressio n determined by
central IHC testingof pretreatm enttumor biopsy ; cut-off will be determined by the Sponsor )
a)Patients m ust have NSCLC, RCC or melano ma;
b)Patients m ust be refractory  to pri or PD-
1/L1 inhibitor defined as: patients m ust have 
had prior PD-
1/L1therapy  within 12 weeks of starting dosing on this study . Patients 
must have progressed on treatme nt with an anti -PD-1/L1 mAb administered either as 
monotherapy , or in combinat ion with other checkpoint inhibitors or other therapies , 
with no intervening therapy  prior to the start of study .  
PD-
1/L1treatm ent progressi on is defined by  meeting all o f thefollowing cri teria: 
i. Patients m ust have had complete response ( CR)/ partial response ( PR)or stable 
disease ( SD)for a durati on of  at least 6 m onths prior to progression. 
ii. Disease progressi on must have been demonstrated per Response Evaluat ion 
Criteria in Solid Tum ors (RECIST) versi on 1.1 (Eisenhauer et al. 2009) .  
iii. The init ial evidence of disease progression is to be confirmed by  a second 
assessment no less than 4 weeks from the date of the first documented disease 
progression, in the absence o f rapid clin ical progressi on.
c)NSCLC p atients withtargetabl e mutations (e.g. ,ROS1, ALK, BRAF, and EGFR) must 
have received prior targeted therapy  with an approved agent.   PD-
1/L1 directed 
treatm ent is not a requirement for EGFR -mutant patients. 
Cohorts D1 and D2: Patients with metastati c CRPC
d)Patients m ust be PD-1/L1 inhibitor therapy naïve;
e)Patients m ust have received treatm ent for metastatic di sease; which should have 
included at least 1 next generation hormonal agent (e.g., Abiraterone, enzalutamide)
f)Patients with small -cell or neuro -endocrine histologies will be excluded 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 41Cohort E: Patients with mTNBC
g)Prior PD -1/L1 inhibitor therapy  allowed;
h)Patients m ust have received treatment for metastatic di sease (at l east 1 regimen of 
cytotoxi c chem otherapy  for m etastat ic disease);
Parti cipants are eligible to be included in the study only if allof the f ollowing criteria apply:
8.Must be able to provide informed consent, as described in Appendix 1, which includes 
compliance wi th the requi rements and restri ctions listed in the inform ed consent form  (ICF) 
and in this protocol, according to local regulat ions and are at least 18 years of age. 
9.Men wi th partners of childbearing potential must use a condom during intercourse.  Men 
with partners of childbearing potential or wom enwith childbearing potential must agree to 
use 2 effect ive methods of contraception including a highly effect ive contraceptive method of 
birth control (Appendix 3) during study  treatm ent and for at l east 120 day s following the l ast 
dose of LY3475070 and pe mbro lizumab or country  requirements, whichever is longer. For 
patients receiving LY3475070 only, contraception should be maintained for 7 day s following 
the last dose.  Additional guidance for contraception during and after study  intervent ion are 
located in Appendix 3.
10.Women of childbearing potential must have a negative urine pregnancy  test at the screening 
visit fo llowed by  a negat iveserum pregnancy  test docum ented wi thin 24 hours prior to 
initiation of t reatment. If the screening urine test is posit ive or cannot be confirmed as 
negat ive, a serum pregnancy test will be required. Additional guidance for pregnancy testing 
during and after study  intervent ion islocated in Appendix 2 and Appendix 3. 
11.Have at least 1 measurable lesio n using standard techniques by RECIST versio n 1.1 
(Eisenhauer et al. 2009) . Exception :  patients enrolled in the dose escalation phase and 
mCRPC patients enro lled in Cohort D1 and D2 are notrequired to have measurable disease .
12.
Have a performance status (PS) of 0 or 1 on the Eastern Cooperative Onco logy Group 
(ECOG) scal e (Oken et al. 1982).
13.Previous treatments: Have discont inued all previo us treatm ents for cancer and recovered 
from the acute effects of therapy (except al opecia) .Patients must have discont inued fro m 
previous treatments, as shown below :
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 42Previous Treatment Length of Time Prior to First Dose of LY3475070
Endocrine therapies ≥14 days
Cytotoxic therapies or targeted agents that are small 
molecule inhibitors≥21 days or ≥5 half -lives, whichever is shorter
Biologic agents that are large molecules including 
immunotherapy (except for patients enrolled in cohort s
C1 and C2)≥28 days
Limited -field radiotherapy (eg, stereotactic body 
radiation therapy [SBRT ])with palliative intent≥14 days
Other radiotherapy≥28 days
Participants must have recovered from all radiation -
related toxicities, not require corticosteroids, and not 
have had radiation pneumonitis .
Major surgery, excluding biopsyPatients with recent major surgery must have recovered, 
in the opinion of the investigator, from the toxicity 
and/o r complicatio ns from the intervention before 
starting therapy.
14.Have adequate organ funct ion, as defined below:
System Laboratory Value
Hematologic
ANC ≥1.5×109/L
Platelets ≥100×109/L
Hemoglobin ≥9 g/dL
Note:  transfusions to increase a patient’s hemoglobin level or initiation of erythropoietin or G -CSF therapy to meet 
enrollment criteria are not allowed in the 14 days preceding the first dose of study drug.  If a patient receives 
transfusions, erythropoietin, or G -CSF therapy ≥14 days prior to the first dose, the hematologic criteria listed above 
must be met following the 14-day  window and prior to the first dose of study therapy.
Hepatic
Total bilirubin≤1.5×ULN
Isolated bilirubin >1.5xULN is acceptable if bilirubin is 
fractionated and direct bilirubin is within normal limits, 
total serum bilirubin <3xULN, and Gilbert’s Syndrome is 
confirmed.
ALT and AST <2.5x ULN 
Renal
Calculated creatinine clearance
based upon the Cock croft-Gault formula≥50 mL/min/1.73 m2
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 43(see Appendix 6)
Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST  = aspartate 
aminotransferase; G-CSF = granulocyte -colon y stimul ating factor; ULN  = upper limit of normal
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if anyof the fo llowing cri teria apply:
Medical Conditions
15.For pati ents who have received prior immunotherapy , the fo llowing patients will be 
excluded:
a)Experi enced a Grade 4 immune -related toxi city or any immune -related toxici ty 
that led to permanent discont inuat ion of prior anti -PD-1, anti -PD-L1, or other 
immunotherapy
b)Experi enced a l ess than or equal to Grade 3 irAE that has not recovered to 
Grade 1 after use of high dose corticosteroids that occurred during prior 
immunotherapy  [except ions:endocrine disorders where pat ients with prior 
endocrine AE sare permitted to enroll if they are asymptomat ic, considered 
clinically stable, and maintained on appropr iate repl acement therapy ]
c)Any grade:
i. ocular irAE, 
ii. serious neurol ogic irAE (e.g., Guillain -Barre syndrome, myasthenia 
gravis, encephalit is) 
iii. Serious cardi ovascular i rAE (e.g., my ocardi tis)
d)Requi red immunosuppressive agents other than corticosteroids for t he 
management of irAE; or currently requires maintenance doses of 10mg 
prednisone/predniso lone (or equivalent) per day  for irAE
16.Have interst itial lung disease or (noninfect ious) pneumonit is; pat ients with a history  
of (noninfectious) pneumo nitis Grade 2 or greater that required steroids (>7 days) to 
assist wi th management
17.Have a serious conco mitant sy stemic disorder that, in the opinio n of the invest igator, would 
compromise the pati ent’s abili ty to adhere to the protocol
18.Hum an Immunodeficiency Virus (HIV) posit ive patients (HIV 1 and/or 2; screening not 
requi red) are excluded unless they are well controlled on highly  active ant iretrovi ral therapy  
with
No evi dence of acquired immunodeficiency syndrome (AIDS) -defining 
opportunist ic infect ions wit hin the last 2 years, and
CD4 count >350 cells/ µl
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 44HIV infected participants with a history  of Kaposi’s sarcoma and/or Multicentric 
Castleman’s Disease are not eligible.
19.Have act ive hepat itis B or C virus infect ion (screening required)
20.Have current untreated tuberculosis
21.Have active infect ion requiring systemic therapy
22.Have prior or second concurrent primary  malignanci es that, in the j udgment of the 
investigator and the Lilly CRP/CRS, may affect the interpr et
ation of results.  Patients with 
carcino ma in situ of  any ori gin and pati ents wi th prior m alignancies who are in remissio n and 
whose likelihood of recurrence is very  low (such as basal  cell carcino ma), as j udged by the 
Lilly CRP/CRS, are eligible for thi s study
23.Have a ctive or suspected autoimmune disease (e.g., autoimmune vasculit is, autoimmune 
myocardi tis) or any illness or treatm ent that coul d com promise the immune system (e.g., 
prior solid organ transplant) within the past 2years, or a syndro me or con dition that requi res 
continuous systemic corticosteroids or immunosuppressive agents. 
This criterion does not apply  to pati ents wi th:  (i) vitiligo, al opeci a, or ty pe I di abetes 
mellitus; (ii) residual hypothy roidism due to an autoimmune condit ion requiri ng only 
horm one repl acement; or (iii) psoriasis not requiring chronic systemic 
immunosuppressive treatment within the past 2y ears, not expected to recur in the absence 
of an external tri gger, (iv) autoimmune -mediated hypothy roidism  that is stable on 
horm one repl acement; (v) Raynaud’s syndro me; or (vi ) Sjogren’s syndrome.  Patients 
with resolved childhood asthma/atopy  are all owed.
24.Areat risk of vascular inflammat ion, such as those with a history  of angiit is, arteri tis, or 
hypersensit ivity vasculit is as an adverse reaction to medicat ion, for example, are not eligible.
25.Are being treated with escalat ing or chronic supraphysio logic doses of corti costeroi ds or 
immunosuppressive agents (such as, exceeding 10 mg/day  of predniso ne or equivalent).  Use 
of topical, o phthalmic, inhaled, intermittent steroid injections, and intranasal corticosteroids 
permitted.
26.Patients wi th condi tions that may  impact absorpti on of  LY3475070, such as bowel  
obstructi on, uncontrolled diarrhea ,or extensive intestinal resection .
27.Have moderate or severe cardiovascular disease, such as the following:
a)presence of cardiac disease, including a my ocardial  infarct ion or any  other arteri al 
thrombotic event, bl ood cl ots not limited to deep vein thrombosis, cerebrovascular 
accident or transi ent ischemic attack within 6 months prior to enrollment; unstable 
angina pectoris; New York Heart Associat ion Class III/IV congest ive heart 
failure; aneurysm of major vessels or heart; left ventricular eject ion fraction <50% 
(evaluat ion based on institutional lower limit of normal); or uncontrolled 
hypertensio n
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 45b)severe, m oderate, or clinically  significant valvulopathy; documented major ECG 
abnorm alities that, i n the j udgment of the invest igator, are clinically significant 
(for example, symptomat ic arrhyt hmias or arrhythmias requiring treatment; 
myocardial  infarct ion within the l ast 3 months; or mean corrected QT interval 
(QTc) >450 msec for male part icipants or QTc >470 msec for female part icipants 
or QTc >480 msec in participants with bundle branch block calcula ted using 
Fredericia’s correction and confirmed by triplicate ECG.
c)previous cardiotoxic cancer treatment associated wit h type 1 damage such as 
anthracyclines (e.g., daunorubicin, doxorubicin, epirubicin, idarubicin) and 
previous thoracic radiotherapy  with a field invo lving the heart .
28.Have symptomat ic central nervous system (CNS) malignancy or metastasis and/or 
carcino matous m eningi tis(screening not required).  Patients with treated CNS metastases are 
eligible for this study  if they  are not currently  receiv ing corticosteroids (exceeding 10 mg/day 
prednisone or equivalent) and/or anticonvulsants to treat CNS metastases, and their disease is 
asymptomat ic and radiographically stable for at least 30 day s.
29.Have received a live vaccine wit hin 30 days before the fi rst dose of study  treatm ent.  
Examples of live vaccines include, but are not limited to, the fo llowing:  m easles, m umps, 
rubella, chicken pox, y ellow fever, rabies, Bacillus Calmette –Guérin, and typho id vaccine.  
Seasonal influenza vaccines for inject ion are generally  killed vi rus vaccines and are allowed; 
however, intranasal influenza vaccines are live attenuated vaccines and are not allowed.
30.Post
-partum patient who is or plans to breast -feed during the study  
31.Has a known psychiatric or substance abuse dis order that woul d interfere wi th the 
participant’s abilit y to cooperate with the requirements of the study
32. H ave current or history  of allergy  or hy persensi tivity to LY3475070 components including 
allergy  to beta lactam  antibiotics.
33.Has severe hypersensit ivity to pembrolizumab and/or any  of its excipients.
34.Has had an allogenic tissue/solid organ transplant.
Prior Therapy
35.Has received prior purinergic based inhibitors defined as adenosine A 2AR, A 2BR, A 3, CD39 
or CD73 .  
36.Has undergone pri or all ogeneic hematopoietic stem cell transplantation wit hin the last 
5years . Patien ts who have had a transplant greater than 5 y ears ago are eligible as lo ng as 
they have no symptom s of graft versus host disease .
Prior/Concurrent Clinical Study Experi ence
37.Patient is current ly enro lled in any other clinical study  involving an invest igational product 
or any  other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study by the investigator and Lilly CRP/CRS.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 465.3. Lifestyle Considerations
Not applicable.
5.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be 
rescreened.  Rescreened participants should be assigned a new participant ident ificat ion number.  
The interval between rescreening should be ≥2 weeks.  Each time rescreening is performed, the 
individual must sign a new ICF and will be assigned a new ident ificat ion number.  A patient may 
not be rescreened in an effort to obtain a different CD73 result.  Rep eating of laboratory  tests 
during the screening period or repeating screening tests to comply  with the protocol  designated 
screening period does not constitute rescreening.  This includes 1repeat for CD73 expressio n to 
determine P hase 1bCohort Celigibil ity if CD73 expressio n was not able to be determined by the 
patient’s init ial sample.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 476. Study Intervention
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), 
placebo ,or medical device (s)intended to be administered to a study participant according to the 
study  protocol .
6.1. Study Intervention(s) Administered
Cohort Dose Level Oral LY3475070 IV P embrolizumab
Cohort ADL1 150mg QD N/A
DL2 300mg QD N/A
DL3 600mg QD N/A
DL4 1000mg QD N/A
Cohort BCDL1 150mg QD 200 mg Q3W
CDL2 300mg QD 200 mg Q3W
CDL3 600mg QD 200mg Q3W
Cohorts C1, D1 and E RP1D c RP1D/MTD 200 mg Q3W
Cohorts C2 and D2 RP1D m RP1D/MTD N/A
Abbreviations:  CDL = combination dose level; DL = dose level; IV = intravenous; N/A = not applicable; MTD = 
maximum tolerated dose; RP1D = recommended phase 1 dose; RP1D c= recommended phase 1 dose (for 
combinatio n therapy ); RP1D m= recommended phase 1 dose (for monotherapy); Q3W = ever y 3 weeks; QD = 
once a day.
Note : Pembrolizumab should be administered for a maximum duration of 24 months (35 cycles).
A delay  of a treatm ent day up to 7 day s due to holidays, weekends, bad weather, unrelated 
medical events, or other unforeseen circumstances will be permitted and not be counted as a 
protocol  deviat ion.  The reason for interruption should be documented on the electronic case 
report form (eCRF).
The doses of LY3475070 will be administered at approximately the same t imes on each day , 
generally at home .Patients should be instructed take LY3475070 on an empt y stom ach, if 
possible.  Otherwise, drug capsules may be taken a minimum o f 1 hour before eating or 2 hours 
after consumption of food.  A LY3475070 administration patient diary must be kept for dosing 
compliance m onitoring. The actual time o f dose administr ations will be transcribed and 
provi ded to the sponsor.
If BID dosing is evaluated ,patients will take doses 12 ±2 hours apart ( i.e., 10 to 14 h ours 
between doses ).  There should at least be 10 hours between each subsequent dose. 
Atclinic visits, pati ents will be directed to take LY3475070 at the site.  LY34 75070 willbe 
administered 30 to 60 minutes post administration of pembro lizumab.
Pembrolizumab will be administered using IV infusion on Day  1 of each 3 -week treatm ent cy cle 
after all procedures and a ssessments have been completed. Pembro lizumab will be administered 
as a dose of 200 mg using a 30 -minute IV infusio n.  Si tes shoul d make every  effort to target 
infusio n timing to be as close to 30 minutes as possible.  However, given the variabilit y of 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 48infusio n pum ps from site to si te, a window between 5 minutes prior to and 10 minutes after 
administration is permitted (i.e., infusio n time is 30 minutes ( -5 min/+10 min).
The actual  time of dose administrations will be transcribed and provided to the spons or.
If LY3475070 is discont
inued, pembro lizumab may be continued alo ne for up to 2 y ears 
(35cycles).  Conversely, if pembrolizumab is discontinued, LY3475070 may be continued alo ne.
6.1.1.
Definition of DLT and DLT -ET
6.1.1.1. DLT
A DLT is defined as any o f the events listed in the table below ,if both of the fo llowing cri teria 
are met:
the event occurs during the DLT observat ion peri od (28 day s) in Phase 1a, and
the event cannot, in the opinio n of the invest igator , be definitely attribu ted to primary  
disease or extraneous cause s,such as accident .
Patients who experience a DLT in the DLT observation period will be discont inued fro m study  
treatm ent.
Dose- Limiting Toxicities 
Hematologic Toxicity
Grade 3 thrombocytopenia associated with clinically significant bleeding and requiring platelet transfusion or 
Grade 4 thrombocytopenia of any duration
Grade 3 febrile neutropenia
Grade 3 anemia requiring a blood transfusion
Other Grade 4 toxicity, excluding toxicities listed below this table
Nonhematologic Toxicity –Nonlaboratory
Grade ≥3irAE
Grade 3 colitis or noninfectious pneumonitis 
Grade 3 pneumonitis or Grade 2 pneumonitis that does not show clinical improvement within 3 days after 
initiatio n of optimal medical management including corticosteroids therapy, which is then treated as Grade 3
Grade 3 nausea, vomiting or diarrhea that lasts more than 48 hrs despite optimal supportive care 
Grade 3 fatigue lasting >7 days
Grade 3 hypertension despite maximal medical therapy
Grade 3 tachycardia
Any other Grade 3 toxicity 
Immune -related adverse event that necessitated permanent discontinuation of study drug(s), regardless of grade
Nonhematologic Toxicity –Laboratory/Investigations
Any Grade 3 laboratory abnormality except for specific exceptions listed below
ALT or AST:
o>8 ×ULN
o≥2-fold above the patient ’s baseline value that lasts >7 days, 
o≥3 ×ULN with concomitant bilirubin >2 ×ULN, in the absence of cholestasis
oTotal bilirubin >3 ×ULN
o≥Grade 3 amylase or lipase that is associated with symptoms or clinical manifestations of pancreatitis
Please refer to Section 8.2.1.1 for additional hepatic safety monitoring guidance.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 49Other Hematologic or Nonhematologic Toxicity That May Be a DLT.
Toxicity deemed by the investigator and Lilly CRP to be dose limiting, such as:
otoxicity that is possibly related to study treatment and requires discontinuation of the patient from the 
study at any time within the DLT observation period , or
opersistent Grade >2 toxicities causi ng a delay o f LY3475070 study treatment >14 day s during the DLT 
observation period.
Abbreviations:  AE =adverse event; ALT =alanine transaminase; AST =aspartate transaminase; CRP =clinical 
research physician; HCC =hepatocellular carcinoma; irAE =immune -related adverse event; IV =intravenous; 
ULN = upper limit of normal. 
The following adverse events are not considered DLTs:
Toxicit y that is cl early and di rectly related to the primary disease or to another etiology
Grade 3 endocrine disorder (thyroid, pituitary, and/or adrenal  insufficiency ), if both the 
following criteria are met:
othe disorder is manageable wit h or without systemic corticosteroid therapy  and/or 
horm one repl acement therapy , and 
othe pati ent is asymptom atic
Grade 3 inflammatory react ion attributed to a local antitumor response (such as, 
inflammatory  react ion in the lymph nodes or at sites of metastatic disease)
Any grade vit iligo or alopecia
≥Grade 3 el ectroly te abnorm ality that lasts <72 hours, i s not clinically complicated and
resolves spontaneous or responds to convent ional medical interventions
≥Grade 3 amylase or lipase that is not associated wit h symptoms or clinical manifestations of 
pancreat itis
Grade 3 or 4 neutropenia, provided both of the fo llowing criteria are met:
oisnot associated with fever or systemic infect ion, and
oimproves by  at least 1 grade wi thin 5days
Grade 3 or 4 lymphopenia
6.1.1.2. DLT -ET
A DLT -equivalent toxicity (ET) is any event listed in Sect ion 6.1. 1.1 occurring after the DLT 
observat ion peri od in Phase 1a orany cycle in Phase 1b . 
A DLT -ETis an AE that meets the DLT criteria as defined above and occurs in any cycle other 
than the DLT assessment period (28 days for Cohorts A 1through A4and B1 through B3). In 
addition to the DLT assessment perio d, available safet y data bey ond the DLT assessment period 
may also be taken into considerat ion prior to a decision to advance to the next DLor the 
determinat ion of the RP2D.
Potenti al DLTs that are AEs, which are reasonably anticipated AEs for concomitant medication 
shoul d be reviewed by the treating invest igator and Lilly CRP/CRS before final determinati on as 
a DLT. Review and discussio n may include addit ional participat inginvest igators. Such review 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 50may determine that confounding factors render the cas e to be not evaluable for the purposes of 
dose sel ection.
6.1.2. Definition of RP2D
The RP2D will be chosen fo llowing di scussi on between the Lilly  CRP/CRS and the invest igators
based on consideration of the totalit y of the data during interim analyses and upon completion of
Phase 1, including but not limited to LY3475070 dose adjustments, AEs, chronic intolerance, 
PK/pharmacodynamics data, and i rAEs. 
6.2. Preparation/Handling/Storage/Accountability
1.The invest igator or designee must confirm appropriate temperature co nditions have been 
maintained during transit for all study  intervent ion received and any discrepancies are 
reported and resolved before use of the study  intervent ion.
2.Only participants enro lled in the study  may receive study  intervent ion and only authorize d 
site staff may supply or administer study  intervent ion. All study  intervent ion must be stored 
in a secure, environmentally controlled, and monit ored (m anual or autom ated) area in 
accordance with the labeled storage condit ions wit h access limited to the invest igator and 
authori zed si te staff.
3.The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance (i .
e., 
recei pt, reconciliat ion, an d final disposit ion records).
4.Further gui dance and information for the final disposit ion of unused study  interventi ons are 
provi ded in the Pharmacy Manual .
5.Invest igators should consult the site training, Pharmacy Manual or label for the specific study  
drug informat ion.
6.3. Measures to Minimize Bias: Randomization and Blinding
This is an open -label dose finding study .
The Phase 1b dose expansio n part will implement a randomization design for Cohorts Cand Dto 
mitigate the select ion bias in allo cating patients to either monotherapy dose expansion or 
combinat ion therapy  dose expansi on.
6.4. Study Intervention Compliance
Parti cipant com pliance wi th study  intervent ion will be assessed at each visit. Com pliance will be 
assessed by  direct questi oning, countin greturned capsules /tablets/packages, and reviewing 
patient diari es.Deviation(s) fr om the prescribed dosage regimen should be recorded in the 
eCRF .Sevent y-five percent of LY3475070 treatment doses must have been received by the 
patient in order to be considered compliant.
For IV medication, study  intervent ion that i s administered intravenously  will be administered 
only at the invest igational sites by  the authorized stud y personnel. As a result, treatment 
compliance is ensured. 
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 5 1 6. 5. C o nc o mit a nt T her a p y 
At  baseli ne, rec or d pri or a n d c o nc urre nt me dicat i o ns.  Rec or d all pre me dicat i o n, s u p p orti ve care, 
a n d c o nc o mit a nt m e dicati o n c o nt i n u o usl y at e ver y visit a n d t hr o u g h o ut t he st u d y. 
T he Lill y C R P/ C R S s h o ul d be c o ntacte d if t here are a n y  q u esti o ns re gar di n g c o nc o mit a nt or 
pri or t hera p y .Patie nts wit h metastatic C R P C ma y c o nti n ue wit h l ut ei nizi n g h or m o ne -releasi n g 
h or m o ne a nal o g u e f o r test oster o ne s u p pressi o n . Z ol e dr o nic aci d or d e n os u ma b gi ve n f or b o ne 
s u p p ort is all o we d t o be c o nti n ue d if starte d 1 wee k pri or t o st u d y  treat m e nt d osi n g.  H o we ver, 
z ol e dr o nic aci d or de ns o u ma b s h o ul d n ot be i nit iate d, es peciall y i n metastatic C R P C patie nts, 
af ter st u d y  tr e at m e nt has c o m me nce d.  N o  o t h er c he m ot hera p y , i m m u n ot hera p y , her bal  
s u p ple me nts a n d/ or her bal dr u gs i nt e n de d t o treat ca ncer, or e x peri me ntal dr u gs will be per mitte d 
w hile t he patie nts are i n t his st u d y .
If pat ie nts ca n’t be s witc he d t o alter nati ve t hera p y 
Lill y C R P/ C R S m ust be c o ns ulte d. F or a list please c o ns ult A p pe n di x 5.  I m m u ne -s u p pressi ve 
gl uc oc orti c oster oi ds ot her t ha n t o treat treat m e nt rel at e d i r A E are als o pr o hi bite d .  
A d mi nistrati o n of  l i ve vacci nes is pr o hi bite d d uri n g t he st u d y  a n d f or 3 m o nt hs f o ll o wi n g t he 
fi nal d ose of st u d y dr u g.   A n y me dicat i o n or vacci ne (i ncl u di n g o ver -t h e-c o u nter or prescri pt i o n 
me dici nes, vit a mi ns, a n d/ or her bal s u p ple me nts) t hat t he partici pa nt is recei vi n g at t he ti me of 
e nr o ll me nt or recei ves d uri n g t he st u d y m ust be rec or de d al o n g wit h: 
Reas o n f or use 
Dates of a d mi nistrati o n i ncl u di n g start a n d e n d dates 
Me dicat i o ns or vacci nat i o ns s pec ificall y  pr o hi bi te d i n t he e xcl usi o n  cri t eri a are n ot all o we d 
d uri n g t he o n g oi n g trial.  If t here is a cli nical i n dicati o n f or a n y me dicat i o n or vacci nat i o n 
s pecificall y pr o hi bite d d uri n g t he trial, disc o nti n uati o n fr o m trial t hera p y or vacci nat i o n ma y be 
re q ui re d.  T he i n vest i gat or s h o ul d disc uss a n y q uesti o ns re gar di n g t his wit h t he S p o ns or .  T he 
fi nal decisi o n o n a n y s u p p orti ve t hera p y or vacci nati o n rests wit h t he i n vest i gat or a n d/ or t he 
parti ci pa nt's pri mar y  p h ysicia n.  H o we ver, t he decisi o n t o c o nti n u e t he parti ci pa nt o n st u d y  
treat m e nt re q ui res t he m ut u al  a gree me nt of t he i n vesti gat or, Lill y C R P/ C R S, a n d t he partici pa nt. 
Liste d bel o w are s pecific restrict i o ns f or c o nc o mit a nt t hera p y  or vacci nat i o n d uri n g t he c o urse of 
t h e st u d y :
A nt i ne o plastic s yste mic c he m ot hera p y or bi o l o gi c al  t hera p y  
I m m u n ot hera p y  n ot s pecifie d i n t his pr ot oc ol 
C he m ot h era p y  n ot s pecifie d i n t his pr ot oc ol 
I n vest i gat i o nal a ge nts ot her t ha n pe m br o liz u ma b 
Ra diati o n t hera p y  
N ote:  Ra diati o n t hera p y t o a s y m pt o mati c s o lit ar y lesi o n or t o t he brai n ma y be all o we d 
at t he i n vesti gat or’s discret i o n. C CI 
C CI 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 52Live vaccines wit hin 30 days prior to the first dose of study  treatm ent and while 
participat ing in the study. Examples of live vaccines include, but are not limited to, th e 
following :  measles, m umps, rubella, varicella/zoster, y ellow fever, rabies, BCG, and 
typhoid vaccine. Seasonal influenza vaccines for inject ion are generally killed virus 
vaccines and are allowed; however, intranasal influenza vaccines are live attenua ted 
vaccines and are not allowed. 
Systemic glucocorti coids for any  purpose other than to modulate symptoms from an AE 
that is suspected to have an immuno logic etiology. The use of physio logic doses of 
corticosteroi ds may  be approved after consultation wi th the Lilly  CRP/CRS .
Note: Inhaled steroids are allowed for management of asthma. 
Parti cipants who, i n the assessment of the invest igator, require the use of any  of the 
aforem entioned treatments for clinical management should be remo ved from the study .
All treatments that the investigator considers necessary  for a parti cipant’s welfare may be 
administered at the discret ion of the invest igator in keeping with the communit y standards of 
medical care. 
All conco mitant m edicat ion will be recorded on the eC RF including all prescription, over -the
-
counter products, herbal supplements, and IV medications and fluids. If changes occur during 
the study  period, docum entati on of  drug dosage, frequency , route, and date should also be 
included on the eCRF.
All conco mitant m edicat ions received wit hin 28 days prior to the first dose of study  treatm ent 
and up to 90 days after the last dose of study treatment should be recorded. Concomitant 
medicat ions administered up to 9 0 days after the last dose of study treatment sho uld be recorded 
for SAEs and events of clinical interest (Section 8.3.7).
6.5.1. Palliative Medicine and Supportive Care for LY3475070
The need for any  form of radiotherapy  (including palliat ive) in Cycles 1and 2will be cause for 
early  discontinuat ion from the study . In Cy cle3and bey ond, palliative radiotherapy  will be 
allowed.
In addit ion, any disease progression requiring other forms of specific antitumor therapy  will also 
necessitate early discont inuat ion from the study .Appropriate documentation for all forms of 
prem edicat ions, supportive care, and conco mitant medicat ions m ust be captured on the case 
report form .
Patients shoul d receive full supportive care. The use of granulocyte -colony stimulating factor 
(G-CSF) is permitted at the discret ion of the investigator based on American Society  for Clinical 
Onco logy (ASCO)(Smit h et al . 2015) and European Societ y for Medical Oncology  (Crawford et 
al. 2009) gui delines . 
If clinically  indicated at any  time during the study , erythropoi etin and packed red blood cell 
transfusio ns m ay be used according to ASCO guidelines (Rizzo et al. 2008). Prophylact ic 
antibiotic treatment should be consistent with ASCO guidelines (Flowers et al. 2013).
All conco mitant m edicat ions shoul d be recorded throughout the patient’s participat ion in the 
study .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 536.6. Dose Modification
6.6.1. Dose Modification and Toxicity Management of LY3475070 for Non-immune -
mediated AEs Associated with LY3475070 and/or in Combination with 
Pembrolizumab
Patient m ay receive up to 2 dose reductions for AEs attributed to LY3475070. LY3475070
treatm ent m ay be interrupted, dose reduced or discontinued due to toxicit y per the tabl es bel ow.
Patients who ha
vedose delays of more than 14 days, unless a different duration is specified in 
the above table, should permanently discont inue from the study . 
Due to i tsMOA , LY3475070 m ay induce irAEs that coul d affect any  organ of the body .  
Previous trials wit h agents inhibit ing the adenosine pathway  have not reported irAEs to the same 
incidence rate as seen wit h other check point inhibitors such as CTLA4 or PD-1/L1.  From  the 
ongoing A 2AR antagonist single agent data only rash/pruritus, and elevated LFTs have been 
reported.  In the event other irAEs occur please consult the table provided in Section 6.6.1.2 for 
management of irAEs .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 54Related AEsToxicity Grade 
or Conditions 
(CTCAE v5.0)Action Taken to Therapy AE Management Monitor and Follow -up
Non hematologic
Acneiform RashGrade 1 Continue treatment Initiate topical prophylactic antibiotic 
(e.g., clindamycin).
Consider using low potency topical 
steroids (e.g., hydrocortisone 2.5% )Monitor for worsening signs and 
symptoms.  
Grade 2 Withhold therapy until ≤ Grade 1 (for 
recurrent Grade 2, or toxicity lasting 
more than 2 weeks proceed as Grade 
3).
If immune mediated rash is suspected 
see below table for management of 
immune mediated AE’s) .Initiate oral antibiotic (e.g., 
doxycycline).
Initiate low potency topical steroid, if 
not already started. 
Consider skin biopsy if immune 
mediated toxicity is suspectedMonitor for worsening signs and 
symptoms weekly
Grade 3 Withhold therapy until ≤ grade 1 then 
dose reduce LY3475070
(if rash worsens or does not improve 
in two weeks permanently 
discontinue) 
If Stevens –Johnson syndrom e or toxic 
epidermal necrosis permanently 
discontinue patientInitiate oral antibiotic (e.g., 
doxycycline).
Initiate sy stemic corticosteroid (e.g., 
prednisone 0.5 mg/kg daily 
(maximum dose, 40 mg).
Consider dermatology consultation.Monitor for worsening signs and 
symptoms weekly until improvement 
to ≤Grade 1.
Resume LY treatment with 1 DL
reduction.
If rash does not improve or worsens 
after 2 weeks of treatment, 
discontinue LY permanently. 
If Stevens –Johnson syndrom e ortoxic 
epidermal necrolysis is suspected, 
discontinue permanently.
Grade 4 Permanently discontinue Initiate oral antibiotic (e.g.,
doxycycline).
Initiate systemic corticosteroid (e.g., 
prednisone 0.5 mg/kg daily 
(maximum dose, 40 mg).
Consider dermatology consultation.
DiarrheaGrade 1 Continue LY 3475070 treatment .
Start loperamide 4 mg initially, 
followed by 2 mg every 4 hours or 
after each stool .Consider discontinue of lactose 
containing products
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 55Related AEsToxicity Grade 
or Conditions 
(CTCAE v5.0)Action Taken to Therapy AE Management Monitor and Follow -up
Grade 2 Continue LY 3475070 treatment if 
Grade 2 diarrhea lasts <48 hours.
Hold LY 3475070 treatment if Grade 2 
diarrhea lasts ≥48hrs treatment until 
resolution to ≤ Grade 1 .Start loperamide 4 mg initially, 
followed by 2 mg every 4 hours or 
after each stool .
Encourage oral hydration .
If immune mediated colitis is 
suspected, consider GI consultation 
and biopsy .
Grade 3 Hold LY 3475070 until resolution to 
Grade ≤ 1.
Resume LY at 1 DLlower upon 
recovery.If not already done, start loperamide 4 
mg initially, followed by 2 mg every 4 
hours or after each stool .
Consider hospitalization for symptom 
and fluid management and GI 
consultation. 
Grade 4 Permanently discontinue LY 3475070
treatmentConsider hospitalization for symptom 
and fluid management, hydration and 
GI consultation. 
AST/ALT elevation or Increased 
bilirubinGrade 1 Continue LY 3475070 treatment Review concomitant medications and 
alcohol use
Grade 2 Continue treatment if immune 
mediated transaminitis is not 
suspected.
Hold LY 3475070 if immune mediated 
transaminitis is suspected (see below 
table for management of immune 
mediated AE’s) .Review concomitant medications and 
alcohol use
Consider hepatology consultat ion and 
rule out biliary obstruction due to 
disease progression
Consider biopsy if immune mediated 
transaminitis suspected .Monitor LFTs every 2 -5 day suntil 
≤Grade 1 (see protocol section 
8.2.1.1)
Grade 3 Hold LY3475070 until ≤Grade 1 .
Resume LY 3475070 treatment at 1 
DLlower if the patient has no 
evidence of drug induced 
hepatocellular injury. 
Patients with evidence of drug 
induced hepatocellular injury (i.e., 
transaminase ≥3XULN and total 
bilirubin ≥2XULN should Review concomitant medications and 
alcohol use
Consider hepatology consultationMonitor LFTs every 2 -5 day suntil 
≤Grade 1 (see protocol section 
8.2.1.1)
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 5 6 Rel ate d A Es T o xicit y Gr a de 
or Co n diti o ns 
( C T C A E v 5. 0) Act i o n Ta ke n t o Ther a p y A E Ma n a ge me nt M o nit or a n d Foll o w -u p 
per ma ne ntl y disc o nti n ue L Y 3 4 7 5 0 7 0 
treat me nt .
Gra de 4 Per ma ne ntl y disc o nti n ue L Y 3 4 7 5 0 7 0 
treat me nt Re vie w c o nc o mita nt me dicati o ns a n d 
alc o h ol use 
C o nsi der he pat ol o g y c o ns ultati o n .M o nit or L F Ts e ver y 2 -5 da y su ntil 
≤ Gra de 1 (see pr ot oc ol secti o n 
8. 2. 1. 1) .
Fati g ue Gra de 1 C o nti n ue treat me nt Ma na ge per r o uti ne cli nical practice 
a n d/ or i nstit uti o nal g ui deli nes 
Gra de 2 C o nti n ue treat me nt Ma na ge per r o uti ne cli nical practice 
a n d/ or i nstit uti o nal g ui deli nes 
Gra de 3 Wit h h ol d L Y 3 4 7 5 0 7 0 u ntil res ol uti o n 
≤ gra de 1 , if res ol ve d wit hi n 7 da ys 
t he n res u me treat me nt . Ma na ge per r o uti ne cli nical pract ice 
a n d/ or i nstit uti o nal g ui deli nes C CI 
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 5 7 Rel ate d A Es T o xicit y Gr a de 
or Co n diti o ns 
( C T C A E v 5. 0) Act i o n Ta ke n t o Ther a p y A E Ma n a ge me nt M o nit or a n d Foll o w -u p 
If gra de 3 persist o ver 7 da ys t he n 
d ose re d uce o ne le vel. 
If rec urre nce after c o nti n ui n g 
treat me nt d ose re d uce o ne le vel .
N o n -He mat ol o gic T o xicit y Gra de 1 C o nti n ue L Y 3 4 7 5 0 7 0 treat me nt Ma na ge per r o uti ne cli nical practice 
a n d/ or i nstit uti o nal g ui deli nes 
Gra de 2 Wit h h ol d L Y 3 4 7 5 0 7 0 treat me nt u ntil 
res ol uti o n t o ≤gra de 1 f or rec urre nt 
Gra de 2, or t o xicit y lasti n g m ore t ha n 
2 wee ks pr ocee d as Gra de 3 Ma na ge per r o uti ne cli nical practice 
a n d/ or i nstit uti o nal g ui deli nes 
Gra de 3 or 
rec urre nt 
Gra de 2 Wit h h ol d treat me nt u ntil res ol uti o n t o 
≤gra de 1 a n d t he n re d uce d ose o ne 
le vel. Ma na ge per r o uti ne cli nical practice 
a n d/ or i nstit uti o nal g ui deli nes 
Gra de 4 Per ma ne ntl y disc o nti n ue Ma na ge per r o uti ne cli nical practice 
a n d/ or i nstit uti o nal g ui deli nes .
He m at ol o gic t o xicit y 
Ne utr o pe nia Gra de 1 C o nti n ue treat me nt 
Gra de 2 C o nti n ue treat me nt 
Gra de 3 Wit h h ol d L Y 3 4 7 5 0 7 0 u ntil res ol uti o n 
≤gra de 1 f or rec urre nt Gra de 3, or 
t o xicit y lasti n g m ore t ha n 2 wee ks 
pr ocee d as gra de 4 .
If fe brile ne utr o pe nia t he n d ose re d uce 
o ne le vel u p o n res ol uti o n ≤gra de 1 If patie nt is a b o ve 3 8. 0° C o n 2
se parate occasi o ns a n d or ass ociate d 
wit h si g ns or s y m pt o ms of se psis start 
i ntra ve n o us i n acc or da nce wit h t he 
l ocal h os pital ne utr o pe nic se psis 
g u i deli nes 
G-C S F s u p p ort ma y be gi ve n as 
dee me d a p pr o priate b y t he p h ysicia n 
per i nstit uti o nal g ui deli nes Perf or m C B C wee kl y ≤ Gra de 3  
Gra de 4 Wit h h ol d L Y 3 4 7 5 0 7 0 u ntil res ol uti o n 
≤gra de 1 t he n res u me at o ne re d uce d 
D L .
If ne utr o pe nia is l o n ger t ha n 5 da y s 
disc o nti n ue patie nt If patie nt is a b o ve 3 8. 0° C o n t w o 
se parate occasi o ns a n d or ass ociate d 
wit h si g ns or s y m pt o ms of se psis start 
i ntra ve n o us i n acc or da nce wit h t he 
l ocal h os pital ne utr o pe nic se psis 
g ui deli nes .Perf or m C B C wee kl y ≤ Gra de 3  C CI 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 58Related AEsToxicity Grade 
or Conditions 
(CTCAE v5.0)Action Taken to Therapy AE Management Monitor and Follow -up
G-CSF support may be given as 
deemed ap propriate by the physician 
perinstitutional guidelines .
AnemiaGrade 1 Continue dose 
Grade 2 Continue dose
Grade 3 Withhold LY3475070 until resolution 
≤grade 1 then resume at one reduced 
DLBlood transfusions as per local 
institutional guidelines Perform CBC weekly ≤Grade 3  
Grade 4 Discontinue treatment Blood transfusions as per local 
institutional guidelines 
ThrombocytopeniaGrade 1 (LLN > 
75,000 mcL)Continue dose 
Grade 2 
(75,000>25,000)Continue dose 
Grade 3 (<25,000 
mcL) with 
significant 
bleeding Withhold LY3475070 until resolution 
≤ Grade 1 and resume treatment .  If 
associated with bleeding, or Grade 3 
reoccurs, then resume at one reduced 
DL.
If thrombocytopenia Grade 3 reoccurs 
at lower DLdiscontinue patient .Platelet transfusion per local 
institutional guidelines .Perform CBC weekly ≤Grade 3 .  
Grade 4 life 
threatening 
spontaneous 
bleedingPermanently discontinue . Platelet transfusion per local 
institutional guidelines 
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 5 9 A b bre viati o ns : C B C =c o m plete bl o o d c o u nt; ; ; G -C S F 
=gra n ul oc yte c ol o n y -sti m ulati n g fact or; L F Ts =li ver f u ncti o n tests; .
6. 6. 1. 1. D ose m o dific ati o n a n d t o xicit y m a n a ge me nt of i nf usi o n - re acti o ns rel ate d t o 
pe m br oliz u m a b 
Pe m br oliz u ma b ma y ca use se vere or life -t h reate ni n g i nf usi o n- react i o ns i ncl u di n g se vere 
h y perse nsit i vit y or a na p h yl a xis .  Si g ns a n d s y m pt o m s us uall y  d e v el o p d uri n g or s h ortl y af t er 
dr u g i nf usi o n a n d ge nerall y res ol ve c o m pletel y wit hi n 2 4 h o urs of c o m plet i o n of  i nf usi o n .  D ose 
m o dificati o n a n d t o xi ci t y  m a na ge me nt g ui deli nes o n pe m br oliz u ma b ass ociate d i nf usi o n react i o n 
are pr o vi de d i n t h e ta ble bel o w. C CI C CI 
C CI 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 60Pembrolizumab Infusion -
Related Reaction Dose Modification and Treatment Guidelines
NCI CTCAE Grade TreatmentPremedication at
Subsequent Dosing
Grade 1
Mild reaction; infusion interruption 
not indicated; intervention not 
indicated .Increase monitoring of vital signs as medically  indicated until the participant is 
deemed medically stable in the opinion of the investigator.None
Grade 2
Requires therapy or infusion 
interruption but responds promptly 
to sy mptomatic treatment (e.g., 
antihistamines, NSAIDs, narcotics, 
IV fluids); prophylactic 
medications indicated for ≤24 hrs.Stop Infusion.
Additional appropriate medical therapy may include but is not limited to:
IV fluids
Antihistamines
NSAIDs
Acetaminophen
Narcotics
Increase mo nitoring of vital signs as medically indicated until the participant is 
deemed medically stable in the opinion of the investigator.
If symptoms resolve within 1 hour of stopping drug infusion, the infusion may be 
restarted at 50% of the original infusion rate (e.g. from 100 mL/hr. to 50 mL/hr.). 
Otherwise dosing will be held until symptoms resolve and the participant should be 
premedicated for the next scheduled dose.
Participants who develop Grade 2 toxicity despite adequate premedication should be 
permanently discontinued from further study drug treatment .Participant may be premedicated 
1.5hrs(±30 minutes) prior to 
infusion of pembrolizumab with :
Diphenhy dramine 5 0 mg po
(or equivalent dose of 
antihistamine).
Acetaminophen 500 to
1000 mg po(or equivalent 
dose of analgesic).
Grades 3 or 4
Grade 3:
Prolonged (i.e., not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of infusion); 
recurrence of symptoms following 
initial improvement; Stop Infusion.
Additional appropriate medical therapy may include but is not limited to:
Epinephrine**
IV fluids
Antihistamines
NSAIDs
Acetaminophen
Narcotics
Oxygen
PressorsNo subsequent dosing
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 61NCI CTCAE Grade TreatmentPremedication at
Subsequent Dosing
hospitalization indicated for other 
clinical sequelae (e.g., renal 
impairment, pulmonary infiltr ates)
Grade 4:
Life-threatening; pressor or 
ventilator support indicatedCorticosteroids
Increase mo nitoring of vital signs as medically indicated until the participant is 
deemed medically stable in the opinion of the investigator.
Hospitalization may be indicated.
**In cases of anaphylaxis, epinephrine should be used immediate ly.
Participant is permanently discontinued fro m further study drug treatment.
Appropriate resuscitation equipment should be available at the bedside and a physician readily  available during the period of drug administration. For further 
information, please refer to the Common Terminology Criteria for Adverse Events v 4.0 (CTCAE) at http://ctep.cancer.gov
Abbreviations:   IV = intravenous; NSAID = non -steroidal anti -inflammatory drug; po= by mouth
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 626.6.2. Dose Modification and Toxicity Management for Immune -Related AEs Associated 
with LY3475070 and/or in Combination with Pembrolizumab
An immune -related AE ( irAE)may be defined as an AEconsistent with an immune -mediated 
chronic inflammatory  reacti on associ ated wi th drug exposure.  These irAEs may  occur shortly  
after the first dose or several mo nths after the last dose of drug and may affect more than on e
body  system
 simul taneously . Therefore, early recognit ion and init iation of treatment is crit ical to 
reduce com plicat ions. Based on exist ing clinical study  data of immune checkpo int inhibitors, 
most irAEs are reversible and can be managed with interruptions of therapy , administrati on of  
corticosteroi ds and/or other supportive care. For suspected irAEs, ensure adequate evaluation to 
confirm et iology or excl ude other causes. Addit ional procedures or tests such as bronchoscopy , 
endoscopy, skin bi opsy  may be included as part of the evaluat ion. Based on the severit y of 
irAEs, wi thhol d or perm anent ly discont inue therapy and administer corticosteroids. Dose 
modificati on and toxici ty management gui delines for potential irAEs are provided in the table 
below.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 63Dose Modification and Toxicity Management Guidelines for Immune -related AEs Associated with Stu dy Treatment 
General Instructions: 
1.Severe and life -
threatening irAEs should be treated with IV corticosteroids followed by oral steroids. Other immunosuppressive treatment should begin if 
the irAEs are not controlled by corticosteroids. 
2.Pembrolizumab m ust be permanently discontinued if the irAE does not resolve or the corticosteroid dose is not ≤10mg/day within 12 weeks of the last 
pembrolizumab treatment. 
3.The corticosteroid taper should begin when the irAE is ≤ Grade 1 and continue at least 4 weeks.
4.If pembrolizumab has been withheld, pembrolizumab may resume after the irAE decreased to ≤Grade1 after corticosteroid taper.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 64irAEsToxicity grade 
(CTCAE V5.0)Action with 
pembrolizumab and 
LY3475070Corticosteroid and/or other 
therapies 
Monitoring and follow -up
Pneumo nitis Grade 2 Withhold Administer corticosteroids 
(initial dose of 1 to2 mg/kg 
prednisone or equivalent) 
followed by taper
Add prophylactic antibiotics 
for opportunistic infectionsMonitor participants for signs and 
symptoms of pneumonitis
Evaluate participants with 
suspected pneumonitis with 
radiographic imaging and initiate 
corticosteroid treatmentRecurrent 
Grade 2, 
Grade 3 ,or 4 Permanently 
discontinue
Diarrhea / Colitis Grade 2 or 3 WithholdAdminister corticosteroids 
(initial dose of 1 to2 mg/kg 
prednisone or equivalent) 
followed by taperMonitor participants for signs and 
symptoms of enterocolitis ( i.e.,
diarrhea, abdominal pain, blood, or 
mucus in stool with or without 
fever) and of bowel perforation 
(i.e., peritoneal signs and ileus )
Participants with ≥Grade 2 
diarrhea suspecting colitis should 
consider GI consultation and 
performing endoscopy to rule out 
colitis
Participants with diarrhea/colitis 
should be advised to drink liberal 
quantities of clear fluids. If 
sufficient oral fluid intake is not 
feasible, fluid and electrolytes 
should be substituted via IV 
infusionRecurrent Grade 3 
orGrade 4Permanently 
discontinue
AST orALT 
elevation or 
Increased 
BilirubinGrade 2aWithholdAdminister corticosteroids 
(initial dose of 0.5 to1 
mg/kg prednisone or 
equivalent) followed by 
taperMonitor with liver function tests 
(consider weekly or more 
frequently until liver enzyme value 
returned to baseline or is stable )
Grade 3bor 4cPermanently 
discontinueAdminister corticosteroids 
(initial dose of 1 to2 mg/kg 
prednisone or equivalent) 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 65irAEsToxicity grade 
(CTCAE V5.0)Action with 
pembrolizumab and 
LY3475070Corticosteroid and/or other 
therapies 
Monitoring and follow -up
followed by taper
Type 1 diabetes 
mellitus (T1DM) 
or HyperglycemiaNew onset T1DM 
or 
Grade 3 or 4 
hyperglycemia 
associated with 
evidence of -cell 
failureWithholddInitiate insulin replacement 
therapy  for participants with 
T1DM
Administer 
antihy pergly cemic in 
participants with 
hyperglycemiaMonitor participants for 
hyperglycemia or other signs and 
symptoms of diabetes
HypophysitisGrade 2 WithholdAdminister corticosteroids 
and initiate hormonal 
replacements as clinically 
indicatedMonitor for signs and symptoms of 
hypoph ysitis (including 
hypopituitarism and adrenal
insufficiency)Grade 3 or 4 Withhold or 
permanently 
discontin ued
Hyperthy roidism Grade 2 ContinueTreat with nonselective 
beta-blockers ( eg,
propranolol) or thionamides 
as appropriateMonitor for signs and symptoms of 
thyroid disorders
Grade 3 or 4 Withhold or 
permanently 
discontinued
HypothyroidismGrade 2 , 3, 4 ContinueInitiate thyroid replacement 
hormones (eg,
levothy roxine or 
liothyronine ) per standard of 
careMonitor for signs and symptoms of 
thyroid disorders
Nephritis:
grading according
to increased 
creatinine or 
acute kidney 
injuryGrade 2 WithholdAdminister corticosteroids 
(prednisone 1 to2mg/kg or 
equivalent) followed by 
taperMonitor changes of renal function
Grade 3 or 4 Permanently 
discontinue
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 66irAEsToxicity grade 
(CTCAE V5.0)Action with 
pembrolizumab and 
LY3475070Corticosteroid and/or other 
therapies 
Monitoring and follow -up
MyocarditisGrade 1 or 2 WithholdBased on severity of AE 
administer corticosteroidsEnsure adequate evaluation to 
confirm etiology and/or exclude 
other causes Grade 3 or 4 Permanently 
discontinue
All Other 
immune- related 
AEsPersistent Grade 2 WithholdBased on severity of AE 
administer corticosteroidsEnsure adequate evaluation to 
confirm etiology or exclude other 
causes Grade 3 Withhold or discontin ue 
based on the evente
Recurrent Grade 3 
or Grade 4 Permanently 
discontinue
aAST/ALT: >3.0 to5.0 x ULN if baseline normal; >3.0 to5.0 x baseline, if baseline abnormal; 
bilirubin:   >1.5 to3.0 x ULN if baseline normal; >1.5 to3.0 x baseline if baseline abnormal
bAST/ALT: >5.0 to 20.0 x ULN, if baseline normal; >5.0 to20.0 x baseline, if baseline abnormal; bilirubin:   >3.0 to10.0 x ULN if baseline 
normal; >3.0 to10.0 x baseline if baseline abnormal
cAST/ALT: >20.0 x ULN, if baseline normal; >20.0 x baseline, if baseline abnormal; 
bilirubin: >10.0 xULN if baseline normal; >10.0 x baseline if baseline abnormal
d The decision to withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physic ian. If control 
achieved or ≤Grade 2, pembrolizumab may be resumed.
eEvents that require discontinuation include but are not limited to: Guillain -Barre Syndrome, encephalitis, Stevens -Johnson Syndrome ,and 
toxic epidermal necrolysis.
Abbreviations: AE = adverse event; ALT = alanine aminotransferase; AST = aspartate transaminase; GI = gastrointestinal; irAE = immune -related adverse event;
IV = intravenous; ULN = upper limit of normal
NOTE: The frequency or severit y of known potenti al irAEs with pembrolizumab m ay be increased in co mbination wit h LY3475070.  
Therefore, particularly close monitoring for irAEs should be standard.  For all irAEs o f grade 2 or above would consider specialist 
consultation and/or addit ional work -up including labs and biopsy to confirm diagnosis.  For certain toxicit ies o f more serious clinica l 
consequence, such as my ocardi tis, neurologic, or ophthalmo logic irAE, consi der wi thhol ding therapy  for grade 2 toxi cities and early 
hospi talizati on for close m onitoring for grade 3 toxicit ies.  For any  grade 2 or greater suspected irAE, please consult wi th Lilly  
CRS/CRP.
For any  other dose m odificati ons, toxi cities,or infusion -related reacti ons rel ated to pembrolizumab, please consult the product label.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 676.6.3. Other allowed dose interruption for pembrolizumab
Pembrolizumab may be interrupted for situations other than treatm ent-related AEs such as 
medical / surgical events or logist ical reasons not rel ated to study  therapy .  
Participants shoul d be 
placed back on study  therapy  within 3 weeks of the scheduled interruption, unless otherwise 
discussed wi th the Sponsor .  The reason for interruption should be documented in the pat ient's 
study  record.
6.7. Intervention after the End of the Study
The end o f study  defini tion is defined in Section 4.4. Invest igators will continue to follow the 
SoA provi ded in Sect ion 1.3 until notified by  Lilly that end of study  has occurred. 
6.7.1. Treatment after Study Completion
Study  com pletion will occur fo llowing the final analysis o f primary  and secondary  object ives, as 
determined by Lilly. Invest igators will cont inue to fo llow the SoA (Section 1.3) for all patients 
until notified by Lilly  that study  com pletion has occurred.
6.7.1.1. Continued Access 
Parti cipants who are still on study  intervent ion at the time o f study  com pletion may cont inue to 
receive study  intervent ion if they are experiencing clinical benefit and no undue risks.
The continued access period will apply  to this study  only if at least 1 parti cipant is still on study  
intervent ion when study  com pletion occurs.   Lilly will notify investigators when the continued 
access peri od begins.
If LY3475070 is discontinued, pembro lizumab may be continued alo ne for up to 2 y ears 
(35cycles). Conversely, if pembrolizumab is discontinued, LY3475070 may be continued alo ne.
Parti cipants are not requi red to si gn a new ICF before treatm ent is provi ded during the continued 
access period; the init ial ICF for this study  includes continued access under this protocol.
The parti cipant’s cont inued access to study intervent ion will end when a criterion for 
discontinuat ion is met (Section 7).Conti nued access fo llow-up will begin when the participant 
and the invest igator agree to discont inue study  intervent ion and lasts approximately 90days.
Follow
-up procedures will be performed as shown in the Cont inued Access SoA.
Parti cipants who are in short -term follow-up when the continued access period begins will 
continue in short -term follow-up unt il the 90-day short -term follow -up visit is completed. Long -
term follow-up does not apply.
Parti cipants who are in l ong-term follow-up when the contin ued access period begins will be 
discontinued fro m long-term follow-up.
In all cases, no fo llow-up procedures will be performed for a participant who withdraws 
informed consent unl ess he or she has explicit ly provided permissio n and consent.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 687. Discontinuatio n of Study Intervention and Participant 
Discontinuation/Withdrawal
The reasons for treatment and study  discont inuation and dates of discont inuat ion will be 
collected for all pat ients.
Patients who discont inue during the study treatment period, whether or n ot they  received study  
treatm ent, will  have fo llow
-up procedures performed as shown in the SoA (Secti on 1.3).
If a patient withdraws informed consent, he or she must not be contacted unless he or she has 
explicit ly provided permissio n and consent.  Lilly m ay cont inue to use previously co llected 
medical research data prior to the withdrawal consistent with the original authorizat ion.
7.1. Discontinuation of Study Intervention 
Discontinuati on of  study  treatm ent does not represent withdrawal fro m the study .
Parti cipants may discontinue study  treatm ent at any  time for any  reason or be di scontinued from 
the study  treatm ent at the di scret ion of the investigator should any untoward effect occur. In 
addition, a subject m ay be withdrawn by the investigator or the sponso r if enro llment into the 
trial is inappropri ate, the trial  plan is vio lated or for administrate and/or other safet y reasons. 
A subject m ust be di scontinued from the trial for the fo llowing reasons:
the participant or the participant’s designee, for exampl e, parents or l egal guardian
requests to discont inue invest igational product.
the subject is lost to follow -up
Asubject m ust be di scontinue dfrom trial treatment but continue to be fo llowed for any  of the 
following reasons:
the pati ent becomes pregnant during the study
the pati ent is significant ly noncom pliant wi th study  procedures and/or treatment
disease progressi on.  Disease progressi on shoul d be confirmed per iRECIST 4 to 8 weeks 
after si te-assessed first radio logicevidence of PD in clinically  stable parti cipants.
Parti cipants, who have unconfirmed disease progressio n may cont inue on treatment at the 
discreti on of  theinvest igator until progression per iRECIST. Any participant deem ed 
clinically unstable should be discontinued from study  treatm ent at first radio logic 
evidence of PD and is not required to have repeat tumor imaging for confirmation o f PD 
by iRECIST.   
unacceptable toxicit y
the pati ent, f or any  reason, requi res treatm ent wi th another therapeuti c agent that has 
been demo nstrated to be effective for treatment of the study indication.  Discont inuat ion 
from study  inventi on will  occur pri or to introduction of the new agent .
Recurrent Grade 2 pneumonit is
Discontinuati on of treatm entmay be considered forparticipants who have attained a
confirmed co mplete response ( CR)andhave been treated foratleast 8
cycles(at least 
24weeks), receiving [for monotherapy :  at least 2 doses of pembrolizumab; for 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 69combination treatment
:  2 cycles of the combination including 2 doses of 
pembrolizumab and at least 75% of the planned doses of LY3475070 ] beyond thedate
when theinitialCRwasdeclared.
Pembrolizumab will be discontinued after completio n of approximately 2 y ears of 
treatm ent wi th pembro lizumab (co mpletion o f 35 treatments with pembro lizumab) . 
Note : The number of treatments is calculated starting with the first dose of 
pembro lizumab.
Parti cipants discont inuing from the invest igational product prematurely  for any reason shoul d 
complete adverse event and other fo llow-up procedure s per Section 1.3 (Schedule o f Activities), 
Secti on 8.3 (Adverse Events and Serious Adverse Events), and Section 8.2 (Safet y Assessments) 
of the protocol.
7.2. Participant Discontinuation/ Withdrawal from the Study
Parti cipants will be discont inued in the following circumstances:
enrollment in any other clinical study involving an invest igational product or 
enrollment in any other type o f medical research judged not to be 
scientifically or medically co mpatible wit h this study
participat ion in the study nee ds to be stopped for medical, safet y, regul atory , 
or other reasons consistent with applicable laws, regulat ions, and good clinical 
practi ce (GCP)
subject decisio n
othe participant or the patient’s designee, for example, parents or legal 
guardi an requests to be withdrawn from the study
the pati ent becomes pregnant during the study .  See Secti on 8.3 regarding 
regul atory  reporting requi rements on fetal  outcom e.
Parti cipants discont inuing from the study  prem aturely for any  reason shoul d 
complete AEand other saf ety follow-up per Secti on1.3(Schedule o f 
Activities), Section 8.3(Adverse Events and Serious Adverse Events), and 
Secti on8.2(Safet y Assessments) of this protocol.
7.2.1. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ify apartici pant who did not meet enrollment criteria and was 
inadvertent ly enro lled, then the patient should be discontinued fro m study  treatm ent unless there 
are extenuat ing circumstances that make it medically necessary for the patient to continue on 
study treatment.  If the invest igator and the sponsor CRP agree it is medically appropriate to 
continue, the invest igator must obtain documented approval fro m the sponsor CRP to allow the 
inadvertent ly enro lledparticipant to continue in the study  with or wi thout treatm ent wi th 
investigat ional product. Safet y follow up i s as outlined in Sect ion1.3(Schedule of Act ivities), 
Secti on8.3(Adverse Events and Serious Adverse Events), and Section 8.2(Safet y Assessments) 
of the protocol.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 70Please refer to Appendix 7 for discont inuat ion of inadvertent ly enrolled pat ients in the United 
Kingdo m.
7.3. Lost to Follow u
p
Aparticipant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site.  Si te personnel are expected to 
make diligent attempts to contact participants who fail to return for a sche duled visit or were 
otherwi se unable to be fo llowed up by the site.
Site personnel, or an independent third party , will  attem pt to collect the vital status of the 
participant within legal and ethical boundaries for all participants rando mized, including th ose 
who did not get invest igational product.  Public sources may be searched for vital status 
inform ation.  If vital status is determined, this will be documented and the participant will not be 
considered lost to fo llow-up.
Lilly personnel will not be inv olved in any attempts to collect vital status informat ion.
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Secti on10.1.7 .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 718. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA (Section 1.3) .
Protocol
waiver s or exem ptions are not allowed.
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study  interventi on.
Adherence to the study  design requi rements, including those specified in the SoA
(Secti on 1.3) , is essent ial and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al 
participant s meet all eligibilit y criteria. The investigator will maintain a screening log to 
record details o f all partici pants screened and to confirm eligibilit y or record reasons for 
screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical manageme nt (e.g., bl ood 
count) and obtained before signing of the ICF may be utilized for screening or baseline 
purposes provided the procedures met the protocol -specified criteria and were performed 
within the t ime frame defined in the SoA (Secti on 1.3) .
8.1. Efficacy Assess ments
8.1.1. RECIST V1.1 for Tumor Response Asses sment
Please fo llow the gui delines below when assessing tumor response:
Response Evaluat ion Cri teria in Solid Tumors ( RECIST )v1.1 will be applied as the 
primary  criteria for assessment of tumor response (Ei senhauer et al. 2009).
The extent of computed tom ography  (CT)or magnetic resonance imaging needed to 
establish baseline tumor burden is based upon the investigator’s determination. 
Tumor assessments will be performed for each patient at the times shown in the SoA 
(Secti on 1.3). Counting fro m C1D1, for the first year of study  treatm ent, disease status 
shoul d be evaluated radiologically per RECIST v1.1 guidelines every  9weeks (±7 days)
for the first year, and every 12 weeks (±7 days) thereafter ( until adiscont inuat ion 
criterion is met ).  
Perform assessments as scheduled, even if study  treatm ent is delayed or omitted, except 
when deemed not feasible in the opinio n of the investigator because of the patient’s 
clinical status.
Standard of care scan (pre -ICF) may be used as baseline provided it meets technical 
requi rements for inclusio n criteria and occurred within 28 day s of treatm ent.
Per RECIST v1.1 imaging guidelines:
imaging modalit y (e.g., CT or magnetic resonance imaging [ MRI ]) obtained for the study  
baseline should be repeated throughout the study  as described in SoA; 
Intravenous and oral contrast should be used as clinically indicated;
While CT imaging with slices ≤5 mm, MRI imaging is also acceptable;
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 72CT images fro m positron emissio n tom ography -CT scans may  be used for response 
assessment if the associated CT scan has the same qualit y as a di agnostic CT.
Best overall response (BOR; e.g., complete or partial response, stable disease or unknown) will 
be determined locally by  the invest igator per RECIST v1.1; there will be no independent review 
of BOR.  When the RECIST v1.1 criteria for progressive disease ar e met, 
clinically stable 
patients may undergo addit ional radio logic imaging progression for confirmat ion of PD per 
iRECIST (Section 8.1.1 , Seymour et al 2017).  For patients who meet criteria to continue
treatm ent after initial progressio n (either awai tingconfirmat ion by iRECIST or have iUPD by 
iRECIST), reconsent ing is required .Patients who discontinue treatment without documented 
progression should cont inue to be assessed for patient swho di scont inue study  treatm ent wi thout 
confirmed PD, periodic imagi ng per SoA (Section 1.3) for PD confirmat ion will cont inue unt il 
PD, or init iation of subsequent therapy  or wi thdrawal  of consent. If the patient is st ill on study 
treatm ent after 1 y ear, perform  tumor imaging Q12W.
8.1.2. iRECIST For Confirmation of PD in Clini cally Stable Patients and Radiologic PD 
per RECIST v1.1. 
RECIST v1.1 will be applied as the primary  criteria for assessment of tumor response 
(Eisenhauer et al. 2009).  The response to immunotherapy  may differ from  the ty pical  responses 
observed wit h cytotoxic chem otherapy, including the fo llowing (Wo lchok et al . 2009; Ni shino et 
al. 2013):
Response to immunotherapy  may be delayed.
Response to immunotherapy  may occur after progressive disease by  convent ional criteria.
The appearance of new lesio ns may not represent progressive disease wit h 
immunotherapy .
Therefore, to adequately characterize addit ional patterns of response and progression specific to 
patients treated with immunotherapy , which cannot be captured using convent ional criteria such 
as RECIST v1. 1, alternat ive measures of tumor assessment have been developed.  The iRECIST 
standard was developed by the RECIST working group for the use of modified RECIST versio n 
1.1 in cancer immunotherapy  trials (Seymour et al. 2017).
After init ial disease progress ion defined by RECIST v1.1, i RECIST gui deline swill be applied in 
the following tum or assessments. In iRECIST, any  new l esions are categorized as measurable or 
non-measurable. Up to 5 lesio ns total (up to 2 per organ) can be selected as new lesio n-target
(NL-T). All other new lesions will be fo llowed as new lesio n-non- target (NL-NT). The NL-T 
sum of diameters will  be calculated and recorded separately fro m the sum  of diameters for target 
lesions i dentified at baseline. 
Tumor response by  iRECIST will  beclassified as confirmed progression (iCPD), or unconfirmed 
progression (iUPD), or stable disease or response (iSD/iPR/iCR) at all subsequent imaging.  The 
initial tumor scan showing disease progression by RECIST v 1.1 will be assigned as unconfirmed 
progre ssion (iUPD) for overall response.
Progression is considered confirmed (iCPD ), if the previous response status was iUPD and any 
of the fo llowing happens:
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 73oFor target lesio ns:  a
nyfurther increase in the previously ident ified target lesio n sum o f 
diameters by 5mm or more after iUPD.
oFor non -target l esions:  any further increase in the size of previously ident ified non-target 
lesion iUPD (the increase doesn’t need to meet RECIST v1.1 cri teria for unequivocal 
progression)
oFor new l esions: 
oan increase in the NL-T previously ident ified as iUPD and increase ≥5mm  in sum 
of diameter OR
oany increase for NL-NT OR
oany appearance o f additional new l esions
The overall response remains iUPD, IF
otarget lesio ns were the cause of the init ial iUPD AND
otarget lesio ns haven’t worsened, but they are still above PD thresho ld (20% increase 
from the nadir), AND
ono above factors of iCPD occur. 
When progression is considered not unconfirmed, the overall response can beco me iSD/iPR/iCR 
instead of iUPD if any o f the following criteria are met: 
oiCR: Target lesio ns and non -target l esions have regressed completely  AND no new 
lesions.
oiPR: Target l esions have regressed to ≥30% decrease fro m baseline (iCR or iPR) 
AND non -target l esionsremain non -iCR/non -iUPDAND no new lesio n
oiSD: Target l esions have regressed to <20% increase from nadir AND non -target 
lesions rem ain non -iCR/non -iUPD AND no new lesion .
Management Guideline sfor Patients Who Have Radiologic Evidence of Progressive 
Disease by RECIST v1.1
If a patient is clinically sta ble at the first radio logic PD by  RECIST v1.1(Eisenhauer et al 2009) , 
the pati ent may be considered for continuat ion on the study  until progressi on is confirmed . 
Confirmation o f progression must occur no less than 4 weeks later by  iRECIST.  For patients to 
be considered for continuation, the fo llowing criteria must allbe met: 
a.Absence of symptoms and signs indicat ing clinically significant progression of disease;
b.No decline in ECO Gor Karnofsky  performance status;
c.Absence of symptomat ic rapi d disease progressi on requi ring urgent medical intervent ion 
(e.g., symptomat ic pleural effusio n, spinal cord compressio n).
The continuat ion of treatm ent after init ial radio logic PD takes into considerat ion the observat ion 
that som e patients may  experience transi ent tum or flare or pseudo -progression with 
immunotherapy  but coul d have disease response later.  Patients may cont inue to receive 
treatm ent after reconsent ing.  For patients who meet criteria to continue treatment after init ial 
progression (either aw aiting confirmat ion by iRECIST or have iUPD by iRECIST), reconsent ing 
is required .  Pati ents who receive confirmatory  imaging do not need to undergo the next 
scheduled tumor imaging if it is less than 4 weeks later; tumor assessment will resume at the next
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 74scheduled imaging t ime point, if clinically stable.  Patients will be discont inued fro m study  
treatm ent if disease progression is confirmed by  iRECIST (Seymour et al. 2017).  
If a patient is clinically unstable, the patient should be discontinued from th e study  treatm ent at 
the first radio logical PD by RECIST v1.1.  The repeat tumor imaging for confirmat ion of PD by 
iRECIST is not required.
Clinical stabilit y is defined as the fo llowing (Seymour et al. 2017):  no worsening of 
perform ance status; absence o f signs or symptoms that are associated with clinically significant 
disease progressi on; no requi rement for intensified management, including increased analgesia, 
radiotherapy , or other palliat ive care.   
Clinical stabilit y is ult imately  defined by the trea ting 
investigator.
A summary  of imaging and treatment guidelines for patients who have first radio logic PD is 
listed in the tabl e bel ow.
Imaging and Treatment Guideline for Patients who have First Radiologic PD by 
RECIST v1.1
Clinically Stable Clinically Unstable
Imaging Treatment Imaging Treatment
First radiologic 
evidence of PD by 
RECIST v1.1Repeat imaging at 4 
to 8 weeks to 
confirm PD by 
iRECISTMay continue study  
treatment while 
waiting for 
confirmatory scan by 
iRECISTNot required; Repeat 
imaging at 4 to 8 
weeks to confirm PD 
per investigator’s 
discretio n onlyDiscontinue 
treatment
Repeat tumor 
imaging confirms 
PD (iCPD) by 
iRECISTNo additional 
imaging required Discontinue 
treatment No additional 
imaging requiredNot applicable
Repeat tumor 
imaging shows 
iUPD by iRECISTRepeat imaging at 4 
to 8 weeks to 
confirm PD by 
iRECIST.  May 
occur at next 
regularly  scheduled 
imaging visit Continue treatment 
at the investigator’s 
discretio nRepeat imaging at 4 
to 8 weeks to 
confirm PD per 
investigator’s
discretio n onlyDiscontinue 
treatment. 
Repeat tumor 
imaging shows iSD, 
iPR, or iCR by 
iRECIST per 
Investigator 
assessment.Continue regularly 
scheduled imaging 
assessments.Continue study 
treatment at the 
Investigator’s 
discretio n.Continue regularly 
scheduled imaging 
assessments.Discontinue 
treatment
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 75Abbreviations:  iCPD = iRECIST confirmed progressive disease; iCR = iRECIST confirmed complete response; 
iSD = iRECIST confirmed stable disease; iUPD = iRECIST unconfirmed progressive disease; PD = progressive 
disease; RECIST= Response Evaluation Criteria in Solid Tumors.
8.1.3. Efficacy Assessment for mCRPC Patients 
For m CRPC pati ents enrolled in this trial (both during dose escalation, 
Cohorts A and B, and 
dose expansio n Cohorts D1 and D2) ,response crit eria set forth by  the Prostate Cancer Clinical 
Trials Working Group 3 will be ut ilized ( Scher et al. 2016) . Efficacy will be evaluated on a 
combinat ion of RECIST v.1.1 (if patient has measurable disease), prostate -specific ant igen 
(PSA)measurements ,and bone scint igraphy  using 99mTc-methylene diphosphonate 
radionucleoti de (99mTc MDP ).Mult i-parametric MRI m ay also be used to evaluate response or 
progression in bone -only disease. Central measurement of c irculating tumor cells is planned at a 
frequency  of every  3 weeks but willnot berequired for efficacy evaluat ion. 
For pati ents wi th measurable disease ,RECIST v1.1, as described above in Section
 8.1.1 , will be 
utilized with the fo llowing caveats: 
I. For nodal lesio ns,separate pelvic vs extra -pelvic disease and record up to 5nodal 
lesions in total .
II. In order to classify as progression ,previously normal lymph nodes (<1 cm) must 
have grown by at least 0.5 cm in the short axis from baselin e scan or nadi r and be 
≥1cm in the short axis. 
III. Nodes that have progressed to 1.5 cm in the short axis are considered 
measurable ;nodes that have progressed to 1 cm to <1.5cmare consider ed 
pathol ogic but subj ect to clinical  discreti on and non -measurable .
IV. Visceral  disease shoul d be designated separately as lung, liver, adrenal, or CNS.
All mCRPC patientswill undergo a 99mTcMDP scintigraphy at baseline to evaluate skeletal 
disease involvement . Bone lesio ns should be evaluated every 9 weeks ( ±7 day s) and can be 
scheduled around CT/MRI disease sta ging. Due to possible bone flare that can be part of bone 
healing in response to treatm ent, and not actual progressio n, a 2+2 rul e shoul d be used for 
assessment. Progression should only be called if at least 2new lesio ns are seen on the first 
on-treatment scan, fo llowed by  at least 2 addi tional lesions on the second or subsequent 
post-treatm ent scan s.
For pati ents wi th non-measurable disease ,PSA evaluations will be utilized forresponse 
assessment to treatment. Prostate -specific ant igen will be measured at each treatment cy cle 
(every 3weeks) ,but b ecause favorable PSA response to treatment may be del ayed ,early PSA 
risesshoul d be i gnored until 12 weeks unless patient is rapidly  progressing (new lesio ns on 
imag e assessment ) with clinical deteri oration. After the first evaluat ion at 12 weeks, PSA 
response should be evaluated at every 9 weeks for progression. A PSA increase of 25% and 2 
ng/dLfrom baseline/nadir ,confirmed wit h a second measurement at least 3 weeks apart , will be 
considered progression. A PSA decrease from baseline that is50% will be considered a 
response and should be confirmed with a repeat measurement at least 3 weeks apart.
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA (Section 1.3) .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 76For each patient, ECGs, vital signs, laboratory  tests, and other tests should be collected as shown 
in the SoA (Section 1.3).
Refer to Section 8.3 for details on the recording of AEs.
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by appropri ate 
methods.
8.2.1.
Clinical Safety Laboratory Assessments
Lilly or i ts desi gnee will  provide the investi gator wi th the re sults of safety  laboratory  tests 
analyzed by a central vendor, if a central vendor is used for the clinical trial .  
See Appendix 2 for the list of clinical laboratory  tests to be performed and to the So A 
(Secti on 1.3) for the timing and frequency.
The inv estigator m ust revi ew the laboratory  report, docum ent thi s review, and record any  
clinically relevant changes occurring during the study  in the AE section of the case report 
form(CRF ). The l aboratory  reports m ust be filed wi th the source documents. Clinically 
significant abnorm al laboratory  findings are those which are not associated with the 
underlying disease, unless judged by the invest igator to be more severe than expected for 
the participant's condit ion.
All laboratory  tests wi th values considered c linically significantly abnormal during 
participat ion in the study or until the co mpletion of Visit 803shoul d be repeated until the 
values return to normal or baseline or are no longer considered clinically significant by 
the invest igator or medical mo nitor.
oIf such values do not return to normal/baseline wit hin a peri od of  time judged 
reasonable by the invest igator, the etio logy shoul d be ident ified and the sponsor 
notified.
oAll protocol -requi red laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual  and the SoA (Section 1.3) .
oIf there is an abnormal laboratory  value or abnormal  value for any  other di agnostic or 
screening test (for example, blood pressure increased, neutrophils decreased, etc.) and 
it is known to be related to a disease diagnosis (for example, hypertensio n, 
neutropeni a, etc.) thi s shoul d be reported in the CRF as an AE.  Do not enter the test 
abnorm ality, enter the disease diagnosis or categorical term. If laboratory  values 
from non-protocol  specified l aboratory  assessments performed at the inst itution’s 
local laboratory  requi re a change in participant management or are considered 
clinically significant by  the investi gator (e .g., SAE or AE or dose modificat ion), then 
the event(s) must be reported i n the CRF as AE(s).
8.2.1.1. Hepatic Safety Monitoring
In study participants with baseline ALT/AST< 1.5× ULN
If a study  parti cipant enrolled wit h baseline alanine aminotransferase ( ALT )/aspartate 
aminotransferase ( AST )<1.5×ULN, experiences elevated ALT/AST ≥3×ULN, liver testing 
(Appendix 4 ) shoul d be repeated wi thin 2to 5 days including ALT, AST, alkaline phosphatase 
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 7 7 (A L P ), t otal  bili r u bi n ( T B L ), di rect bilir u bi n, ga m ma -gl uta m yl tra nsferase, a n d creati ne ki nase t o 
c o nfir m t h e a b n or m ali t y  a n d t o deter mi ne if it is i ncreasi n g or decreasi n g. If t he a b n or malit y 
persists or w orse ns, cli nical a n d la b orat or y  m o ni t ori n g a n d e val uat i o n f o r p ossi ble ca uses of 
a b n or m al  li ver tests, s h o ul d be i ni ti ate d b y  t he i n vesti gat or i n c o ns ulta ti o n wi t h  t he st u d y  m e dical 
m o nit or.  M o nit ori n g of A L T, A S T, T B L, a n d A L P s h o ul d c o nti n ue u nt il le vels n or m alize or 
ret ur n t o a p pr o xi mate baseli ne le vels .  
I n st u d y p artici p a nts wit h b aseli ne A L T/ A S T ≥ 1. 5 x U L N 
If a st u d y  p arti ci pa nt e nr olle d wit h baseli n e A L T/ A S T ≥ 1. 5 ×U L N, e x perie nces ele vate d 
A L T/ A S T ≥ 2 ×baseli ne, li ver testi n g ( A p pe n di x 4) i ncl u di n g A L T, A S T, T B L, direct bilir u bi n, 
ga m ma -gl uta m yl  tra nsferase, a n d creati ne ki nase s h o ul d be re peate d wit hi n 3 t o 5 da y s t o 
c o nfir m t he a b n or malit y a n d t o de t e r mi ne if it is i ncreasi n g or decreasi n g.   If t he a b n or malit y 
persists or w orse ns, cli nical a n d la b orat or y  m o ni t ori n g a n d e val uat i o n f o r p ossi ble ca uses of 
a b n or m al  li ver tests, s h o ul d be i ni ti ate d b y  t he i n vesti gat or i n c o ns ultat i o n wi t h  t he st u d y  
C R P/ C R S. M o ni t ori n g of A L T, A S T, a n d T B L s h o ul d c o nti n ue u nt il le vels n or m alize or ret ur n 
t o a p pr o xi mate baseli ne le vels. 
8. 2. 1. 1. 1. S peci al He p atic S afet y D at a C ollecti o n 
A d dit i o nal safet y data s h o ul d be c o llecte d via t he C R F/electr o nic data e ntr y/ desi g nate d data 
tra ns missi o n met h o ds if 1 or m ore of t he f o ll o wi n g c o n di ti o ns occ ur: 
I n p artici p a nts e nr olle d wit h b aseli ne A L T/ A S T < 1. 5 ×U L N: 
Ele vat i o n of ser u m A L T/ A S T t o ≥ 5 ×U L N o n 2 or m ore c o nsec ut i ve bl o o d tests 
Ele vate d A L T/ A S T ≥ 3 ×U L N a n d ele vate d T B L ≥ 2 ×U L N 
I n p artici p a nts e nr olle d wit h b aseli ne A L T/ A S T ≥ 1. 5 ×U L N 
Ele vate d A L T/ A S T ≥ 3 ×baseli ne o n 2 c o nsec ut i ve tests 
Ele vate d A L T/ A S T ≥ 2 ×baseli ne a n d ele vate d T B L ≥ 2 ×U L N 
I n all st u d y p artici p a nts 
Di sc o nti n uati o n f r o m  st u d y  treat m e nt d ue t o a he pati c e ve nt or a b n or malit y of 
li ver tests 
Occ urre nce of a he pat ic e ve nt c o nsi dere d t o be a S A E 
8. 2. 1. 2. Aller gic re acti o n a n d H y perse nsiti vit y 
F or s us pecte d h y perse nsi ti vit y react i o n, la b or at or y tests ma y be o btai ne d at t he f oll o wi n g t i me 
p oi nts: 
I n t he prese nce of ge neralize d urticaria or if a na p h yla xis is s us pecte d. 
After t he s u bject has bee n sta bilize d, o btai n a sa m ple wit hi n 1 t o 2 h o urs of t he e ve nt, 
h o we ver, sa m ples ma y  b e o btai ne d as late as 1 2 h o urs after t he e ve nt as a nal ytes ca n 
r e m ai n altere d f or a n e xte n de d peri o d of ti me.  Rec or d t he ti me at w hic h t he sa m ple was 
c ollecte d. 
O btai n a f o ll o w- u p sa m ple at t he ne xt re g ularl y sc he d ule d visit or after 4 wee ks, w hic he ver is 
later. 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 78All biologic agents carry  the risk of systemic allergic/hypersensit ivity react ions.Clinical 
manifestations of these reactions may include but are not limited to:
Skin rash
Pruri tus (i tching)
Dyspnea
Urticarial  (hives)
Angioedema (for example, swelling of the lips and/or tongue)
Hypotensi on
Anaphylactic reaction
Parti cipants wi th clinical manifestations of systemic allergic/hypersensit ivity reacti ons shoul d be 
treated per local standard of care.  Addit ional data describing each symptom should be provided 
to the sponsor in the CRF.  
In case of anaphylaxis or generalized urticaria, addit ional blood sam ples shoul d be collected as 
close as possible to the onset of the event (see Sectio n 8.2.1 Clinical Safet y Laboratory  
Assessments).  Follow -up samples should be ob tained at the next regularly  scheduled visi t or 
4weeks after the event, whichever is later.  The lab results are provided to the sponsor via the 
central  laboratory  or via CRF.
8.3. Adverse Events and Serious Adverse Events
Invest igators are responsible for mon itoring the safety  ofpartici pants who have entered this 
study  and f or alerting Lilly  or its designee to any  event that seem s unusual, even if this event 
may be considered an unant icipated benefit to the participant .
The invest igator is responsible for the appropriate medical care of participants during the study .
Invest igators must document their review of each laboratory  safety  report.
The invest igator should provide AE verbat im terms and then the terms will be mappe d by Lilly  
or its desi gnee to corresponding termino logy within the Medical Dict ionary for Regulatory  
Activities (MedDRA) Lower Level Term (LLT) dicti onary .  The invest igator will use Commo n 
Termino logy Cri teria for Adverse Events ( CTCAE )version 5.0 to ass ign AE severit y grades.
The invest igator remains responsible for fo llowing, through an appropriate healt
h care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or that caused the participant to discont inue the invest igational product 
before complet ing the study.  The participant should be fo llowed unt il the event resolves, 
stabilizes with appropriate diagnostic evaluat ion, or i s otherwise explained.  The frequency  of 
follow-up eva luations of the AE is left to the discretion of the investigator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the ICF is signed, study  site personnel will record vi a CRF the occurrence and nature of 
each participant ’s preexist ing condit ions, including clinically  significant si gns and symptom s of 
the disease under treatment in the study .  In addi tion, si te personnel will record any  change in the 
condi tion(s) and any  new condi tions as AEs. Investi gators shoul d record thei r assessment of the 
potenti al relatedness of each AE to protocol procedure, invest igational product, via CRF.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 79The invest igator will interpret and document whether or not an AE has a reasonable possibi lity 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account the 
disease, concomi tant treatm ent or pathologies.
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the 
investigat ional product, study  device and/or study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If aparticipant ’s invest igational product is discont inued as a result of an AE, study  site personnel  
must report this to Lilly or its designee via CRF, clarifying if possible, the circumstances leading 
to any  dosage m odificat ions,or discont inuat ions of treatment.
Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1 of the f ollowing outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life
-threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or hospitalizat ion but m ay jeopardize the participant or may require 
intervent ion to pr event one of the other outcomes listed in the definit ion above.  
Examples of such medical events include allergic bronchospasm requiring 
intensive treatm ent in an emergency  room  or at home, blood dyscrasias or 
convulsio ns that do not result in inpatient ho spitalization, or the development of 
drug dependency  or drug abuse.
All AEs occurring after signing the ICF are recorded in the CRF and assessed for serious criteria.  
The SAE reporting to the sponsor begins after the participant has signed the ICF and has
received invest igational product.  However, if an SAE occurs after signing the ICF, but prior to 
receiving invest igational product, the SAE should be reported to the sponsor as per SAE 
reporting requirements and t imelines (see Sect ion8.3.1 ) if it is cons idered reasonably possibly 
related to study  procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to b e immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 24 -
hour notificat ion requirement refers to the init ial SAE informat ion and all fo llow-up SAE 
inform ation.  Parti cipants with a seri ous hepatic AEshould have addit ional da ta collected using 
the CRF.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 80Pregnancy (during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requirements any pregnancy should be 
reported fo llowing the SAE process to collec
t data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in participants once they  have 
discontinued and/or completed the study  (the participant disposi tion CRF has been com pleted).  
However, if the inve stigator learns of any SAE, including a death, at any time after a participant 
has been discharged from the study , and he/she considers the event reasonably  possibly related to 
the study  treatm ent or study  parti cipati on, the investi gator m ust prom ptly noti fy Lilly.
Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to investigational product or procedure.  
United States 21 CFR 312.32 and European Unio n Clinical Trial Direct ive 2001/20/EC and the 
associ ated detailed guidances or nati onal regulatory  requirements in parti cipat ing countries 
requi re the reporting of SUSARs.  Lilly  has procedures that will be followed for the 
ident ificat ion,recording and expedited reporting of SUSARs that are consistent with global 
regul ations and the associ ated detailed guidances.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
Although all AEs after signing the ICF are recorded by the site in the CRF/electronic data entry, 
SAE reporting to Lilly begins after the patient has signed the ICF and has received study  
treatm ent.  However, if an SAE occurs after signing the ICF, but pri or to receiving study  
treatm ent, it needs to be reported ONLY if it is considered reasonably possibly  related to study  
procedures.  
Medical occurrences that begin before the start of study  interventi on but after obtaining informed 
consent will be reported on the adverse events CRF.
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hou rs. The investigator will submit any updated SAE data to 
the sponsor within 24 hours of i t being a vailable. Serious adverse events, including death, 
caused by  disease progressi on shoul d not be reported unless the invest igator deems them to be 
possibly  related to study  treatm ent.
Invest igators are not obligated to actively seek AE sor SAE safter concl usion of the study  
participat ion.  However, if the invest igator learns of any SAE, including a death, at any t ime after 
a participant has been discharged from the study , and he/she considers the event to be reasonably  
related to the study  intervent ion or st udy participatio n, the invest igator must prompt ly notify  the 
sponsor .
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non
-leading verbal quest ioning of the participant is the preferred method to inquire about 
AEoccurrences .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 818.3.2. Follow -up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/contacts. All SAEs, will be followed until reso lution, stabilizat ion, the event 
is otherwi se explained, or the participant is lost to fo llow
-up (as defined in Sect ion 7.3 ). 
8.3.3. Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator to the sponsor of a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y 
of a study  intervent ion under clinical invest igation are met.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The sponsor will co mply wi th country -specific regulatory  requi rements 
relating to safet y reporting to the regulatory  authorit y, Institutional Review Boards 
(IRB)/Independent Ethics Co mmittees (IEC) , and investigat ors.
Invest igator safet y reports must be prepared for SUSAR according to local regulatory  
requi rements and sponsor policy and forwarded to investigators as necessary .
An invest igator who receives an invest igator safety report describing a SAE or other 
specific safet y informat ion (e.
g., summary or list ing of SAEs) fro m the sponsor will 
review and then file it along wit h the IBand will notify the IRB/IEC, if appropriate 
according to local requirements.
8.3.4. Pregnancy
Details o f all pregnancies in female parti cipants and, if indicated, female partners of 
male participants will be collected after the start of study  intervent ion and unt il the 
completion of V isit 803.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of 
learnin g of the pregnancy and should follow the procedures outlined in Appendix 3.
Abnorm al pregnancy outcom es (e.
g., spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, ectopi c pregnancy) are considered SAEs.
Addit ional requirements for pregnancy test ing during and after study  intervent ion are 
located in Appendix 3.
The invest igator is responsible for review of medical history, menstrual history, and 
recent sexual act ivity to decrease the risk for inclusion of a wom an wi th an early 
undetected pregnancy
All pregnancies and exposure during breastfeeding, from the time of treatment through 
120 day s following cessat ion of study  treatm ent, or 30 day s following cessat ion of study  
treatm ent if the participant init iates new ant icancer therapy must be reported by  the 
investigator
8.3.5. Cardiovascular and Death Events
Events leading to the clinical outcome of death due to study disease that are part of the efficacy 
analyses for this study  will not be reported to Lilly or its des ignee as SAEs unless the 
investigator believes the event may have been caused by the invest igational product.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 828.3.6. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to e nsure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Parti cipants will be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational pr oduct so that the situation can be assessed.
8.3.7 . Events of Clinical interest
Selected non -serious and seri ous adverse events are al so known as Events of Clinical Interest 
(ECI) and must be reported to the Sponsor.
Events of clinical interest for this tr ia
l include: 
1.an overdose of Sponsor's product, as defined in Section 8.4 –Treatment of Overdose, that 
is not associated with clinical symptoms or abnormal laboratory  resul ts.
2.an elevated AST or ALT lab value that is greater than or equal to 3 ×the ULN and an 
elevated total  bilirubin lab value that is greater than or equal to 2 ×the ULN and, at the same 
time, an alkaline phosphatase lab value that is less than 2 ×the ULN , as determined by way  of 
protocol -specified laboratory  testi ng or unscheduled la boratory  testing.*
*Note:  These criteria are based upon available regulatory  guidance docum ents. The purpose 
of the cri teria is to specify a threshold of abnormal hepat ic tests that may require an 
additional evaluat ion for an underlying et iology. The tr ial site gui dance for assessment and 
follow up of these criteria can be made available.  It may also be appropri ate to conduct 
additional evaluat ion for an underlying et iology in the setting of abnormalit ies of liver blood 
tests including AST, ALT, bilirub in, and alkaline phosphatase that do not meet the criteria 
noted above. In these cases, the decision to proceed with addit ional evaluat ion will be made 
through consultation between the study  invest igators and the Lilly CRP/CRS . However, 
abnorm alities of liver blood tests that do not meet the criteria noted above are not ECIs for 
this trial.
8.4. Treatment of Overdose
For this study , an overdose of pembro lizumab will be defined as any dose of 1000 mg or ≥5 
times the indicated dose. 
No specific inform ation is available on the treatment of overdose of pembrolizumab .  In the 
event of overdose, the participant shoul d be observed closely for signs of toxicity.  Appropriate 
supportive treatment should be provided if clinically  indicated.
8.5. Pharmacokinetics
At the visit s and t imes specified in the SoA (Secti on 1.3 ),venous blood samples of 
approximately  2mLwill be co llected to determine the plasma concentrations of LY3475070.
Aberrat ionsto specified sampling times in the SoA (Section 1.3) will not be considered protocol 
deviat ions as l ong as the samples are taken and the actual  sampling time is recorded .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 83Prior to dosing, pati ent shoul d voi d bladder.  Follo wing administration of LY3475070
, the total 
urine output from 0 (post dose) to 8hours will be col lected, pooled, and refrigerated (Section 
1.3).Urine should not be fractionated unless scientifically just ified. From  thetime period, 1
aliquot will be used to measure LY 3475070 for urinary creatinine concentration and 2aliquots of 
approximately  10 mL each will be stored frozen unt il further analysis. The total vo lume of urine 
will be recorded and the remaining urine will be discarded .  Serum samples for creatinine 
measurement should be co llected as specified in the stud y SoA in Section 1.3 (Clinical 
Chemistry ).
Blood and urine samples will be analyzed at a laboratory  approved by the sponsor.   Plasma and 
urine concentrations of LY3475070 w ill be assayed using a validated liquid
chromatography -tandem  mass spectrom etry (LC-MS/MS) method. 
Bioanaly tical samples collected to m easure invest igational product concentrations and 
metabo lism and/or protein binding will be retained for a maximum o f 2 years fo llowing last 
participant visit for the study .  During this t ime, blood and urine samples remaining after the 
bioanalyses will be analyzed for exploratory  metaboli teident ificat ion, as deemed appropriate by  
the sponsor. The results of such exploratory metabolism work may only be included in the 
clinical study  report if deemed appropri ate by  thesponsor or m ay be reported in a separate 
exploratory  metabo lism report .
8.6. Pharmacodynamics
See Section 1.3.1fora schedule of serum  collecti onfor CD73 inhibit ion ex vivo 
pharmacodynamic assay to be collected in this study .
8.7. Genetics
8.7.1. Whole Blood Sample for Pharmacogenetic Research
A who le blood sample will be co llected for pharmacogenet ic analysis as specified in the SoA
(Secti on1.3) where local regulat ions allow.  
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable response to LY3475070 and to 
investigate genet ic variants though t to pl ay a rol e in cancer .  Samples may also b e used to 
determine the somatic or germline origin o f ident ified genet ic alterations in tumor sam ples.
Assessment of variable response may  include evaluati on of  AEs or differences in efficacy.  
All samples will be coded with the patientident ification number.  These samples and any  data 
generated can be linked back to the patient only by the investigator site personnel.  
Samples will  be retained at a facilit y selected by  Lilly  or its designee for a m aximum  of 15years 
after the l ast participant visit for the study , or f or a shorter peri od if l ocal regulat ions and/or 
ERBs /IRBs impose shorter time limits. This retentio n peri od enables use of new techno logies, 
response to regulatory  quest ions, and invest igation of variable response that may not be observed 
until later in the development of LY3475070 or after LY3475070 beco me(s) commercially 
available.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 84Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, exist ing approaches incl ude whol e genom e or exome 
sequencing, geno me wide association studies, and candidate gene studies.  Regardless of 
techno logy utilized ,data generated will be used only for the specific research scope described in 
this secti on.
8.8. Biomarkers
Biomarker research is performed to address questions of relevance to drug disposit ion, target 
engagement, pharmacodynamics , 
MOA , variabilit y of participant response (including safet y), 
and clinical outcome.  Sample collect ion is incorporated into clinical studi es to enable 
examinat ion of these questions through measurement of bio molecules including 
deoxy ribonucleic acid, ribonucleic acid, proteins, lipids, and other cellular elements.
Serum , plasma, tumor tissue, and whole blood for bio marker research will be co llected at the 
times specified in the SoA (Secti on1.3) where local regulat ions allow. A maximum of 5 
samples may  be drawn, collected, or removed at addit ional timepoints during the study  if 
warranted and agreed upon by  the invest igator and Lilly. If these addit ional samples are 
requested, they  will be used to further investigate bio markers that may explain treatment 
response and resistance mechanisms.
Samples will  be used for research on the drug target, disease process, variable response to 
LY3475 070, pathway s associ ated wi th cancer , MOA of LY3475070 , and/or used to develop 
research methods or tovalidat ediagnostic tools or assay(s) related to cancer .  
Collect ion of the fo llowing tum or tissue sample(s) is required for patients to parti cipate in t his 
study :
Phase 1a:
oA mandatory  archival  FFPE tumor tissue sample.  While the tissue can be from 
either ini tial diagnosis or l ater, the sam ple shoul d be the m ost recent available 
specimen containing adequate material.  Sites should confirm the availabilit y of 
archival tumor tissue wit h the pathology  laboratory  during screening and pri or to 
enrollment.  Tumor tissue should be submitted within 30days fo llowing 
enrollment. 
oIf an archival sample is unavailable, then a pretreatment biopsy (core or 
excisio nal)of a tum or lesi on from a primary or m etastatic site may be submitted 
to meet eligibili ty requi rements .  
Phase 1b:
oA newly obtained core or excisio nal baseline biopsy o f a tum or lesion from a 
primary  or m etastatic si te. Archived tissue obtained fro m a recent biopsy may be 
permitted in lieu o f the baseline biopsy after discussion between the Lilly  
CRP/CRS and investigator if a patient has not received any  therapies for the 
disease between the time the archived t issue was collected to the start of 
LY345070 treatm ent; the decision to use an archived tissue sample will be 
docum ented .
oA tum or tissue sam ple from a newly  obtained core or excisio nal biopsy  specimen 
collected during the study  treatm ent peri od as shown in the SoA (Section 1.3) .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 85Patients m ust be will ing to undergo baseline and on -study  biopsies that shoul d not put pati
ents at 
undue risk greater than that which comes with a core biopsy .
Collect ion of biopsies, as outlined above, is mandatory  for pati ents enrolled in Cohorts D1 and 
D2only in cases in which these pat ients present with accessible so ft tissue m etastasis that can be 
safely biopsied . Exceptions will be made in all other cases.
Collect ion of the fo llowing tum or tissue sample(s) is optional for pati ents parti cipat ing in this 
study :   
Phase 1a:
oIf archival t issue is submitted to meet eligibilit y requi rements, a newly obtained 
core or excisio nal pretreatment biopsy  of a tum or lesi on fromaprimary  or 
metastati c site.
oA tum or tissue sam ple from a newly  obtained core or excisio nal biopsy  specimen 
collected during the study  treatm ent peri od as shown in the SoA (Section 1.3) .
Phase 1b:
oAn archival FFPE tumor tissue obtained from  the primary  tumor site, if available 
and not restricted by  local regulati ons.  Regardl ess of whether or not the ar chival 
tissue is submitted, patients are still required to undergo pretreatment and 
on-treatment biopsies, as indicated above and in the SoA (section 1.3).
All patients:
oA tum or tissue sam ple from a newly  obtained bi opsy  specimen collected after 
disease pr ogressi on or at addi tional study  time points, if warranted and agreed 
upon by  the invest igator and Lilly.  Such addit ional biopsies are optional and 
shoul d be perform ed only if clinically  feasible.  If these addit ional samples are 
requested, they  will be u sed to further investigate biomarkers that may explain 
treatm ent response and resistance mechanisms.  If a biopsy is performed as part of 
clinical care after the patient signs the ICF, Lilly may  request a ti ssue sample 
from the biopsy  for addi tional biomarker testing at any  time during the study  
including post -progression.
The ti ssue samples should be obtained using an appropriate method.  Tumor tissue should be 
submitted as a newly  acqui red endoscopic core needl e (minimum 18 gauge) or surgi cal biopsy .  
Cytological or fine -needle aspirationspecimens may be acceptable for NSCLC patients upon 
discussio n with the Lilly  CRP/CRS, but are not acceptable for other cancer ty pes.  An attem pt to 
obtain up to 4 core -needle biopsies, surgical biopsy, or endoscopic b iopsy is required, unless 
medically contraindicated or unsafe and discussed with the Lilly CRP/CRS.  Optimally , biopsies 
shoul d be taken from  the same metastati c lesi on and f rom areas not previously  irradiated (except 
if the lesio nprogressed after radiati on).  See the Laboratory  Manual for details regarding sample 
collect ion and handling.  If addit ional tumor biopsies are collected as part of clinical care, they  
shoul d be submi tted, al ong wi th pathol ogy reports, for further analysis.  When a biopsy is 
subm itted, due diligence should be used to ensure that tumor specimens (not a normal adjacent or 
a tum or margin sample) are provided and that the tumor sample contains tumor cells prior to 
shipment to the central laboratory .  If a pre-treatm ent sampledoes not contain adequate ti ssue for 
analysis, the patient may be replaced.  Lilly may replace up to 10% of the total patients who are
unable to submit an adequate tumor sample.   The pathology  report accom panying archival t issue 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 86may also be requested.  The patholo gy report must be coded with the patient number.  Personal 
ident ifiers, including the patient’s name and init ials, must be removed from the inst itutional 
pathol ogy report pri or to submissio n.  Lilly has a right to retain a portion of the submitted tissue. 
Archival blocks will be sect ioned and returned to the study  site.  Slides and t issue samples 
collected on -study  will not be returned.
All samples will be coded with the participant identification number.  These samples and any 
data generated can be linked back to the participant only by  the invest igator site personnel.  
Samples will  be retained at a facilit y selected by  Lilly  or its designee for a m aximum  15 years 
after the l ast participant visit for the study , or f or a shorter peri od if l ocal regulat ionsand ERBs 
impose shorter time limits.  This retention period enables use of new technologies, response to 
regul atory  questi ons, and invest igation of variable response that may not be observed unt il later 
in the development of LY3475070 or after LY3475070 become(s) commercially available.
Techno logies are expected to improve during the 15 -year storage period and therefore cannot be 
specifically named. Existing approaches, including mutation pro filing, copy  number vari ability 
analysis, gene expressio n assays , m
ultiplex assays, and/or immunohistochemistry  may be 
perform ed on these tissue samples to assess potential associat ions between these bio markers and 
clinical outcomes.
It is possible that bi omarker data for patients in the study  have al ready been generat ed fro m 
samples that were collected and analyzed prior to enro lling in this study . This m ay include data 
generated fro m genet ic analyses. If available, these data may be requested fro m medical records 
for use in the research described in Sect ions 8.7 and 8.8.
8.8.1. Tumor Tissue Samples for Determination of CD73 Expression
Patients m ust submit all samples from the pretreatment biopsy and be posi tive for CD73 
expressio n as determined at a central labora tory to confi rm study  eligibilit y into Phase 1b Cohort 
C.  Patients that are not posit ive forCD73 expression, despite meet ing all other eligibilit y 
criteria, will be screen failures.   Unused tissue from screen failures will be returned to the sites .  
Samples fro m patients that are posit ive forCD73 expressio n and proceed to enroll into the study  
will be retained for biomarker testing.
8.9. Medical Resource Utilization and Health Economics
Health economics and medical resource utilizat ion parameters will not be evaluated in this study .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 879. Statistical Considerations
9.1. Statistical Hypotheses
In the dose escalat ion phase, our hy pothesis is that there is a tolerable DLfor LY3475070 in both 
monotherapy  and in combinat ion treatm ent wit
h pembro lizumab . 
In the dose expansio n phase, the objective is to assess the safet y and tolerabilit y,as well as 
clinical act ivity of LY3475070 as monotherapy  and in combinat ion with pembro lizumab .  No 
formal hypothesis testi ng will be performed to demo nstrate any  stati stically significant 
improvement in objective response rate. Therefore, s pecification o f alternat ive hypothesis on the 
objective response rate does not apply. 
9.2. Sample Size Determination
The primary  object ive of this study  is to assess the safet y and tolerabilit y of LY3475070, thereby 
ident ifying and confirming the RP2D of LY34 75070, to be administered as monotherapy  and in 
combinat ion with pembrolizumab , in pat ients with advanced solid malignancies.  The primary 
objective of the Phase 1b portion of this study also includes preliminary clinical  activity 
evaluat ion by overall response rate (ORR )per RECIST v1.1, as monotherapy and in co mbinat ion 
with pembro lizumab . The secondary  object ive is to evaluate PK and any observed evidence of 
clinical efficacy .  
With a total sample size of N= 20or N=40, example point estimates of incidence rates and 
corresponding 2- sided 95% confidence intervals ( CIs) are summarized in the table below. The 
values are provided as a reference for estimat ion rather than a basis o f any decisio n criteria. The 
RP2D m ay be revi sed based on the safet y data obtained in the expansi on phase (Iasonos and 
O’Quigley  2013).
Estimated Incidence Rate and 2 -Sided 95% CI
N=20 N=40
Number 
of CasesEstimated
Rate95% C IaNumber 
of CasesEstimated
Rate95% CIa
Lower Limit Upper Limit Lower Limit Upper Limit
0 0.0 0.0 0.17 0 0.0 0.0 0.09
3 0.15 0.03 0.38 5 0.12 0.04 0.27
5 0.25 0.09 0.49 10 0.25 0.13 0.41
10 0.50 0.27 0.73 15 0.38 0.23 0.54
15 0.75 0.51 0.91 20 0.50 0.34 0.66
Abbreviations:  CI =confidence interval; N =number of patients .
a95% Clopper -Pearson interval for binomial dis tribution . 
In the dose escalat ionphase , once a given DLis cleared for DLT evaluation and is deemed safe , 
the dose cohort may be expanded with backfill pat ients to further invest igate the safe ty, PK, 
pharmacodynamic , and clinical act ivity of LY3475070 and the combinat ion with 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 88pembro lizumab.  The re will be up to 20 backfill patients enrolled across all DLs in Cohorts A 
and B co mbined in the phase 1a study .  
Enrollment of pat ients to the dose coh ort for DLT 
evaluat ion/dose escalat ion decisio n will take precedent. A Bayesian toxicit y monitoring rule will 
be implemented to ensure continuous safet y monitoring , assuming DLT or DLT -equivalent 
events arise from a bet a-binomial model. Specifically , if the Prob(true DLT or DLT-equivalent 
rate >3 5%) > 55% in any given cohort, the enrollment to that cohort will be halted.  A 35% rate
is targeted to be consistent with the mTPI
-2 equivalence interval upper bound. A Beta(1, 1) prior 
for the t rue rate is ut ilized. Thestopping boundaries for this safet y monitoring rul e based on the 
aggregated data is listed in the fo llowing tabl e. 
Bayesian Toxicity Monitoring Rules
Number ofPatients Pause ifNumber ofPatients with DLT or DLT Equivalent
4-5 ≥2
6-8 ≥3
9-11 ≥ 4
12-14 ≥5
15-16 ≥6
17-19 ≥7
20 stop
Abbreviations:  DLT = dose -limiting toxicity.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 899.3. Populations for Analyses
For purposes of analysis, the following populat ions are defined:
Population Description
Entered All participants who sign informed consent
DLT evaluable All patients enrolled in the dose escalation phase (phase 1 a) who either complete 
3 weeks of follow -up and treatment or discontinue treatment prior to 3 weeks 
due to a DLT.
PK Evaluable All enrolled patients w ho have at least 1 post baseline evaluable PK sample
Safety All participants who take at least 1 dose of study treatment.  Participants will be 
included in the treatment group corresponding to their initial dose of study 
treatment, even if it is not the treatment to which they were assigned.  In the 
event of a treatment error, participants will be analyzed according to the 
treatment they actually received.
“Enrolled” population also refers to the “Safety” population in this study.
Phase 1 a All patients assigned t o a treatment cohort during the dose escalation portion of 
the study .
Phase 1b All patients assigned to a treatment cohort during the dose expansion portion of 
the study .
CD73+ CD73+ by IHC
Abbreviations:  DLT = dose -limiting toxicity; IHC = immuno -histochemistry; PK = pharmacokinetics .
9.4. Statistical Analyses
9.4.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y ofLilly o r its desi gnee .
Efficacy analyses will be conducted on the set of all enro lled patients.This set includes all data 
from all participants receiving at least 1dose of the invest igational product according to the 
treatm ent the participants were assigned .
All tests of treatment effects will be conducted at a 1-sided 0.05 al pha level , as appropri ate for 
the com parison , unless otherwise stated.
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis 
methods d escribed in the protocol, and the just ification for making the change, will be described 
in the clinical study  report (CSR) .  Additional exploratory analyses of the data will be conducted 
as deemed appropriate.
9.4.2. Treatment Group Comparability
9.4.2.1. Participant Disposition
A detailed description o f participant disposit ion will be provided at the end of the study ,
including a summary of the number and percentage of patients entered into the study , enrolled in 
the study , and treated as well as number and percentage of patients complet ing the study, as 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 90defined in the statistical analysis plan ( SAP), or di scontinuing ( overall and by reason for 
discontinuat ion).  A summary of all important protocol deviat ions will be provided . 
9.4.2.2. Participant Character istics
Dem ographic data are collected and reported to demo nstrate that the study  populati on represents 
the target patient po pulat ion considered for regulatory  approval .  
A summary of baseline patient 
and disease characteri stics, histori cal diagnoses, preexist ing condit ions,and prior therapies will 
be reported using descript ive statist ics.
9.4.2.3. Concomitant Therapy
A summary of priorand concomitant medications will be reported .
9.4.2.4. Treatment Compliance
Study  treatm ent com pliance will be assessed as the proportion of treatment that is actually taken, 
relative to what is expected, after accoun ting for protocol -defined dose adjustments.  St udy 
treatm ent taken will be derived from the difference between the total number of capsules/ tablets 
dispensed and returned over the course of the patient’s treatment. The number of cycles 
received, dose omissio ns, dose reductions, dose delays, and dose i ntensity will be summarized 
for all treated pati ents by  treatm ent arm .
9.4.3. Efficacy Analyses
9.4.3.1. Primary Analyses
Overall response rate is defined as the number of patients who achieve a best overall response of 
CR or PR divided by the total number of patients treated (safet y popul ation).  The ORR, with 
95% CI, will be summarized for each study  part.
9.4.3.2. Secondary Analyses
The disease control rate (DCR), defined as the proportion of patients who achieved a CR or PR 
or SD) out of all pat ients treated, will also be su mmar ized.  Best response is determined fro m a 
sequence of responses assessed.  Two object ive status determinations of CR before progression 
are required for a best response of CR.  Two determinat ions of PR or better before progression, 
but not qualifying f or a CR, are requi red for a best response of PR.
Duration of response (DoR)is defined as the time fro m the date m easurement criteria for CR or 
PR (whichever is first recorded) are first met unt il the first date that disease is recurrent or 
objective progr ession is observed, per RECIST v1.1 criteria, or the date of death fro m any cause 
in the absence of object ively determined disease progression or recurrence.  Duration of SD will 
be calculated only  for pati ents wi th best response of SD. It is measured fro m the date of start of 
treatm ent to the date of first progression o f disease or the date of death due to any  cause, 
whichever i s earlier. For each patient who is not known to have died or to have had a 
progression of disease as o f the data -inclusio n cut -off date, duration of SD will be censored at 
the date of last objective response assessment prior to the date of any subsequent systemic 
anticancer therapy .
Progression -free survival (PFS) i s defined as the time from the date of start of treatment to the 
first date of the observed clinical or radiologically  docum ented PD or death due to any  cause, 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 91whichever occurs first.  For patients who are not known to have died or progressed as of the 
data-inclusio n cut -
off date, PFS time will be censored at the date of the last obj ective 
progression -free di sease assessment prior to the date of any  subsequent sy stem atic ant icancer 
therapy .
PFS Event/Censoring Scheme
Situa tionaEvent/Censor Date of Event or Censor
Tumo r progression or death Event Earliest date of PD or death
No tumor progression and no death Censored Date of last adequate tumor 
assessment per RECIST v1.1, or 
date of first dose (whichever is 
later)b
Unless
No baseline radiologic tumor 
assessment available Censored Date of first dose
No adequate postbaseline tumor 
assessment available anddeath 
reported after 2 scan intervals 
following the first doseb, cCensored Date of first dose
Tumo r progression or death 
documented immediately after 2 or 
more scan intervals following last 
adequate tumor assessment or 
randomization (whichever is later)b,cCensored Date of last adequate tumor 
assessment, per RECIST v1.1, or 
date of first dose
(whichever is later)b
New therapeutic anticancer 
treatment started prior to tumor 
progression or deathCenso red Date of last adequate radiological 
assessment prior to new therapeutic 
anticancer therapyb
Abbreviations : CR = complete response; PD = progressive disease; PFS = progression -free survival; PR = partial
response; RECIST v1.1 = Response Evaluation Criteria in Solid Tumors; SD = stable disease.
aSymptomatic deterioration (i .e., symptomatic progression that is not confirmed per RECIST v1.1) will not be
considered as tumor progression.
bAdequate tumor assessment per RECIST v1.1 refers to an assessmen t with one of the following responses :  CR,
PR, SD, or PD.
cRefer to the statistical analysis plan for the definition of 2 scan intervals, including any adjustment for scan
window.
Time to response (TTR) is defined as the time from the date of start of treatm ent to the date 
measurement criteria for confirmed CR or PR (whichever is first recorded) are first met.  For 
patients who are not known to have achieved CR or PR as of the data -inclusio n cut -off date, TTR 
will be censored at the date of the last obj ective disease assessment prior the date of any 
subsequent systematic ant icancer therapy .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 929.4.3.3. Tertiary/Exploratory Analyses 
Overall survival ( OS), as well as the efficacy  parameters based on iRECIST will also be 
analyzed as the exploratory  object ives. The de finition of efficacy endpo ints based on iRECIST 
will be described in the SAP.
Overall survival is defined as the time fro m the first start of study  treatm ents unt il death fro m 
any cause. If the patient is alive, l ost to foll ow-up, or wi thdrawn fro m study  at the time o f data 
analysis, OS data will be censored on the last date the patient is known to be alive. 
9.4.4. Safety Analyses
All patients who receive at least 1 dose of any study therapy will be evaluated for safet y and 
toxicity. 
The MedDRA Versio n 22.0 (or higher) will be used when reporting AEs by  MedDRA terms. 
The MedDRA Lower Level Term (LLT) will be used in the treatment -emergent computation. 
Treatment -emergent adverse events will be summarized by System Organ Class (SOC) an d by 
decreasing frequency of Preferred Term (PT) within SOC.
Safety analyses will include summaries of the fo llowing:
DLTs at each DLin the dose escalat ion phase and DLT -equivalent AEs for expans ion 
cohorts ;
AEs, including severit y and possible rel ationship to study  drug;
SAEs, including possible relationship to study  drug;
AEs leading to dose adjust ments;
discontinuat ions from  study  treatm ent due to AEs or death;
treatm ent emergent abnormal changes in laboratory  values;
treatm ent emergent abnormal changes in 
vital signs and ECGs .
9.4.5. Pharmacokinetic/Pharmac odynamic Analyses
Selected PK descriptors for LY3475070 (based on actual sampling times), including C max, 
approximate time of C max(tmax), and AUC will be calculated by nonco mpartmental analysis 
methods and/ or model simulat ions. As an exploratory  analysis, PK descriptor estimates for 
trough concentrations (C min) at steady  state following repeated dose may be evaluated.  
In addit ion, PK parameter estimates for LY3475070 as single agent and in combinat ion with 
pembro lizumab maybe calculated, data allowing. The version o f any so ftware used for the 
analysis will be documented, and the program will meet the Lilly requirements of so ftware 
validat ion. It is possible that other validated, equivalent PK software p rograms may be used if 
appropriate, warranted, and approved by  Global PK/pharmacodynamics management.
PK/pharmacodynamics analyses may be conducted to explore exposure -response relat ionships
between LY3475070 concentrations in systemic circulat ion and various pharmacodynamic
measures as second step if dose- response relationship is positively assessed .
Renal clearance of LY3475070 will be calculated as the ratio of amount excreted/AUC from 
time 0 to time t (AUC 0-t), and will be co mpared with unbound glo merular filtrat ion rate, 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 93estimated using creat inine renal clearance and plasma unbound fraction (Fu) (Fu ×amount of  
creatinine excreted/creatinine AUC 0-t).
9.4.6. Other Analyses
Subgroup Analyses A prespecified list of subgroups will be ident ified in the SAP.  The treatment 
effect within each subgroup will be summarized.  Other subgroup analyses not specified in the 
SAP m ay be performed as deemed appropriate.  These subgroups will be based on important 
characterist ics, for exam ple, prognosti c significance.
9.4.6.1. Biomarker Analyses
Single-marker and/or mult i
-marker statistical analysis may be performed to explore the 
associ ation between bio markers, dose/exposure, and clinical outcomes. For an example, a n 
associ ation analysis between CD73 expressio n and clinical benefit maybe tri ggered after data in 
Phase 1b Cohort C i s collected. 
9.5. Interim Analyses 
In the Phase 1aporti on of  this study , dose -escalat iondata (monotherapy  and co mbinat ion) will 
be reviewed for safet y on a cohort-by-cohort basis, until the MTDs (or the highest DLs if MTDs 
are not reached) are determined for each treatment part.  The purpose of these cohort -by-cohort 
reviews is to evaluate the safet y data at each DLand determine if a DLT has been observ ed that 
woul d suggest MTD has been met or exceeded.  The invest igators and the Lilly study team will 
make the determinat ion regarding dose escalat ion based upon their review of the safet y and 
tolerabilit y data as described in this protocol.
In the Phase 1bporti on of  this study , asafety  review will be perform ed after the first 20 patients 
across all dose-expansio n cohorts are enrolled and treated for 1 cy cle, and then every  6 months 
afterward. For preliminary efficacy evaluations, the fo llowing interim an alyses are pl anned:
Cohort C(patients with CD73+ tumors) and Cohort D(castrate resistant prostate cancer) : 
for each cohort, an interim analysis of safet y and efficacy  is planned after 10 patients in 
the monotherapy  arm are treated and com pleted 2 cy clesor have discont inued before the 
first postbaseline tumor assessment. Per 2:1 randomizat ion rati o, at this interim analysis 
approximately  20 pati ents in the combinat ion arm  are treated. Preliminary efficacy will 
be evaluated on these 20 patients in the c ombinat ion arm and on these 10 patients in the 
monotherapy  arm, and the combinat ion arm may be expanded wit h addit ional 20 patients 
if the totalit y of efficacy , safet y, and PK/pharmacodynamics data warrant expansio n
.  If 
no object ive responses are observed, both as monotherapy or combination therapy, the 
combinat ion arm (s) will not continue enrollment.
Cohort E (TNBC): an interim o f safet y and efficacy  is planned after approximately  20 
patients are treated and comple ted 2 cy cles or have discont inued before the first 
postbaseline tumor assessment. The t rial may continue to enroll 20 additional patients for 
the final analysis if the totalit y of efficacy, safety , and PK/pharm acodynamics data 
support s the addition of pat ients.  If no objective responses are observed, addit ional 
patient enrollment to Cohort E will be terminated.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 94The interim analyses may be combined if they are expected to occur within a similar timeframe; 
interim analyses may  also be combined wit h any pres pecified safet y review or annual reporting 
(such as an update to the IB or Development Safety Update Review, etc.).
If it is deemed that enough data are obtained to assess the primary  object ive and the secondary
objectives, a CSR might be created before th e last pati ent visi t.  In this case, all data until the
data-cutoff date will be used for the analysis of safety, efficacy, PK, and pharm acodynamic
biomarkers. Alldata defined in the protocol will continue to be collected fro m patients on 
treatm ent after thedata-cutoff date. These data may be reported separately and the analyses on 
all patients including these data may not be performed.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 9510. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council f or Internati onal Organizat ions of Medical Sciences 
(CIOMS) International Ethical Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, ICF, IB, and other relevant documents (e .
g., 
advert isements) must be submitted to an IRB/IEC by the investigator and reviewed and 
approved by  the IRB/IEC before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation 
of changes made to the study  design, except for changes necessary
 to eliminate an 
immediate hazard to study  parti cipants.
The invest igator will be responsible for the fo llowing:
oProvi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or 
more frequent ly in accordance wit h the requirements, policies, and procedures 
established by  the IRB/IEC
oNotifying the IRB/IEC of SAEs or other significant safet y findings as required by 
IRB/IEC procedures
oProvi ding oversight of the conduct of the study  at the site and adher ence to 
requi rements of 21 CFR, ICH guidelines, the IRB/IEC, European regulat ion 536/2014 
for clinical studi es (if applicable), and all other applicable local regulat ions
After reading the protocol, each principal invest igator will sign the protocol signat ure page and 
send a copy  of the signed page to a Lilly representative.   
The CSR coordinat ing invest igator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct a nd results 
of the study .
10.1.2. Informed Consent Process
The invest igator or his/her representative will explain the nature of the study , including 
the risks and benefits, to the parti cipant or hi s/her legally authorized representative and 
answer all quest ions re garding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Participants or thei r 
legally authorized representative will be requi red to si gn a statem ent of informed consent 
that meets the requirements of 21 CFR 50, local regula tions, ICH gui delines, Healt h 
Insurance Portabilit y and Accountabilit y Act (HIPAA) requirements, where applicable, 
and the I RB/IEC or study  center.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 96The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained 
before the participan t was entered in the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during th eir 
participat ion in the study.
Parti cipants otherwise eligible for Phase 1bCohort Cwill sign the Cohort Cinformed 
consent prior to collection o f the fresh tissue sample for determinat ion of CD73 
expressio nand potenti ally retained for biomarker testing .
A copy  of the IC F(s) m ust be provi ded to the participant or the participant’s legally  
authori zed representati veand i s kept on file .
Parti cipants who are rescreened are required to sign a new ICF.
The ICF will contain a separate section that addresses the use of remaining mandatory  samples 
for opti onal expl oratory  research. The invest igator or authorized designee will explain to each 
participant the obj ectives of the exploratory research. Participants will be told that they  are f ree 
to refuse to participate and may  withdraw thei r consent at any  time and for any  reason during the 
storage peri od. A separate signature will be required to document a participant's agreement to 
allow any  remaining specimens to be used for exploratory  research. Participants who decline to 
participate in this optional research will not provide this separate signature.
10.1.3. Data Protection
Parti cipants will be assigned a unique ident ifier by the investigator . Any part icipant 
records or datasets that are transferred to the sponsor will contain the ide ntifier only; 
participant names or any  information which would make the participant ident ifiable will 
not be transferred.
The parti cipant m
ust be inform ed that hi s/her personal  study -related data will  be used by  
the sponsor i n accordance with local data pr otecti on law. The level o f disclosure m ust 
also b e explained to the participant.
The parti cipant must be inform ed that hi s/her m edical  records m ay be examined by 
Clinical Qualit y Assurance auditors or other authorized personnel appo inted by  the 
sponsor, b y appropriate IRB/IEC members, and by inspectors from regulatory  
authori ties.
10.1.4. Dissemination of Clinical Study Data
10.1.5. Data Quality Assurance
To ensure accurate, complete, and reliable data, the sponsor or its representatives will do the 
following:
provi de ins tructi onal materi al to the study  sites, as appropriate
provi de sponsor start- up training to instruct the investigators and study 
coordinators.  This training will give instruction on the protocol, the complet ion 
of the CRFs, and study  procedures.
make periodic visi ts to the study  site
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 97be available for consultation and stay  in contact with the study  site personnel by  
mail, tel ephone, and/or fax
review and verify  data reported to detect potential errors 
In addit ion, the sponsor or its representatives wil l periodically  check a sample of the participant 
data recorded against source documents at the study site.  The study  may be audi ted by the 
sponsor or its representatives and/or regulatory  agencies at any  time.  Invest igators will be given 
notice before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicab le ERBs with direct access to original source 
docum ents.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor. 
An electronic data capture sy stem  (EDC) w ill be used in this study  for the collect ion of CRF 
data.  The investigator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system.  The invest igator is responsible for the 
ident ificat ion of an y data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the CRF .
Addit ionally , clinical  outcom e assessment (COA) data will be collected by  the subject, vi a a 
paper source document and will be transcri bed by the invest igator site personnel into the EDC 
system .
Data collected via the sponsor
-provided data capture system will be stored at third party. The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem .  Pri or to decommissio ning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s databas e system  and the resul ts will  be provi ded to the investigator for 
review and retention.  Data will subsequent ly be transferred fro m the central  vendor to the Lilly  
data warehouse.
Data from co mplaint forms submitted to Lilly will be encoded and stored in t he global product 
complaint m anagement sy stem .
10.1.6. Source Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of the data collected. Source documents are filed at the invest igator’s site.
Data report ed on the CRF or entered in the eCRF that are transcribed fro m source 
docum ents m ust be consistent with the source documents or the discrepancies must be 
explained. The investigator may  need to request previous medical records or transfer 
records, dependi ng on the study . Also, current medical records must be available.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 9810.1.7. Study and Site Closure
10.1.7.1. Discontinuation of the Study
The study  will be di scontinued if Lilly or i ts desi gnee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
10.1.7.2. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 9910.2. Appendix 2: Clinical Laboratory Tests
The tests detailed below will be performed as indicated in the table below .  
Local  laboratory  resul ts are requi red for inclusi on/exclusi on determinat ion, study  
intervent ion administration ,and/or response evaluation. If a local sample is required, it is 
important that the sample for central analysis is obtained at the same time. Addit ionally, 
if the local laboratory  resul ts are used to m akeeither a study  interventi on decisi on or 
response evaluat ion, the clinically significant abnormalit iesmust be entered into the AE 
CRF.  
If there is an abnormal laboratory  value or abnorm al value for any  other diagnosti c 
or screening test (for example, blo od pressure increased, neutrophils decreased, etc.) and 
it is known to be related to a diagnosis (for example, hy pertensi on, neutropeni a, etc.) this 
shoul d be reported i n the CRF as an AE.  Do not enter the test abnormalit y;enter the 
disease diagnosis or categorical term.
Addit ional tests may be performed at any  time during the study  as determined necessary  
by the investigator or required by  local regulat ions and clinically significant findings 
shoul d be recorded reported in the CRF as an AE.  
Enrollment and treatment decisio ns may be based upon local laboratory  resul ts.  Discrepancies 
between l ocal and central  laboratory  resul ts will  not be considered a protocol deviat ion.
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 1 0 0 Cli nic al L a b or at or y Tests 
He m at ol o g y a-l oc al l a b or at or y 
Le u k oc ytes ( W B C) Bas o p hils 
Ne utr o p hils Er y t hr oc ytes ( R B C) 
L y m p h oc ytes He m o gl o bi n ( H G B) 
M o n oc ytes He mat ocrit ( H C T) 
E osi n o p hils Platelets ( P L T) 
C o a g ul ati o n -l oc al l a b or at or y 
P T/I N R P T T/a P T T 
Cli nic al c he mistr y a-l oc al l a b or at or y 
Ser u m c o nce ntrati o ns of: 
Ala ni ne a mi n otra nsferase ( A L T) Calci u m 
Al b u mi n Creati ni ne 
Al kali ne p h os p hatase Gl uc ose (ra n d o m) 
A m ylase Li pase 
As partate a mi n otra nsferase ( A S T) P otassi u m 
Bilir u bi n, direct Pr otei n 
Bilir u bi n, t otal S o di u m 
Bl o o d urea nitr o ge n ( B U N) or bl o o d urea 
Uri n al ysis -l oc al l a b or at or y 
Bl o o d Pr otei n 
Gl uc ose S pecific gra vit y 
Ket o nes Uri ne le u k oc yte esterase d
p H 
Pre g n a nc y Test c - -l oc al l a b or at or y 
Uri ne pre g na nc y test Ser u m pre g na nc y test 
N ote : Uri ne pre g na nc y test at a mi ni m u m se nsiti vit y of 2 5 I U/ L or e q ui vale nt u nits of β- h C G .  If uri ne pre g na nc y res ults ca n n ot 
be c o nfir me d as ne gati ve, a ser u m pre g na nc y test will be re q uire d 
T h yr oi d p a nel -l oc al l a b or at or y 
Trii o d ot h yr o ni ne ( T 3) or Free Trii o d ot h yr o ni ne ( F T 3) T h yr oi d -sti m ulati n g h or m o ne ( T S H) 
Free T h yr o xi ne ( FT 4) 
T u m or m ar kers -l oc al l a b or at or y 
P S A C A - 1 2 5 
C E A C A 1 9 - 9 C CI 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 101IHC -Central laboratory
CD73 expression for Phase 1b Cohort C
Selected tests may be obtained in the event of anaphylaxis or generalized urticaria.
Hypersensitivity Testsb–Central laboratory
Anti-LY antibodies (immunogenicity) Basophil Activation Test
LY concentration (PK) Complements
Tryptase Cytokine Panel
N-methy lhistamine
Abbreviations:  aPTT = activated partial thromboplastin time; CA-125 = cancer antigen 125; CA 19 -9 = cancer 
antigen 19 -9; CEA = carcinoembryonic antigen; CRF = case report form; hCG = human chorionic gonadotropin; 
HCT = hematocrit; HGB = hemoglobin; INR = international normalized ratio; MB = muscle and brain; PLT = 
platelets; PK = pharmacokinetics; PT = prothrombin time; PTT = partial thromboplastin time; PSA = prostate 
specific a ntigen; RBC = red blood cells; WBC = white blood cells.
aTreatment and enrollment decisions will be based on local laboratory results.
Note:  Neutrophils reported by automated differential hematology instruments include both segmented and band 
forms. When a manual differential is needed to report the neutrophils, the segmented and band forms should be 
added together and recorded on the CRF, unless the CRF specifically provides an entry field for bands.
bCentral laboratory.  In addition, local labs may be collected at investigator’s discretion.
cFor female patients of childbearing potential.
dUrine microscopy may be used in place of the urine leukocyte esterase assessment to test for the presence of 
WBC .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 10210.3. Appendix 3: Contraceptive Guidance and Collecti on of Pregnancy 
Information
Definitions:
Woman of Childbearing Potential (WOCBP)
A wo man is considered fertile fo llowing menarche and unt il beco ming post -menopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (e .
g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study  intervent ion, addi tional eval uation shoul d be considered.
Women in the fo llowing categori es are not considered WOCBP
1.Prem enarchal
2.Prem enopausal  female wi th 1 of t he following:
a.Docum ented hysterectomy
b.Docum ented bilateral  salpingectomy
c.Docum ented bilateral  oophorectomy
For individuals wit h perm anent infert ility due to an alternate medical cause other than the above,
(e.g., mullerian agenesis, androgen insensit ivity), investi gator di scret ion shoul d be appl ied to 
determining study  entry .
Note :  Documentation can co me from the site personnel’s :  review of the participant’s medical 
records, medical examinat ion, or m edical history  interview.
3.Postmenopausal  female
A postm enopausal  state is defined as no menses for 12 months without an alternat ive medical 
cause. 
A high fo llicle stimulat ing horm one (FSH) l evel in the postm enopausal range m ay be used to 
confirm a postmenopausal state in wo men not using hormonal contra cepti on or horm onal 
replacement therapy  (HRT). However, in the absence o f 12 m onths of amenorrhea, 
confirmat ion with more than 1FSH measurement is required. 
Females on HRT and whose menopausal status is in doubt will be required to use one of the 
non-estrogen horm onal hi ghly effective contraceptio n methods if they wish to continue their 
HRT during the study . Otherwi se, they  must di scont inue HRT to allow confirmat ion of 
postm enopausal status before study  enrollment.
Contraception Guidance:
1.Women of child- bearing potenti al who are abst inent (if this is co mplete abst inence, as their 
preferred and usual lifest yle) or in a same sex relatio nship (as part of their preferred and 
usual lifest yle) must agree to either remain abstinent or stay in a same sex relat ionship 
without sexual relat ionships wi th males. Periodic abstinence methods (e.g., calendar, 
ovulation, symptothermal, post -ovulation methods), declarat ion of abst inence for the duration 
of a trial, and wi thdrawal )are not acceptable methods of contracepti on. 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 1032.
Women of child -bearing potenti al must use 2 effective methods of contraception for the 
entirety of the study . Abst inence or contraception must continue fo llowing com pletion of
study  drug administrati on, LY3475070 and pembrolizumab, for at least 120 d ays following 
the last dose of study  drugs or coun try requi rements, whichever is lo nger.  For patients 
receiving LY3475070 only, contracepti on shoul d be m aintained for 5 half -lives or until 
plasma concentrations are equal to 1/25th of the nonclinical NOAEL exposure, (NOAEL/25)
predi cted to be 7 days .
a.Women of child- bearing potenti al parti cipat ing must test negative for pregnancy  prior to 
initiation of treatment as indicated by  a negat ive urine pregnancy test at the screening 
visit fo llowed by  a negat ive ser um pregnancy  test wi thin 24 hours pri or to study  drug 
exposure. Pregnancy test ing is conducted at monthly intervals during study treatment in 
both treatment arms, and up to 120 days after study discont inuat ion for pati ents receiving 
LY3475070 and pembrolizumab, and at 7 days after study  discontinuation for patients 
receiving LY3475070 monotherapy .
b.Two effe ctive methods of contraception, such as male or female condoms with 
spermicide, diaphragms wit hspermicide or cervical sponges, will be used. The subject 
may choose to use a double barrier method of contraception. Barrier protection methods 
without concomi tant use of a spermicide are not a reliable or acceptable method. Thus, 
each barrier method must include use of a spermicide. It should be no ted that the use of 
male and female condo ms as a double barrier method is not considered acceptable due to 
the high failure rate when these methods are combined. 
i. One of the 2methods of contraception mustbe a highly effect ive (less than 1% 
failure rate) method of contraception, such as co mbinat ion oral  contraceptives, 
implanted con tracep tives or intrauterine devices.
Collection of Pregnancy Information
Male participants wi th partners who become pregnant
The invest igator will attempt to collect pregnancy inform ation on any male participant’s 
female partner who becomes pregnant while the male participant is in this study .
After obtaining the necessary  signed informed consent from the pregnant female partner 
directly, the invest igator will record pregnancy i nform ation on the appropri ate form  and 
submit it to the sponsor within 24 hours of obtaining informed consent fro m the pregnant 
female partner. The female partner will also be fo llowed to determine the outcome of the 
pregnancy.   Inform ation on the status of the m other and child will be forwarded to the 
sponsor. Generally, the fo llow-up will be no l onger than 6 to 8 weeks fo llowing the 
estimated delivery  date. Any terminat ion of the pregnancy  will be reported regardl ess of 
fetal status (presence or absence of ano malies) or indicat ion for the procedure. 
Female Participants who become pregnant
The invest igator will co llect pregnancy information on any female part icipant who becomes 
pregnant while part icipating in this study .Information will be recorded on the appropriate 
form and submi tted to the sponsor wi thin 24 hours of learning of a parti cipant's pregnancy. 
The parti cipant will be fo llowed to determine the outcom e of the pregnancy . The 
investigator will co llect fo llow-up inform ation on the participant and the neonate and the 
inform ation will be forwarded to the sponsor. Generally, fo llow-up will not be requi red for 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 104longer than 6 to 8 weeks beyo nd the estim ated delivery  date. Any terminat ion of pregnancy  
will be reported, regardless of fetal status (presence or absence of ano malies) or indicat ion 
for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  com plicat ion 
or elective terminat ion of a pregnancy will be reported as an AE or SAE. A spontaneous 
aborti on is always considered to be an SAE and will be reported as such. Any post -study 
pregnancy related SAE considered reasonably related to the study  intervent ion by the
investigator will be reported to the sponsor as described in Section8.3.2 . While the 
investigator is not obligated to actively seek this informat ion in former study  parti cipants, he 
or she may learn of an SAE through spontaneous reporting.
Any female pa rticipant who becomes pregnant while participat ing in the study  will be 
discontinued fro m study  treatm ent.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 10510.4. Appendix 4: Liver Safety: Suggested Actions and Follow -up 
Assessments 
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th participants in consultat ion with the Lilly, or i ts desi gnee,
CRP /CRS .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin (HGB)
Hematocrit (HCT) Hepatic Coagulation a
Erythrocy tes (RBC) Prothrombin time(PT)
Leukocytes (WBC) Prothrombin time, INR
Neutrophilsb
Lymphocy tes Hepatic Serologies a,c
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets (PLT) Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
Alanine aminotransferase (ALT) Antinuclear Antibody a
Aspartate aminotransferase (AST)
Gamma -glutamyl transferase (GGT) Anti -smooth Muscle Antibody a
Creatine phosphokinase (CPK)
Anti-actin Antibody a
Abbreviations:  IgG = immunoglobulin G; IgM= immunoglobulin M;INR = international n ormalized ratio .
aAssay ed by local laboratory.
bNeutrophils reported by automated differential hematology instruments include both segmented and band 
forms. Whenever a manual differential is needed to report the neutrophils, the segmented and band forms should 
be added together and recorded on the CRF, unless the CRF specifically provides an entry field for bands.
cReflex/confirmation dependent on regulatory requirements and/or testing availability.
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 1 0 6 1 0. 5. A p pe n di x 5: C CI 
C CI 
C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 1 0 7 C CI 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 10810.6. Appendix 6: Creatinine Clearance Formula
Note:   This formula is to be used for calculat ing creatinine clearance (CrCl) fro m local 
laboratory results only.  
For serum creatinine concentration in mg/dL:
CrCl = (
140 – agea) (wt)    0.85 (if female) , or1.0 (if male)
(mL/min) 72serum creatinine (mg/dL )
For serum creatinine concentration in mol/L:
CrCl   = (140 – agea) (wt)  0.85 (if female) , or1.0 (if male)
(mL/min)                0.81 x serum creatinine (µmo/L )
aage in y ears, weight (wt) in kilograms.
Reference:  Cockcroft and Gault 1976.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 10910.7. Appendix 7: Country -specific Requirements
10.7.1. Discontinuation of Inadvertently Enrolled Patients in the UK
If the sponsor or invest igator ident ifies a participant who did not meet enrollment criteria and 
was inadvertently enrolled, then the participant should be discontinued from study  treatm ent and 
safet y follow up shoul d be perform ed as outlined in Section 1.3 (Schedule of Act ivities), Secti on 
8.3 (Adverse Events and Serious Adverse Events), and Sect ion 8.2 (Safety  Assessments) of the 
protocol .
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 11010.8. Appendix 8: Dose-Finding Algorithm of the Modified Toxicity 
Probability Interval -2 Met hod Showing Number of Patients Treated
The number of pat ients dosed at a given DLisshown in the co lumns ( X
-axis), while the number 
of DLTs experi enced isshown in the rows ( Y-axis).  The rules in this figure will be used for each 
DLevaluated; the pati ent numbers and DLTs do not carry  over f rom cohort to cohort.  By  
locating the intersection of the number of patients dosed and the number of DLTs, 1 of 4 
predefined rules is used:
E:  Escal ate the dose
S:  Stay  at the same dose
D:  De -escalate the dose
DU:  De -escalate the dose due to unacceptable toxicit y.  The dose cannot be re -escalated 
to this DLat a future point in the escalation.
For example, within a cohort:
If 1 of 3 pati ents experiences a DLT, stay  at the same dose (see “S” in co lumn 3 ,row 1).  
The fourthpatient m ust be treated at the same DL.
If 1 of 6 patients experiences a DLT, escalate the dose (see “E” at column 6 ,row 1).
If 2 of 3 pati ents experience a DLT the dose to treat the next patient is de -escalated (see 
“D”at col umn 3, row 2).
If 5 of 7 patients experience a DLT, the dose is determined to be unacceptably toxic, and 
the previous dose is defined as theMTD.

C O N FI D E N TI A L Pr ot oc ol  J 2I -M C -J Z M A( d) 
L Y 3 4 7 5 0 7 0 1 1 1 1 0. 9. A p pe n di x 9: A b bre vi ati o ns 
T er m D efi niti o n 
9 9 m T c M D P 9 9 m T c -met h y le ne di p h os p h o nate 
A1 A R ade n osi ne 1 A rece pt or 
A2 A R ade n osi ne 2 A rece pt or 
A2 B R ade n osi ne 2 B rece pt or 
A3R ade n osi ne 3rece pt or 
A E a d verse e ve nt:  A n y u nt o war d me dical occ urre nce i n a patie nt or cli nical i n vesti gati o n 
s u bject a d mi nistere d a p har mace utical pr o d uct t hat d oes n ot necessaril y ha ve a ca usal 
relati o ns hi p wit h t his treat me nt.  A n a d verse e ve nt ca n t heref ore be a n y u nfa v ora ble a n d 
u ni nte n de d si g n (i ncl u di n g a n a b n or mal la b orat or y fi n di n g), s y m pt o m, or disease 
te m p orall y  ass ociate d wit h t he use of a me dici nal (i n vesti gati o nal) pr o d uct, w het her or 
n ot relate d t o t he me dici nal (i n vesti gati o nal) pr o d uct. 
AI D S ac q uire d i m m u n o deficie nc y s y n dr o me 
A L P al kali ne p h os p hatase 
A L T ala ni ne a mi n otra nsferase 
A M P ade n osi ne m o n o p h os p hate 
A S C O/ C A P A merica n S ociet y of Cli nical O nc ol o g y/ C olle ge of A merica n Pat h ol o gists 
A S T as partate a mi n otra nsferase 
A T P ade n osi ne tri p h os p hate 
A U C Area u n der t he c ur ve 
BI D t w o ti mes a da y 
B O R best o verall res ults 
C D 7 3 ect o - 5′- n ucle oti dase 
CI O M S C o u ncil f or I nter nati o nal Or ga nizati o ns of Me dical Scie nces 
C M c uta ne o us mela n o ma 
C N S ce ntral ner v o us s yste m 
C O A cli nical o utc o me assess me nt C CI 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 112complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality , purity , durability , reliability , safety  or effectiveness, or 
performance of a drug or drug delivery system.
compliance adherence to all study -
related, good clinical practice (GCP), and applicable regulatory 
requirements.
CRF/eCRF case report form/electronic case report form
CRP/CRS clinical research physician /clinical research scientist : Individual responsible for the 
medical conduct of the study.  Responsibilities of the CRP /CRS may be performed by a 
physician, clinical research scientist, global safety physician or other medical officer.
CSR clinical study report
CT computed tomography
CTCAE Common Terminology Criteria for Adverse Events
CTLA -4 cytotoxic T-lymphocy te-associated protein 4
DCR disease control rate
DL dose level
DLT dose-limiting toxicity
DOR duration of response
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
EDC electronic data capture system
EGFR epidermal growth factor receptor
EI equivalence interval
enroll the act of assigning a participant to a treatment.  Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ERB ethical review board
ET equivalent toxicity
FFPE formalin -
fixed paraffin -embedded
FSH follicle stimulating hormone
GCP good clinical practice
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 113G
-CSF granulocyte -colon y stimulating factor
HER2 human epidermal growth factor receptor 2
HIPAA Health Insurance Portability and Accountability Act
HIV Human Immunodeficiency Virus 
HRT hormonal replacement therapy
IB Investigator’s Brochure
ICF informed consent form
ICI immune checkpoint inhibitor
ICH International Council for Harmonisation
IHC immunohistochemistry
Informed consent aprocess by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate.  Informed consent is 
documented by means of a written, signed and dated informed consent form .
interim analysis an interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
productapharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
market ed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
irAE immune- related adverse event
IRB/IEC Institutio nal Review Board/Independent Ethics Committee
ITT intention to treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a participant (that is, the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequenc e that participant allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.
IV intravenous
IVRS/IWRS interactive voice -response system/interactive web -response system
LLT lower level term
mAb monoclonal antibody
mCRPC metastatic castrate resistant prostate cancer
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 114MedDRA Medical Dictionary for Regulatory Activities
MOA mechanism of action
MRI magnetic resonance imaging
mTNBC metastatic triple negative breast cancer
MN micronucleus
MSI
-H microsatellite instability -high
MTD maximum tolerated dose
mTPI -2 modified toxicity probability interval
NL-NT new lesion -non- target
NL-T new lesion -target
NOAEL no observed adverse effect level
NSCLC non-small cell lung cancer
ORR overall response rate
OS overall survival
PBPK physiologically -based pharmacokinetics
PD progressive disease
PD-
1 programmed cell death protein 1
PD-1/L1 programmed cell death protein 1 /ligand 1
PD-L2 programmed cell death protein/ligand 2
PFS progression -
free survival
PK pharmacokinetics
PPS per-protocol set:  The set of data generated by the subset of participant who sufficiently 
complied with the protocol to ensure that these data would be l ikely  to exhibit the 
effects of treatment, according to the underlying scientific model.
PS performance status
PSA prostate -specific antigen
PT preferred term
Q2W every 2 weeks
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 115Q3W every 3 weeks
QD once a day
QTc corrected QT interval
RCC renal cell carcinoma
RECIST/iRECIST Response Evaluation Criteria in Solid Tumors/immune Response Evaluation Criteria in 
Solid Tumors
RP1D recommended phase 1 dose
RP2D recommended phase 2 dose
SAE serious adverse event
SAP statistical analysis plan
screen the act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study. 
SoA schedule of activities
SOC System Organ Class
SUSARs suspected unexpected serious adverse reactions
TBL total bilirubin
TEAE treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
TME tumor microenvironment
TNBC triple negative breast cancer
TTR time to response
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 11610.10. Appendix 10: Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
Amendment a (02-Oct-
2019)
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
This amendment incorporates changes requested by regulatory  agencies. In addit ion, thi s 
amendment includes changes made to correct and clarify informat ion for sites. 
Section # and Name Descriptio n of Change Brief Rationale
Secti on 6.6.1 Dose 
Modificat ion and Toxi city 
Management Addit ion of monitoring and 
management guidelines for 
infusio n-related reacti onsBased on regulatory  agency  
feedback
Secti on 5.1 Incl usion 
CriteriaAmended criteria to specify 
minimum treatments patients 
shoul d have received for phase 1aBased on regulatory  agency  
feedback
Secti on 5.1 Incl usion 
CriteriaAmended criteria to specify  
minimum treatments patients 
shoul d have received for 
phase 1bBased on regulatory  agency  
feedback
Secti on 1.3.1 Sam pling 
Schedule for 
Pharmacokinet ics and 
BiomarkersRevised ECG monitoring plan to 
add an ECG collect ionBased on regulatory  agency  
feedback
Secti on 6.1.1 Definit ion of 
DLT and DLT -ETModificat ion of dose limit ing 
toxicity criteria and clarification 
of defini tion of DLT -ETBased on regulatory  agency  
feedback
Secti on 5.2 Excl usion 
CriteriaSeparated exclusio n criteria a 
through j  from Criterion 17 into 
numbered criteriaBased on regulatory  agency  
feedback
Secti on 8.1.2 i RECIST fo r 
Confirmation o f PD in 
Clinically Stable Patients 
and Radio logic PD per 
RECIST v1.1Modificat ion of management 
guidelines for pati ents who have 
radiologic evidence of 
progressive disease by  
RECIST v1.1Based on regulatory  agency  
feedback
Secti on 4.1 Overall Design Clarificat ion regarding dose 
escalat ion timelineBased on regulatory  agency  
feedback
Secti on 1.1 Synopsis, Reso lved inconsistencies Based on regulatory  agency  
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 117Section # and Name Descriptio n of Change Brief Rationale
Secti on 1.2 Schema ,
Secti on 4.1 Overall Design,
Secti on 6.1 Study  
Intervention(s) 
Administeredregarding nam ing of 
recommended dosefeedback
Secti on 6.1 Study  
Intervention(s) 
AdministeredAdded instruction on how to 
administer LY3475070 with 
regards to food intakeBased on regulatory  agency  
feedback
Secti on 5.1 Incl usion 
CriteriaRemoved duplicate inclusio n 
criteria rel ated to inform ed 
consentDuplicat ion
Secti on 1.3 Schedule of 
ActivitiesSpecificat ion of requirements 
related to short -and long -term 
follow-up visitsClarificat ion for sites
Throughout protocol Minor form atting and editorial 
changesMinor, therefore not detailed
Amendment b (24 -Feb-2020)
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
The purpose of this amendment is to add updated informat ive language for pembrolizumab and 
address regulatory  concerns.
Section # and Name Description of Change Brief Rationale
Throughout Addit ion of pembro lizumab -
specific languageLanguage added as a result of 
pembro lizumab language 
requi rements 
Secti on 1.3 SoA Added language regarding 
iRECIST evaluat ionClarificat ion
Secti on 1.3 SoA Amended language regarding 
urinalysis co llectionClarificat ion
Section 1.3 SoA, Section 
5.1 Incl usion Criteria, 
Secti on 5.2 Excl usion 
Criteria, Secti on 6.5 
Concomitant Therapy , 
Appendix 3:  Contraceptive 
Guidance and Co llection of 
Pregnancy InformationAdded and amended 
pregnancy/contraception 
languagePer regul atory  feedback
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 118Secti on 5.1 Incl usion 
CriteriaAmended hepat ic inclusio n 
languagePer regul atory  feedback
Secti on 5.1 Incl usion 
CriteriaFor Incl usion Criteria 2 and 5, 
revised requirements for prior 
lines o f therapy  for all indicat ions Per investigator feedback
Secti on 10.2 Appendix 2: 
Clinical Laboratory  TestsAmended language regarding 
local laboratory  resul tsClarificat ion
Throughout protocol Minor form atting and editorial 
changesMinor, therefore not detailed.
Amendment c (22 -Mar -2020)
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
The purpose of this amendment is to add updated informat ive language for pembrolizumab and 
address regulatory  concerns.
Section # and Name Description of Change Brief Rationale
Secti on 1.3. Schedul e of 
ActivitiesRemoval of stool  sample 
collect ionClarificat ion; site/invest igator 
feedback
Secti on 1.3.1 Sampling 
Schedule for 
Pharmacokinet ics and 
BiomarkersChange of mandatory  biopsies to 
optional for Phase 1a pati ents; 
removal of collect ion of stool 
samplesUpdated for enrollment and 
study  participati on purposes
Secti on 5.1 Incl usion 
CriteriaAddit ion of inclusio n criterion 2 
for archival sample collection; 
changed m andatory  biopsies to 
optional for Phase 1a pati ents Updated for enrollment and 
study  participati on purposes
Secti on 5.1 Incl usion 
CriteriaRemoved l anguage regarding 
intervening treatm ent for PD -1 
indicat ions in Phase 1a for 
inclusio n criterion 3; am ended 
language o f “activating EGFR 
mutati ons” to “targetable 
mutati ons”Updated for enrollment and 
study  participati on purposes
Secti on 5.1 Incl usion 
CriteriaMoved inclu sion cri terion 9 to 
criterion 6 and am ended languageUpdated for enrollment and 
study  participati on purposes
Secti on 5.1 Incl usion 
CriteriaAddit ion of language for 
inclusio n criterion 13; am ended 
language regarding wash -out 
period for pri or therapyClarification; site/invest igator 
feedback
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 119Secti on 5.1 Incl usion 
CriteriaUpdated pl atelet lab value in 
inclusio n criterion 14 to 
100×109/LClarificat ion; site/invest igator 
feedback
Secti on 5.2 Excl usion 
CriteriaAmended language for exclusio n 
criterion 26Clarificat ion
Secti on 5.2 Excl usion 
CriteriaDeletion of exclusio n criterion 37 
regarding prior participation in a 
clinical trialClarificat ion; site/invest igator 
feedback
Secti on 8.8 Bi omarkers Amended language regarding the 
collect ion of tum or tissue 
sample(s) and stool collectionUpdated for enrollment and 
study  participati on purposes
Throughout protocol Minor form atting and editorial 
changesMinor, therefore not detailed.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 12011. References
Allard B,Turcotte M ,Stagg J . CD73 -generated adenosine: orchestrating the tumor -stroma 
interplay  to prom ote cancer growth. J Biomed Biotech nol. 2012;2012:485156.
Allard D,Chrobak P ,Allard B,Messaoudi N, Stagg J . Targeting the CD73 -adenosine axis in 
immuno -oncol ogy.Immunol Lett. 2019;205:31 - 39.
Bendell J, Bauer T, Patel M, Falchook G, Karlix JL, Lim E, Mugundu G, Mitchell PD, Pouliot 
GP, Moorthy  G, Linghu B, McGrath L, Harrop B, Shao W, Drake CG, Sachsenmeier K, 
Merchant MS. Evidence of immune activation in the first -in human Phase 1a dose escalat ion 
study  of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid 
tumors[abstract] .In: Proceedings of the American Associat ion forCancer Research Annual 
Meet ing 2019; 2019 Mar 29 -Apr 3:Atlanta, GA. Philadelphia (P A): AACR; Cancer Res . 
2019;79 (13 Suppl ):Abstract nr CT026 .
Brahmer JR, Pardoll DM. Immune checkpo intinhibitors: making immunotherapy a realit y for 
the treatment of lung cancer. Cancer Immunol Res . 2013 ;1(2):85 -91.
Chiappori  A, Williams CC, Creelan BC, Tan vetyanon T, Gray  JE, Haura EB, Thapa R, Chen 
DT, Beg AA, Boyle TA, Bendiske J, Morris E, Tao A, Hurtado FK, Manenti L, Castro J, 
Antoni a SJ. Phase I/II study  of the A2AR antagonist NIR178 (PBF -509), an oral 
immunotherapy , in pat ients with advanced NSCLC. JClin Oncol . 2018; 36(15 Suppl) : 9089-
9089.
Cockcroft DW, Gault MD. Prediction of creat inine clearance fro m serum  creat inine. Nephron . 
1976;16 (1):31-
41.
Crawford J, Caserta C, Roila F ;ESMO Gui delines Working Group. Hematopoiet ic growth 
factors: ESMO recommendat ions for the applicat ions. Ann Oncol . 2009;20 Suppl 4:162 -165.
De Bono J S, Goh JCH, Ojamaa K, Rodriguez JMP, Drake CG, Hoimes CJ, Wu H, Poehle in CH, 
Antonarakis ES. KEYNOTE -199: Pembro lizumab (pembro) for docetaxel -refractory  
metastati c castrati on-resistant prostate cancer ( mCRPC ). J Clin Oncol . 
2018;36(15 Suppl):5007 -5007.
Dubyak GR, el-Moatassim C. Signal transducti on via P2- purinergic receptors for extracellular 
ATP and other n ucleotides.Am J Physiol .1993;265(3 Pt 1):C577 -606.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, 
Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Laco mbe D, Verweij J. 
New response evaluat ion criteria in so lid tumors: revised RECIST guideline (ver sion 1.1). Eur 
J Cancer . 2009;45(2):228 -247.
Fishman P, Bar -Yehuda S, Synowitz M, Powell JD, Klotz KN, Gessi S, Borea PA. 
Adenosine receptors and cancer. Handb Exp Pharmacol .2009;(193):399 -441.
Flowers CR, Sei denfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston 
AA, Marr KA, Rolston KV, Ramsey SD. Antimicrobial prophylaxis and outpatient 
management of fever and neutropenia in adults treated for malignancy: American Societ y of 
Clinical Onco logy clinical  pract ice guideline. J Clin Oncol . 2013;31(6):794 -810.
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 121Fong L, Forde PM, Powderly JD, Goldman JW, Nemunait is JJ, Luke JJ, Hellman MD, Kummar 
S, Doebele RC, Mahadevan D, Gadgeel SM, Hughes BGM, Markman B, Riese MJ, Brody  J, 
Emens LA, McCaffrey  I, Miller RA, Laport G. Safety  and clinical act ivity of adenosine A2a 
receptor (A2aR) antagonist, CPI -444, in ant i
-PD1/PDL1 treatment -refractory renal cell (RCC) 
and non -small  cell lung cancer (NSCLC) patients. J Clin Oncol . 2017; 35(15 Suppl):3004 -
3004.
Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy  
using ant iangiogenics: opportunit ies and challenges. Nat Rev Clin Oncol . 2018;15(5):325 -340.
Guo W, Wang SJ, Yang S, Lynn H, Ji Y. A Bayesian interval dose -finding design addressing
Ockham's razor: mTPI -2. Contemporary ClinTrials. 2017;58:23-33.
Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu -Axelerad A, Lew M, Kozyo lkin O, 
Neale A, Resburg C, Mey a U, Kenney  C, Bandak S. Tozadenant (SYN115) in pat ients with 
Parkinson’s disease who have motor fluctuations on levodopa: a phase 2b , doubl e-blind, 
rando mized trial. Lancet Neurol . 2014; 13(8):767 -776.
Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K. Interferon 
Gamma Messenger RNA Signature in Tum or Bi opsies Predi cts Outcom es in Patients with 
Non–Small Cell  Lung Carcino ma or Urothelial Cancer Treated with Durvalumab. Clin Cancer 
Res. 2018; (24(16):3857
-3866.
Horenstein AL, Bracci C, Morandi F, Malavasi F. CD38 in Adenosinergic Pathways and 
Metabo lic Re-programming in Human Mult iple Myelo ma Cells: In -tandem Insights From 
Basic Science to Therapy .Front Immunol .2019;10:760.
Hotson D, Powderly  J, Em ens L, Forde P, Hellman M, Fong L, Markman B, Hughes B, 
Goldman J, Sznol  M, Mahadevan D, Kummar S, Brody  J, Bonomi P, Luke J, Riese M, 
Owoni koko T, Loi  S, Wi ese A, Doebele R, Lee J, Gu C, Willingham S, Laport G, Miller R, 
McCaffery I. Clinical activit y of adenosine A2A receptor (A2aR) inhibitor CPI -444 is 
associ ated wi th tumor expressio n of adenosine pathway genes and tumor immune modulat ion. 
J ImmunoTherapy of Cancer. 2017;5(Suppl 2; abstract O4):86.
Iasonos A,O'Quigle y J. Design c onsiderat ions for dose -expansio n cohorts in phase I trials. J 
Clin Oncol . 2013; 31(31):4014 - 4021.
Leclerc BG, Charlebo is R, Chouinard G, Allard B, Pommey S, Saad F, Stagg J. CD73 
Expressio n is an independent prognostic factor in prostate cancer. Clin Cancer Res. 
2016;22(1):158 -166.
Leone RD, Horton MR, Powell JD. Something in the air: hyperoxic condit ioning of the 
tumormicroenvironment for enhanced immunotherapy .Cancer Cell . 2015; 27(4):435 - 43 6.
Leone RD, Em ens LA. Targeting adenosine for cancer immunotherapy .J Immunother 
Cancer . 2018 ;6(1):57.
LoiS,Pommey S ,Haibe -Kains B ,Beavis PA ,Darcy  PK,Smyt h MJ ,Stagg J . CD73 promotes 
anthracycline resistance and poor prognosis in triple negat ive breast cancer. Proc Natl Acad 
SciUSA. 2013 ;110(27):11091 -1109 6.
Luke J, Powderly JD, Merchan JR, Barve MA, Hotson AN, Mobasher M, Kwei L, Luciano G, 
Buggy  JJ, Picci one E, Miller RA. Immunobio logy, preliminary  safety , and efficacy of CPI -
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 122006, an ant i
-CD73 ant ibody  with immune modulating act ivity, in a phase 1 trial in advanced 
cancers. J Clin Oncol . 2019;37(suppl; abstract 2505) .
Monteiro I, Vigano S, Faouzi M, Treilleux I, Michielin O, Ménétrier -Caux C, Caux C, Romero 
P, de Leval L. CD73 expressio n and clinical significance in human metastatic mela noma.
Oncotarget .2018;9(42):26659 -26669.
Nishino M, Gi obbie -Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a 
commo n language for tumor response to immunotherapy: immune -related response cri teria 
using unidimensio nal measurements. Clin Cancer Res.2013;15;19(14):3936 -3943.
O’Donnell JS, Smyt h MJ, Teng MW. Acquired resistance to anti -PD1 therapy : checkmate to 
checkpoint blockage? Genome Med .2016;8(1) :111.
Ohta A,Sitkovsky M. Role of G-protein -coupl ed adenosine receptors in downregulat ion of 
inflammat ion and protection fro m tissue damage. Nature .2001;414(6866):916-920.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP . Toxicit y 
and response criteria of the Eastern Cooperative Onco logy Group. Am J Clin Oncol . 
1982;5 (6):649-655.
Pembrolizumab [ Summary of product characterist ics]. Whitehouse Station, NJ: Merck & Co., 
Inc.; 2014.
Pembrolizumab [US package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2014.
Rizzo JD, Somerfield MR, Hagerty  KL, Sei denfeld J, Bohlius J, Bennett CL, Cella DF, 
Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Licht in AE ; American 
Society of Clinical  Oncol ogy; American Society  of Hematol ogy. Use of epoetin and 
darbepoetin in pat ients with cancer: 2007 American Society  of Clinical Onco logy/American 
Society of Hematol ogy clinical pract ice guideline update. J Clin Oncol. 2008;26( 1):132 -49.
Robeva AS,Woodard R ,Luthin DR ,Taylor HE ,Linden J . Doubl e tagging recombinant A1 and 
A2A-adenosine receptors with hexahist idine and the FLAG epitope. Development of an 
efficient generic protein purificat ion procedure. Biochem Pharmacol . 1996; 51(4):545 -555.
Salazar R, Sol orzano J, Solis L, Behrens C, Mino B, Parra E, Zhang J, Vaporciyan A, Rice D, 
Kalhor N, Moran C, Gibbons D, Weissferdt A, Sepe si B, Wistuba I. CD73 
Immunohistochemical expressio n in malignant cells and correlat ion with immune infiltrate in 
non-small  cell lung carcino ma (NSCLC). J Thoracic Oncol . 2018;13(10),S upplement: S533-
S
543.
Scher HI, Morri s MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, 
Carducci  MA, Chi  KN, Corn PG, de Bon oJS, Dreicer R, Geo rge DJ, Heath EI, Hussain M, 
Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ry an CJ, 
Sartor O, Sm all EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz 
LH, Hal abi S, Kantoff PW, Armstrong AJ; Prostate Cancer Clinical Trials Working Group 3. 
Trial design and objectives for castrati on-resistant prostate cancer: updated recommendat ions 
from the prostate cancer clinic al trials working group 3. J Clin Oncol . 2016 ;34(12): 1402
-
1418.
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Lit ière S, 
Dancey  J, Chen A, Hodi  FS, Therasse P, Hoekstra OS, Shankar LK, Wo lchok JD, Ballinger 
CONFIDENTIAL Protocol  J2I-MC-JZMA( d)
LY3475070 123M, Caram ella C, de Vries EG; RECIST Working Group. iRECIST: guidelines for response 
criteria for use in trials testing immunotherapeutics. Lancet Oncol . 2017;18(3):e143
-e152.
Smith TJ, Bohl ke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, 
Khatcheressian JL, Leig hl NB, Perkins CL, Somlo  G, Wade JL, Wozniak AJ, Armitage JO; 
American Societ y of Clinical  Oncol ogy. Recommendat ions for the use of WBC growth 
factors: American Societ y of Clinical  Oncol ogy clinical practice guideline update. J Clin 
Oncol . 2015;33(28):3199- 3212.
Streicher K, Higgs BW, Wu S, Coffman K, Damera G, Durham N, Greenlees L, Lazdun Y, 
Cheng L, Cooper Z, Ranade K. Increased CD73 and reduced IFNG signature expressio n in 
relation to response rates to anti -PD-1(L1) therapi es in EGFR-mutant NSCLC. J Cli n Oncol. 
2017;35(15 Suppl):11505 -11505.
SuiH,Ma N ,Wang Y ,Li H,Liu X,Su Y ,Yang J . Anti -PD-1/PD -L1 therapy  for non -small-cell 
lung cancer: toward personalized medicine and combinat ion strategies. J Immun Res .
2018;2018:6984948.
Tripathi S,XieW,Flaifel A,Steinharter JA,Stern Gatof A,Jennings RB,Bouchard G,Fleischer
J,Chanza NM,Gray C,Mant iaC,Wei XX,Giannakis M,McGregor BA,Choueiri TK,
McDermott DF,Signoretti S, Harshman LC. Prognostic significance o f CD73 expressio n in 
localized ren al cell carcino ma (RCC). J Clin Oncol . 2019;37: (15 Suppl) ,4582 -4582.
van der Putten C,Veth J ,Sukurova L ,Zuiderwijk -Sick EA ,Simonetti E,Koenen HJPM ,Burm  
SM,van Noort JM ,IJzerman AP ,van Hijum Saft,Diavatopoul os D ,Bajramovic JJ . TLR -
Induced IL -12 and CCL2 Production by Myelo id Cells Is Dependent on Adenosine
A3Receptor -Medi ated Si gnaling. J Immunol . 2019; 202(8):2421 -2430.
Willingham SB,Ho PY ,Hotson A ,Hill C ,Piccione EC ,Hsieh J ,Liu L ,Buggy  JJ,McCaffery  
I,Miller RA . A2AR antagoni sm wi th CPI-444 induces antitumor responses and augments 
efficacy  to anti -PD-(L)1 and ant i-CTLA4 in preclinical models. Cancer Immunol Res . 
2018;6(10):1136 -1149.
WolchokJD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Sc hadendorf D, 
Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C.
Ipilimumab mo notherapy  in patients with pretreated advanced melano ma: a rando mised, 
doubl e-blind, mult icentre, phase 2, dose -ranging study .Lancet Oncol . 2010;11(2):155 -164.
L e o  D o c u m e n t  I D  =  b 0 d a 0 e a f - d 5 4 6 - 4 b e 9 - 8 d 6 0 - 1 d 3 9 3 9 9 2 7 8 d f 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  0 2 - S e p - 2 0 2 0  1 5 : 5 9 : 4 6  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  0 2 - S e p - 2 0 2 0  1 8 : 5 8 : 2 0  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 